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Bifidobacteria are Gram positive, anaerobic, typically Y-shaped bacteria which are 
naturally found in the digestive tract of certain mammals, birds and insects. 
Bifidobacterium breve strains are numerically prevalent among the gut microbiota of 
many healthy breast-fed infants. The prototypical B. breve strain UCC2003 has 
previously been shown to utilise numerous carbohydrates of plant origin. Various 
aspects of host-derived carbohydrate metabolism occurring in this bacterium will be 
described in this thesis. 
Chapter II describes B. breve UCC2003 utilisation of sialic acid, a nine-carbon 
monosaccharide, which is found in human milk oligosaccharides (HMOs) and the 
mucin glycoprotein. B. breve UCC2003 was also shown to cross-feed on sialic acid 
released from 3’ sialyllactose, a prominent HMO, by the extracellular sialidase 
activity of Bifidobacterium bifidum PRL2010. 
Chapter III reports on the transcriptional regulation of sialic acid metabolism in B. 
breve UCC2003 by a transcriptional repressor encoded by the nanR gene. NanR 
belongs to the GntR-family of transcriptional regulators and represents the first 
bifidobacterial member of this family to be characterised.  
Chapter IV investigates B. breve UCC2003 utilisation of mucin. B. breve UCC2003 
was shown to be incapable of degrading mucin; however when grown in co-culture 
with B. bifidum PRL2010 it exhibits enhanced growth and survival properties. A 
number of methods were used to investigate and identify the mucin components 
supporting this enhanced growth/viability phenotype.  
xvi 
 
Chapter V describes the characterisation of two sulfatase-encoding gene clusters 
from B. breve UCC2003. The transcriptional regulation of both sulfatase-encoding 
gene clusters was also investigated. 
The work presented in this thesis represents new information on the metabolism of 
host-derived carbohydrates in bifidobacteria, thus increasing our understanding of 

















The gastrointestinal tract (GIT) of mammals is the natural habitat for a diverse 
community of facultative and obligate anaerobic bacteria, collectively known as the 
gut microbiota. The human GIT is home to an estimated 1014 microorganisms, 1011-
1012 of which reside in the large intestine (Ley et al., 2006). The overall gene set 
carried by the gut microbiota, also called the gut microbiome, of which 99 % is 
deemed to be of bacterial origin, is approximately 150 times larger than that of the 
human genome (Gill et al., 2006; Qin et al., 2010).  
Immediately following birth, the essentially sterile GIT becomes colonised by 
microbes, followed by an increase in microbial diversity throughout early 
development (Koenig et al., 2011; Palmer et al., 2007; Vaishampayan et al., 2010). 
A number of microbiota and metagenomic studies have provided an in depth analysis 
of the microbial diversity of a typical infant gut (Avershina et al., 2013; Koenig et 
al., 2011; Palmer et al., 2007; Turroni et al., 2012b; Vaishampayan et al., 2010; 
Yatsunenko et al., 2012). In one such study, which monitored the diversity of the gut 
microbiota through the first year of life, it was found that while members of the 
genera Escherichia and Bacteroides were dominant after one month, they were 
quickly supplanted by bacteria belonging to the genus Bifidobacterium, which was 
then clearly dominant for up to eleven months (Vaishampayan et al., 2010). These 
data were substantiated by later studies, for example showing that members of the 
Bifidobacteriaceae family dominated the gut microbiota of infants between one and 
five months in age (Turroni et al., 2012b), or that (in a study of 87 infants and based 
on 16S rRNA sequencing) bifidobacteria constitute approximately 60 % of the total 
bacterial load at four months of age (Avershina et al., 2013). Another comprehensive 
metagenomic study characterised bacterial species in faecal samples from infants and 
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adults from the United States, the Amazonas of Venezuela and rural Malawi. 
Perhaps unsurprisingly, it was found that there were significant differences in the 
phylogenetic diversity between the three countries, and while bifidobacteria were 
again dominant in the three groups, their proportional representation diminished 
during the first year of life of the investigated infants (Yatsunenko et al., 2012).  
A number of factors have been shown to influence the establishment and consequent 
development of the gut microbiota in infants. The mode of delivery is considered an 
important factor which provides the initial microbial components to shape the infant 
intestinal microbiota: studies have shown that infants born by Caesarean section 
have lower numbers of bifidobacteria compared with vaginally delivered infants 
(Biasucci et al., 2010; Huurre et al., 2008). Also the method of feeding, i.e. breast-
fed versus formula-fed, influences the development and diversity of the infant 
microbiota (Fanaro et al., 2003; Roger et al., 2010). Furthermore, studies have 
described the influence of antibiotic treatment on the development of the infant gut 
microbiota, with the administration of antibiotics being associated with a reduction 
in phylogenetic diversity (Antonopoulos et al., 2009; Fouhy et al., 2012; Koenig et 
al., 2011; Palmer et al., 2007). Within the first three years of human life the 
composition of the associated bacterial community in the gut evolves towards an 
adult-like microbiota, with one study noting that genes predicted to encode enzymes 
for plant-derived fibre metabolism, indicative of an adult diet, are present in the 
microbiome prior to the introduction of solid foods (Koenig et al., 2011; Yatsunenko 
et al., 2012). 
Analysis of the GIT microbiota in healthy adults has shown that the bacterial 
composition varies throughout the intestinal tract. In the upper part of the small 
intestine, native conditions such as the acidic pH (the pH of the duodenum is 6.0, 
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rising to 7.4 in the terminal ileum), rapid luminal flow and presence of bile salts are 
responsible for keeping the cell biomass relatively low (Fallingborg, 1999; Walter & 
Ley, 2011). The diversity of microbial populations in the small intestine is also 
relatively low, with the duodenum and jejunum dominated by acid-tolerant bacteria 
such as Streptococcus and lactobacilli, while members of the genera Bacteroides and 
Clostridia dominate the ileum (Wang et al., 2005). Bifidobacteria have also been 
identified in the ileum of children (aged between ten and fourteen years) and adults 
(Reuter, 2001). 
The native conditions of the large intestine are more conducive to bacterial 
populations with higher densities, due to a near neutral pH, lower bile levels (the 
terminal ileum is the main site of bile acid reabsorption (Dawson et al., 2009)) and a 
slower rate of peristalsis compared to the small intestine. Unlike the small intestine, 
the epithelial layer of the large intestine lacks Peyer’s patches, the purpose of which 
is to sample bacteria and direct immune responses, thereby resulting in an increased 
tolerance for bacteria in the large intestine (Heel et al., 1997; Walter & Ley, 2011). 
Similar to the small intestine, members of the genera Bacteroides and Clostridium 
are abundantly present, in addition to members of the phyla Actinobacteria, 
Verrucomicrobia, Proteobacteria and Fusobacteria (Eckburg et al., 2005; 
Turnbaugh et al., 2008). Large scale metagenomic sequencing projects have 
demonstrated the variability in the composition of the microbiota among individuals, 
as even identical twins share less than 50 % of their species level bacterial taxa 
(Turnbaugh et al., 2010). Lifestyle factors, such as a shift in diet from a high fat/low 
fibre to a low fat/high fibre diet, can cause significant changes in the microbiota 
within a day (Turnbaugh et al., 2009; Wu et al., 2011). It was also found that there is 
increased inter-personal variability in older people (in a study of 178 people aged 
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between 64 and 102) compared to younger adults (mean age of 36), and that diet is 
the main factor that influences the composition of the gut microbiota (Claesson et 
al., 2012). This study found that the gut microbiota of older people in long term care 
was significantly less diverse compared to their counterparts living in the community 
and this correlated with the moderate to high fat/low fibre diet typical of the 
individuals in long term care (Claesson et al., 2012).  
Given the sheer size and diversity of the gut microbiome, it is no surprise that the gut 
microbiota has been implicated in various health and disease states of the host. The 
(development of the) gut microbiota is associated with maturation and activity of the 
immune system. Germ-free animals tend to show defects in the development of gut-
associated lymphoid tissues, as well as having smaller Peyer’s patches and 
mesenteric lymph nodes and they are also more susceptible to infection by certain 
bacteria, viruses and parasites (reviewed in Round & Mazmanian, 2009). The 
commensal microbiota can induce repair of damaged intestinal epithelium (Pull et 
al., 2005), while in mice the gut microbiota has been shown to protect against Type I 
diabetes, an autoimmune disease (Wen et al., 2008).  Microorganisms also impact on 
the structure of the protective mucus layer of the GIT, a number of studies have 
found variations in the biochemical composition and thickness of the mucus layer in 
germ-free animals as compared to their conventionally raised counterparts (Meslin et 
al., 1999; Petersson et al., 2011; Sharma et al., 1995; Szentkuti et al., 1990). The 
genomic content of the gut microbiota, and particularly the microbiome of the colon, 
is enriched with genes involved in the metabolism of carbohydrates, the fermentation 
products of which are short chain fatty acids (SCFA) that account for approximately 
10 % of the calories extracted from a Western-style diet per day, while also playing a 
role in the regulation of inflammation and protection against colonic carcinogenesis 
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(Gill et al., 2006; McNeil, 1984; Velázquez et al., 1996; Vinolo et al., 2011). 
Members of the gut microbiota, in particular representatives of the lactic acid 
bacteria (LAB) and bifidobacteria, have also been shown to synthesise certain B 
vitamins which cannot be produced by the host (LeBlanc et al., 2011; LeBlanc et al., 
2013; Pompei et al., 2007). 
Changes in the composition and diversity of the gut microbiota have been implicated 
in a number of diseases, including Crohn’s disease, ulcerative colitis, irritable bowel 
disease and colorectal cancer (de Vos & de Vos, 2012), as well as increased frailty in 
the elderly (Claesson et al., 2012). A number of large scale metagenomic studies 
have focused on finding correlations between the composition of the microbiota and 
specific disease states such as obesity (Turnbaugh et al., 2008), irritable bowel 
disease (Frank et al., 2007; Greenblum et al., 2012) and diabetes (Karlsson et al., 
2013; Larsen et al., 2010). The purpose of these studies is to identify particular 
microbiota-related changes which can then be used as potential biomarkers for 
impending or fully manifest diseases, while also leading to a greater understanding 
of how the composition of the gut microbiota relates to its function in the gut 
(Bäckhed et al., 2005). 
 
1.2 General features of bifidobacteria 
Bifidobacteria are Gram positive, saccharolytic, typically Y-shaped bacteria which 
are members of the Bifidobacteriaceae family and the Actinobacteria phylum. They 
were first isolated in 1900 by Henri Tissier, when he worked in the Pasteur Institute, 
from the faeces of a breast-fed infant. Tissier recommended that such bifidobacteria 
be administered to infants suffering from diarrhoea, believing that they would 
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displace the microbes that were causing this gastrointestinal malfunction (Tissier, 
1900). Today various members of the Bifidobacterium genus, as well as strains 
belonging to the lactobacilli, are commercially exploited as so-called probiotic 
bacteria, defined as live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host (Hill et al., 2014; Stanton et al., 2005). 
As of 2014, the Bifidobacterium genus consists of 48 species, which fall within six 
phylogenetic clusters, namely (i) Bifidobacterium pseudolongum, (ii) 
Bifidobacterium pullorum, (iii) Bifidobacterium longum, (iv) Bifidobacterium 
adolescentis, (v) Bifidobacterium asteroides and (vi) Bifidobacterium boum (Lugli et 
al., 2014; Ventura et al., 2006). The vast majority of bifidobacterial species have 
been isolated from the GIT of mammals, birds or insects, as well as from sewage and 
fermented milk (Ventura et al., 2007; Ventura et al., 2014). The first bifidobacterial 
genome to be sequenced was that of B. longum subsp. longum NCC2705 (Schell et 
al., 2002) and as of December 2014, forty complete bifidobacterial genome 
sequences are available in the database of the National Centre of Biotechnology 
Information (located at the folllowing web site: 
http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi) (Table 1.1), while a 
recent study investigated another forty two draft genome sequences (Milani et al., 
2014). Nine species are represented by complete genome sequences, as well as 
recently published pangenome analyses of the Bifidobacterium breve and 
Bifidobacterium animalis subsp. lactis species, along with a core genome analysis of 
the B. adolescentis phylogenetic group, which includes the B. adolescentis, 
Bifidobacterium catenulatum and Bifidobacterium pseudocatenulatum species 
(Bottacini et al., 2014; Duranti et al., 2012; Milani et al., 2013). Bifidobacterial 
genomes typically have a GC content that varies between 58 and 61 %, and range in 
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size between 1.73 and 3.25 Mb, with the genome of Bifidobacterium biavatii the 
largest sequenced to date (Milani et al., 2014; Ventura et al., 2014). This rapidly 
increasing collection of genomic data has allowed for comprehensive investigations 











Genes Proteins Source Genbank  
No. 
Reference 
Bifidobacterium adolescentis ATCC 15703 2.1 59.20 1702 1632 Human GIT NC_008618 Unpublished 
Bifidobacterium adolescentis 22L 2.2 59.30 1812 1725 Human milk CP007443 (Duranti et al., 2014) 
Bifidobacterium animalis subsp. lactis AD011 1.93 60.50 1603 1527 Infant faeces NC_011835 (Kim et al., 2009) 
Bifidobacterium animalis subsp. lactis BI-04 1.94 60.50 1631 1567 Human faeces NC_012841 (Barrangou et al., 2009) 
Bifidobacterium animalis subsp. lactis DSM 10140 1.94 60.50 1628 1565 Fermented milk NC_012815 (Barrangou et al., 2009) 
Bifidobacterium animalis subsp. lactis BB-12 1.84 60.50 1706 1642 Human GIT NC_017214 (Garrigues et al., 2010) 
Bifidobacterium animalis subsp. lactis V9 1.94 60.50 1636 1572 Human faeces NC_017217 (Sun et al., 2010) 
Bifidobacterium animalis subsp. lactis CNCM I-2494 1.94 60.50 1724 1660 Human faeces NC_017215 (Chervaux et al., 2011) 
Bifidobacterium animalis subsp. lactis BLC1 1.94 60.50 1607 1518 Human GIT NC_017216 (Bottacini et al., 2011) 
Bifidobacterium animalis subsp. lactis ATCC 25527 1.93 60.50 1601 1538 Human GIT NC_017834 (Loquasto et al., 2013) 
Bifidobacterium animalis subsp. lactis B420 1.94 60.50 1625 1561 Human GIT NC_017866 (Stahl & Barrangou, 2012) 
Bifidobacterium animalis subsp. lactis BI-07 1.94 60.50 1661 1597 Human faeces NC_017867 (Stahl & Barrangou, 2012) 
Bifidobacterium animalis subsp. lactis Bl12 1.94 60.50 1607 1518 Human GIT NC_021593 (Milani et al., 2013) 
Bifidobacterium animalis subsp. lactis ATCC 27673 1.96 60.50 1620 1558 Human GIT NC_022523 (Loquasto et al., 2013) 
Bifidobacterium animalis RH 1.93 60.50 1603 1539 Human faeces CP007755 (Liu et al., 2014) 
Bifidobacterium asteroides PRL2011  2.17 60.10 1731 1658 Insect hindgut NC_018720 (Bottacini et al., 2012) 
Bifidobacterium bifidum PRL2010 2.21 62.70 1791 1706 Infant faeces NC_014638 (Turroni et al., 2010) 
Bifidobacterium bifidum S17 2.19 62.80 1845 1783 Infant faeces NC_014616 (Zhurina et al., 2011) 
Bifidobacterium bifidum BGN4 2.22 62.60 1902 1834 Infant faeces NC_017991 (Yu et al., 2012) 
Bifidobacterium breve ACS-071-V-Sch8b 2.33 58.70 2011 1826 Human GIT NC_017218 Unpublished 
Bifidobacterium breve UCC2003  2.42 58.70 1985 1854 Infant faeces NC_020517 (O'Connell Motherway et al., 
2011b) 
Bifidobacterium breve 12L 2.25 58.90 1847 1765 Human milk CP006711 (Bottacini et al., 2014) 
Bifidobacterium breve JCM 7017 2.29 58.70 1873 1770 Infant faeces CP006712 (Bottacini et al., 2014) 
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Bifidobacterium breve JCM 7019 2.36 58.60 1999 1915 Human faeces CP006713 (Bottacini et al., 2014) 
Bifidobacterium breve NCFB 2258 2.32 58.70 1873 1770 Infant faeces CP006714 (Bottacini et al., 2014) 
Bifidobacterium breve 689b 2.33 58.70 1914 1821 Infant faeces CP006715 (Bottacini et al., 2014) 
Bifidobacterium breve S27 2.3 58.70 1896 1748 Infant faeces CP006716 (Bottacini et al., 2014) 
Bifidobacterium coryneforme LMG 18911 1.76 60.50 1422 1364 Honeybee gut CP007287 (Milani et al., 2014) 
Bifidobacterium dentium Bd1 2.64 58.50 2195 2127 Dental caries NC_013714 (Ventura et al., 2009) 
Bifidobacterium longum NCC2705 2.26 60.11 1799 1728 Infant faeces NC_004307 (Schell et al., 2002) 
Bifidobacterium longum DJO10A 2.39 60.12 2073 2001 Human GIT NC_010816 (Lee et al., 2008) 
Bifidobacterium longum subsp. infantis ATCC 15697 2.83 59.90 2588 2416 Infant GIT NC_011593 (Sela et al., 2008) 
Bifidobacterium longum subsp. longum JDM301 2.48 59.80 2035 1958 Human faeces NC_014169 (Wei et al., 2010) 
Bifidobacterium longum subsp. longum BBMN68 2.27 59.90 1876 1804 Human faeces NC_014656 (Hao et al., 2011) 
Bifidobacterium longum subsp. longum JCM1217 2.39 60.30 2009 1924 Human faeces NC_015067 (Fukuda et al., 2011) 
Bifidobacterium longum subsp. infantis 157F 2.41 60.11 2070 1999 Infant faeces NC_015052 (Fukuda et al., 2011) 
Bifidobacterium longum subsp. longum KACC 91563 2.4 59.81 2050 1985 Infant faeces NC_017221 (Ham et al., 2011) 
Bifidobacterium longum BXY01 2.48 59.80 1997 1901 Human GIT CP008885 Unpublished 
Bifidobacterium longum subsp. longum GT15 2.34 60.00 1989 1893 Human GIT CP006741 Unpublished 




1.3 Carbohydrate metabolism in bifidobacteria 
The carbohydrate-containing fraction present in the human diet can be separated at a 
basic level into two groups, based on their digestibility by host-encoded enzymes in 
the GIT. The first group consists of simple sugars, which are absorbed in the small 
intestine either directly or following hydrolysis by host-encoded enzymes. The 
second group consists of complex carbohydrates, often plant cell wall 
polysaccharides, such as cellulose, pectin, (arabino)xylan, arabinan and resistant 
starch, that are resistant to digestion by host-encoded glycosyl hydrolases and 
absorption in the small intestine (Bond et al., 1980; Englyst et al., 1992; Lattimer & 
Haub, 2010). It has been estimated that between 10 and 60 g of dietary carbohydrate 
reaches the colon on a daily basis (Cummings & Macfarlane, 1991), providing a 
consistent nutrient supply to the gut microbiota. In addition, the mucus layer, which 
can extend up to 150 µm from the epithelial surface (Johansson et al., 2011), 
provides another source of carbohydrate in the form of the mucin glycoprotein 
(Salyers et al., 1977a). Other host-derived carbohydrates in the large intestine 
include heparan sulfate, which is present in low quantities in the mucus layer of the 
large intestine (Oshiro et al., 2001) and chondroitin sulfate which is also present in 
the colonic mucosa (Eliakim et al., 1986). In total, it is estimated that mucin and 
related muco-polysaccharides such as chondroitin sulfate provide 3-5 g of 
carbohydrate for fermentation by the intestinal microbiota per day (Stephen et al., 
1983). 
Bifidobacteria are saccharolytic organisms whose ability to colonise and survive in 
the large intestine is largely dependent on the ability to metabolise certain diet- 
and/or host-derived carbohydrates as mentioned above. The majority of the gut 
microbiota is assumed to employ the glycolytic pathway when metabolising 
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carbohydrates (Macfarlane & Macfarlane, 2003). In contrast, the characteristic 
central metabolic pathway of bifidobacteria is the fructose-6-phosphate 
phosphoketolase pathway, also known as the bifid shunt (de Vries & Stouthamer, 
1967; Scardovi & Trovatelli, 1965) (Fig. 1.1). The key enzyme of this pathway is 
fructose-6-phosphate phosphoketolase (F6PPK), the presence of which is considered 
a reliable indicator of the presence of bifidobacteria, although it is also produced by 
Gardnerella vaginalis, which belongs, like bifidobacteria, to the Bifidobacteriaceae 
family (Gao & Gupta, 2012; Gavini et al., 1996; Palframan et al., 2003). From 1 
mole of fermented glucose, the fructose-6-phosphate phosphoketolase pathway 
yields 2.5 ATP molecules, thus providing more energy than the carbohydrate 
fermentation pathways present in other gut bacteria, such as lactic acid bacteria 
(Palframan et al., 2003). However, it should be noted that this does not take into 
account the energy cost of internalising the carbohydrate substrate. In general, 
bifidobacteria internalise sugars through ABC-type transport systems, which require 
ATP (Davidson & Chen, 2004), as opposed to the cost-neutral phosphoenolpyruvate-
phosphotransferase systems (PEP-PTS; see below) (Postma et al., 1993). The 
fructose-6-phosphate phosphoketolase pathway produces SCFAs which are 
perceived to be beneficial to the host (Palframan et al., 2003). The bifid shunt-
mediated fermentation of 1 mole of hexose sugar theoretically yields 1.5 moles of 
acetate and 1 mole of lactate, while pentose sugars result in a 1:1 ratio of acetate to 
lactate, although these ratios can vary depending on the carbon source, growth phase 
of the cells and the environmental pH (Macfarlane & Macfarlane, 2003; Palframan et 
al., 2003).  
When the first bifidobacterial genome, that of B. longum subsp. longum NCC2705, 
was sequenced in 2002 it was noted that more than 8.5 % of the predicted proteins 
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were assigned to the cluster of orthologous groups (COG) in the carbohydrate 
transport-metabolism category (Schell et al., 2002), a characteristic which was later 
found to be shared among the genomes of many other bifidobacterial species (Lugli 







Figure 1.1: Schematic representation of carbohydrate degradation through “bifid shunt” in bifidobacteria. Abbreviations: AckA, acetate kinase; 
Adh2, aldehyde-alcohol dehydrogenase 2; Aga, α-galactosidase; Agl, α-glucosidase; Bgl, β-glucosidase; GalE1, UDP-glucose 4-epimerase; 
GalK, galactokinase; GalM, galactose mutarotase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase C; GlkA, glucokinase; Gnt, 6-
phosphogluconate dehydrogenase; Gpi, glucose 6-phosphate isomerase; Frk, fruktokinase; F6PPK, fructose-6-phosphoketolase; FucI, L-fucose 
isomerase; FucK, L-fuculose kinase; FucA, L-fuculose-1P aldolase; FucO, lactaldehyde reductase; Ldh2, lactate dehydrogenase; LNBP, lacto-N-
biose phosphorylase;Pgk, phosphoglyceric kinase; Pgm, phosphoglucomutase; Pfl, formate acetyltransferase; Rk, ribokinase; R5PI, ribose-5-
phosphate isomerase; R5PE, ribulose-5-phosphate epimerase; Tal, transaldolase; Tkt, transketolase; TpiA, triosephosphate isomerase;UgpA, 
UTP-glucose-1-phosphate uridylyltransferase; XPPKT, xylulose-5-phosphate/fructose-6-phosphate phosphoketolase; XylA, xylose 




1.4 Carbohydrate uptake by bifidobacteria 
Carbohydrate uptake by bifidobacteria is achieved through a combination of ATP-
binding cassette (ABC) transporters, proton symporters and proton motive force-
driven permeases (Pokusaeva et al., 2011a; Schell et al., 2002; Ventura et al., 2009). 
PEP-PTS (phosphoenolpyruvate-phosphotransferase systems) systems are less 
frequently identified in bifidobacterial genomes compared to other uptake systems, 
with Bifidobacterium bifidum PRL2010 being an exception. This strain is predicted 
to encode just two ABC-type transport systems, four PEP-PTS systems and four 
secondary transporters (Turroni et al., 2012a). PEP-PTS systems have been 
associated with the transport of glucose and fructose in B. breve NCFB 2257 
(Degnan & Macfarlane, 1993). Four putative PEP-PTS systems were identified on 
the B. breve UCC2003 genome (Maze et al., 2007), however, carbohydrate uptake in 
this strain typically involves ABC-type transport systems (Egan et al., 2014a; 
O'Connell et al., 2013; O'Connell Motherway et al., 2013; Pokusaeva et al., 2011a). 
An in-depth study of the transport systems of B. longum subsp. longum NCC2705 
identified 13 ABC-type transport systems, predicted to be involved in the transport 
of di-, tri- and higher order oligosaccharides, three permeases of the major facilitator 
superfamily predicted to internalise glucose, lactose and sucrose, and just one PEP-
PTS for the transport of glucose (Parche et al., 2007). The predominance of ABC 
transporters on bifidobacterial genomes is perhaps a reflection of the availability of 
more complex carbohydrates rather than monosaccharides in the large intestine, as 
mentioned above. ABC transporters, in particular the CUT1 subfamily, transport a 
variety of oligosaccharides (Schneider, 2001), whereas the PEP-PTS system is 
typically limited to monosaccharides or certain disaccharides such as sucrose 
(Deutscher et al., 2006; Lengeler et al., 1982). 
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1.5 Glycosyl hydrolases in bifidobacteria 
As mentioned above, the carbohydrates present in the large intestine are believed to 
be predominantly di-, tri-, or higher order oligosaccharides, thus their metabolic 
processing requires them to be degraded to their constituent monosaccharides. This 
necessitates a specific type of enzyme, namely a glycosyl hydrolase (GH). GHs are 
responsible for the hydrolysis of the glycosidic bond between monosaccharides and 
are found in all three kingdoms (Archaebacteria, Eubacteria and Eukaryota) 
(Cantarel et al., 2009; Henrissat, 1991). In 1991, Bernard Henrissat devised a 
method of classifying GHs based on their amino acid sequence similarity and, as of 
December 2014, 133 different GH families have been recognised and are listed at 
www.cazy.org (Henrissat, 1991; Lombard et al., 2014). According to the current 
information on www.cazy.org (December 2014), bifidobacterial genomes are 
predicted to encode between 25 and 87 GHs, which in turn represent between 12 and 
28 GH families per genome (Table 1.2). The currently available information on this 
website lists the genome of Bifidobacterium dentium Bd1 as encoding the highest 
number of predicted GHs among bifidobacteria (87) (Ventura et al., 2009). When 
this genome was sequenced it was suggested that the relatively high number of 
predicted GHs is a reflection of the typical niche of this bacterium, i.e. the oral 
cavity, where the bacteria are exposed to the full contents of the ingested foods 
(Ventura et al., 2009). The number of predicted GHs on the genomes of B. animalis 
subsp. lactis DSM 10140 and Bl-04 are among the lowest (35 and 38, respectively) 
and this correlates with the relatively small size of the typical B. animalis subsp. 




Table 1.2: Glycosyl hydrolase (GH)-encoding genes on bifidobacterial genomes. 




Bifidobacterium adolescentis 22L 22 61 
Bifidobacterium adolescentis ATCC 15703 22 58 
Bifidobacterium animalis RH 16 39 
Bifidobacterium animalis subsp. animalis ATCC25527 13 34 
Bifidobacterium animalis subsp. lactis AD011 16 38 
Bifidobacterium animalis subsp. lactis ATCC 27673 17 35 
Bifidobacterium animalis subsp. lactis B420 16 38 
Bifidobacterium animalis subsp. lactis BB12 16 42 
Bifidobacterium animalis subsp. lactis Bi-07 16 40 
Bifidobacterium animalis subsp. lactis Bl-04 16 38 
Bifidobacterium animalis subsp. lactis Bl-12 15 36 
Bifidobacterium animalis subsp. lactis BLC1 16 38 
Bifidobacterium animalis subsp. lactis CNCM I-2494 16 40 
Bifidobacterium animalis subsp. lactis DSM 10140 16 35 
Bifidobacterium animalis subsp. lactis V9 16 38 
Bifidobacterium asteroides PRL2011  22 48 
Bifidobacterium bifidum BGN4 22 41 
Bifidobacterium bifidum PRL2010 22 43 
Bifidobacterium bifidum S17 22 39 
Bifidobacterium breve 12L 22 47 
Bifidobacterium breve 689b 27 55 
Bifidobacterium breve ACS-071-V-Sch8b 22 49 
Bifidobacterium breve JCM 7017 24 51 
Bifidobacterium breve JCM 7019 26 54 
Bifidobacterium breve NCFB 2258 25 51 
Bifidobacterium breve S27 24 50 
Bifidobacterium breve UCC2003 26 55 
Bifidobacterium coryneforme LMG18911 14 26 
Bifidobacterium dentium Bd1 25 87 
Bifidobacterium indicum LMG 11587 13 25 
Bifidobacterium longum 105-A 23 70 
Bifidobacterium longum BXY01 28 65 
Bifidobacterium longum DJO10A 25 67 
Bifidobacterium longum NCC2705 24 56 
Bifidobacterium longum subsp. infantis 157F 28 61 
Bifidobacterium longum subsp. infantis ATCC15697 22 46 
Bifidobacterium longum subsp. infantis JCM1222 23 49 
Bifidobacterium longum subsp. longum BBMN68 24 60 
Bifidobacterium longum subsp. longum F8 23 54 
Bifidobacterium longum subsp. longum GT15 25 59 
Bifidobacterium longum subsp. longum JCM1217 23 59 
Bifidobacterium longum subsp. longum JDM301 28 64 
Bifidobacterium longum subsp. longum KACC91563 22 55 
Bifidobacterium pseudocatenulatum D2CA 20 60 
Bifidobacterium thermophilum RBL67 12 31 
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Interest in GHs encoded by bifidobacteria has grown, which is not surprising when it 
is considered that GH activity of a bifidobacterial species or strain is likely to 
correspond to the ability to utilise certain prebiotics. A prebiotic is defined as “a 
selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microflora that confers benefits 
upon host well-being and health” (Gibson et al., 2004). In order to be considered a 
prebiotic, an ingredient must be scientifically proven to (i) resist gastric acidity, 
hydrolysis by mammalian enzymes and gastrointestinal absorption, (ii) be fermented 
by the intestinal microbiota, and (iii) stimulate the growth and/or activity of 
intestinal bacteria associated with health and well-being (Gibson et al., 2004). As 
mentioned above, a significant proportion of the carbohydrate ingested by the host 
reaches the colon undigested, making them candidates for prebiotic status. Such 
prebiotic candidates include inulin, fructo-oligosaccharides (FOS), (trans)galacto-
oligosaccharides (TOS/GOS) and lactulose (Gibson et al., 2004; Macfarlane et al., 
2006). Inulin, which belongs to a class of dietary fibre known as fructans, has long 
been associated with promoting bifidobacterial growth, using both in vivo and in 
vitro studies (reviewed in Gibson et al., 2004). TOS is a mixture of oligosaccharides 
derived from lactose by enzymatic transglycosylation (Crittenden & Playne, 1996). 
In a clinical trial, TOS has been shown to increase bifidobacterial numbers in 
patients with irritable bowel syndrome (IBS) and alleviate IBS-associated symptoms 
(Silk et al., 2009). Lactulose is a disaccharide formed by the isomerisation of lactose. 
In a clinical trial using 16 healthy volunteers, it was found that 10 g of lactulose per 
day could significantly increase faecal bifidobacterial counts (Bouhnik et al., 2004). 
Other potential prebiotics include xylo-oligosaccharides (XOS), fructo-
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oligosaccharides (FOS) and isomalto-oligosaccharides (Gibson et al., 2004; 
Macfarlane et al., 2006).  
There have been previous review articles dedicated to GHs characterised from 
bifidobacteria and their relation to prebiotic metabolism (Pokusaeva et al., 2011a; 
van den Broek & Voragen, 2008; van den Broek et al., 2008) and since then 
additional GHs specific for potential prebiotics have been characterised. For 
example, B. breve UCC2003 encodes an extracellular β1-4 endogalactanase (GalA) 
that hydrolyses galactan to produce galacto-oligosaccharides, which are then 
internalised and further metabolised to galactose by a β-galactosidase (GalG) 
(O'Connell Motherway et al., 2011a). Four β-galactosidases were characterised from 
B. longum subsp. infantis ATCC15697, which release monosaccharides from GOS 
(Garrido et al., 2013), while an exo-β1-3-galactanase from B. longum subsp. longum 
JCM1217 was active on β1-3 linked GOS as well as arabinogalactan (Fujita et al., 
2014). A novel α-glucosidase, MelD, as well as two α-galactosidases, RafD and 
MelE, from B. breve UCC2003, were shown to exhibit activity towards plant-
derived raffinose and melibiose (O'Connell et al., 2013). A β1-4 xylanase capable of 
the complete hydrolysis of XOS was characterised from B. adolescentis DSMZ 
18350 (Amaretti et al., 2013). Finally, two arabinofuranosidases, AbfA and AbfB, 
were characterised from B. adolescentis LMG10502 which were shown to hydrolyse 





1.6 Metabolism of host derived carbohydrates by bifidobacteria 
1.6.1 Mucin metabolism by bifidobacteria 
The GIT is coated with a continuous layer of mucus, the main component of which is 
mucin glycoprotein. Given its ubiquity, and the fact that carbohydrate constitutes 
approximately 80 % of the total mucin mass (Larsson et al., 2009), it is surprising 
that only a small proportion of the culturable intestinal microbiota is believed to 
encode enzymes required for (partial) mucin degradation into free sugars, including 
members of the Bifidobacterium, Bacteroides and Ruminococcus genera, and the 
more recently characterised gut commensal Akkermansia muciniphila (Crost et al., 
2013; Derrien et al., 2004; Hoskins et al., 1985; Salyers et al., 1977b; Sonnenburg et 
al., 2005; Turroni et al., 2010). Mucins are both highly complex and diverse. The 
original investigations on the (bio)chemical composition of human colonic mucin 
described twenty-one discrete oligosaccharide structures (Podolsky, 1985). It is now 
presumed that MUC2, the prominent secretory mucin in the colon, contains more 
than 100 structurally different O-linked glycans, with four distinct core structures, 
which can be elongated by the addition of galactose, N-acetylgalactosamine 
(GalNAc) and N-acetylglucosamine (GlcNAc), and substituted with sialic acid, 
fucose or sulfate residues in terminal or branched positions (Capon et al., 2001; 






Figure 1.2: Representative examples of complex O-GalNAc glycans from human mucin (Varki et al., 2009). The core structures, 1-4, are 
indicated with a grey box. Each core structure can be elongated by the addition of galactose, GalNAc and GlcNAc. The oligosaccharide chains 
can be substituted with sialic acid, fucose or sulfate residues in. Ser, serine; Thr, threonine. The monosaccharide key is shown on the right.  
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Mucin-degrading bifidobacteria, first described in 1985, were shown to 
constitutively express extracellular enzymes capable of degrading oligosaccharide 
side chains of gut mucins (Hoskins et al., 1985). The degradation of mucin occurs 
sequentially with the removal of component monosaccharides, thus requiring a 
multitude of enzymes with various glycosidic specificities (Corfield et al., 2002) 
(illustrated in Fig. 1.3). Cell surface-anchored GHs were later characterised, 
including two α-L-fucosidases, AfcA and AfcB, from B. bifidum JCM1254 (Ashida 
et al., 2009; Katayama et al., 2004) and an endo-α-N-acetylgalactosaminidase, 
EngBF, from B. longum subsp. longum JCM1217, which hydrolyses the linkage 
between GalNAc of the core 1 disaccharide and the serine or threonine residue of the 
proteinaceous backbone (Fujita et al., 2005). Additionally, an extracellular, 
membrane bound, exo-α-sialidase, SiaBb, that releases sialic acid from porcine 
gastric mucin was characterised from B. bifidum JCM1254 (Kiyohara et al., 2011). 
Recently, a cell-membrane anchored α-N-acetylglucosaminidase, designated AgnB, 
which is specific to the GlcNAc-α1-4-Gal structure found in gastroduodenal and 
colonic mucin, was characterised from B. bifidum JCM1254 (Shimada et al., 2014). 
Interestingly, the only intracellular mucin-degrading enzyme characterised from B. 
bifidum is an α-N-acetylgalactosaminidase (designated NagBb) which hydrolyses the 
α1-linkage between GalNAc and the serine or threonine residue of mucin core 3 
structures. It was hypothesised by the authors that extended mucin core 3 structures 
are extracellularly hydrolysed by sialidase (SiaBb), β-galactosidase (BbgIII) and β-
N-acetylhexosaminidase (BbhI) activity, resulting in GalNac-α1-Ser/Thr (also 
known as the Tn antigen), which is assimilated through unknown transporters and 
intracellularly hydrolysed by NagBb (Kiyohara et al., 2011; Kiyohara et al., 2012; 







Figure 1.3: Schematic representation of mucin degradation by B. bifidum JCM1254 glycosyl hydrolases. (A) In extended core 1 and core 2 
structures, terminal sialic acid or fucose residues are removed by sialidase (SiaBb) or fucosidase (AfcA or AfcB) activity, respectively. The 
oligosaccharide chain is sequentially degraded by β-galactosidase (BbgIII) and β-N-acetylhexosaminidase (BbhI) activity. The resulting GNB is 
cleaved from the Ser/Thr amino acids by an endo-α-N-acetylgalactosaminidase (EngBF) and assimilated into the cell through a GNB/LNB-
specific solute binding protein of an ABC transport system. (B) Core 3 mucin structures are similarly degraded, followed by the hydrolysis of the 
GalNAc-Ser/Thr linkage by the NagBb enzyme. The characterised glycosyl hydrolases are indicated in red. The monosaccharide key is shown at 




When the genome of B. bifidum PRL2010 was sequenced in 2010, it was observed 
that 60 % of the identified GHs are linked to mucin degradation (Turroni et al., 
2010). This included two putative exo-α-sialidases, two putative α-L-fucosidases and 
a predicted endo-α-N-acetylgalactosaminidase, all of which are presumed to be 
extracellular based on to the presence of a putative signal peptide (Turroni et al., 
2010). Other possible mucin-degrading enzymes encoded by the genome of B. 
bifidum PRL2010 include four N-acetyl-β-hexosaminidases (two of which are 
predicted to be extracellular) and four β-galactosidases (one of which is presumed to 
be extracellular) (Turroni et al., 2010). Comparative genome hybridisation analysis 
revealed that most of the genes encoding the aforementioned enzymes are conserved 
within the examined members of the B. bifidum species and of a number of 
bifidobacterial strains tested, only members of this species were capable of growth in 
media containing porcine gastric mucin as the sole carbon source (Turroni et al., 
2010). That such a large number of predicted GHs are extracellular seems 
significant, especially when it is considered that despite the presence of genes 
encoding a predicted sialidase and fucosidase on its genome, sialic acid and fucose 
only support poor/no growth of B. bifidum PRL2010 (Turroni et al., 2012a). In a 
recent in vitro study it was shown that fucose and galactose accumulate in the 
medium during B. bifidum PRL2010 growth on porcine gastric mucin (Egan et al., 
2014b). Indeed, it has been suggested that the function of these enzymes is to 
provide the strain access to specific mucin components, for example galacto-N-biose 
(Galβ1-3GalNAc; GNB) and galacto-N-tetraose (Galβ1-3-GalNAc-β1-3Galβ1-
4GlcNAc; GNT) (Turroni et al., 2010; Turroni et al., 2014). The metabolic cluster 
required for the utilisation of GNB, as previously characterised in B. longum subsp. 
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longum JCM1217, is conserved among B. bifidum strains (Kitaoka et al., 2005; 





1.6.2 HMO metabolism by bifidobacteria 
Mucin-derived oligosaccharides and human milk oligosaccharides (HMOs) share a 
number of primary monosaccharide components including galactose, GlcNAc, 
glucose, sialic acid and fucose (Bode & Jantscher-Krenn, 2012; Urashima et al., 
2012). There are at least 200 known HMO structures, yet they are not believed to be 
metabolised by the infant and hence reach the colon undigested (Ninonuevo et al., 
2006). The type 1 structure found among HMOs is lacto-N-biose (Galβ1-3GlcNAc; 
LNB), which requires the same metabolic pathway as GNB from mucin (Kitaoka et 
al., 2005; Nishimoto & Kitaoka, 2007), and the type II structure is N-
acetyllactosamine (Galβ1-4GlcNAc). HMOs containing the type I structure are more 
abundant than those containing the type II structure (Urashima et al., 2012). Both 
LNB and N-acetyllactosamine are linked to a lactose residue at their reducing end by 
a β1-3 linkage to form lacto-N-tetraose (Galβ1-3GlcNAcβ1-3Galβ1-4Glc; LNT) and 
lacto-N-neotetraose (Galβ1-4GlcNAcβ1-3Galβ1-4Glc; LnNT), respectively (Bode & 
Jantscher-Krenn, 2012). The oligosaccharide chains can be elongated with up to a 
dozen repeats of LNB or N-acetyllactosamine, with further modification of the 
backbone through the addition of fucose and sialic acid to the non-reducing end or to 
an internal GlcNAc (Bode & Jantscher-Krenn, 2012). In addition, a lactose residue 
can be fucosylated through an α1-2/3 linkage or sialylated through an α2-3/6 linkage, 
to produce fucosyllactose (2’ or 3’ fucosyllactose) or sialyllactose (3’ or 6’ 
sialyllactose), respectively (illustrated in Fig. 1.4). Approximately 77 % of HMOs 
are fucosylated and 16 % are sialylated (Ninonuevo et al., 2006). A small number of 
HMO structures contain both sialic acid and fucose, such as 3’sialyl-3-fucosyllactose 
(Bode & Jantscher-Krenn, 2012) and monofucosyl-monosialyllacto-N-hexaose 
(Ninonuevo et al., 2006). In quantitative terms, three of the four most abundant 
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HMOs are fucosylated, namely 2’-fucosyllactose (0.45 to 3.93 g L-1), lacto-N-
fucopentaose (0.67 to 2.08 g L-1) and lacto-N-difucohexaose (0.5 to 1.87 g L-1) 
(Asakuma et al., 2007; Chaturvedi et al., 2001; Coppa et al., 1993; Kunz et al., 








Figure 1.4: Structures of selected HMO mentioned in this review. The addition of fucose (α1-2 or α1-3 linkage) or sialic acid (α2-3 or α2-6) 
linkage to lactose results in fucosyllactose or sialyllactose, respectively. Alternatively, lactose can be elongated with LNB (Type I structures) or 
N-acetyllactosamine (Type II structures). Further additions in a β1-3 linkage extends the chain (para HMO) or a β1-6 linkage introduces chain 




HMOs have long been associated with promoting bifidobacterial growth (György et 
al., 1954) and in recent years the metabolic pathways by which certain species of 
bifidobacteria utilise HMOs have come under intense scrutiny. Much of this research 
has focused on B. bifidum and B. longum subsp. infantis, and it seems that these two 
species are the most adapted to HMO utilisation. Given the similar oligosaccharide 
structures and monosaccharide components of mucin and HMOs, it is not surprising 
that B. bifidum PRL2010 was shown to achieve good growth on HMOs (Turroni et 
al., 2010). A later study showed that B. bifidum JCM1254 also achieves high levels 
of growth on HMOs, while providing interesting analysis of the HMO components 
utilised by this strain (Asakuma et al., 2011). Similar to B. bifidum PRL2010 
degradation of mucin, it was found that hydrolysis of HMO components occurs 
extracellularly, as evident from a decrease in LNT and 2’-fucosyllactose and a 
concurrent increase in LNB, fucose and lactose in the media in the early logarithmic 
growth phase, indicating extracellular hydrolysis of these oligosaccharides 
(Asakuma et al., 2011). B. bifidum JCM1254 encodes an extracellular α1-2 
fucosidase, which is believed to be required for growth on 2’-fucosyllactose (Ashida 
et al., 2009; Katayama et al., 2004). A predicted extracellular lacto-N-biosidase 
which liberates LNB from LNT was also characterised from this strain (Wada et al., 
2008) (Fig. 1.5B). By mid-exponential phase, 2’-fucosyllactose, LNB and LNT were 
absent, while only trace amounts of lactose remained. After 24 h of growth, all 
detectable oligosaccharides had been consumed, with only fucose and galactose 
remaining in the growth medium (Asakuma et al., 2011). The results of this study 
were in accordance with previous findings, which showed that B. bifidum utilises 
high molecular weight HMOs, and that fucose accumulates in the growth medium 
(Ward et al., 2007). In a very recent publication, B. bifidum PRL2010 was shown to 
32 
 
extracellularly hydrolyse 3’ sialyllactose, of which it only utilises lactose, with sialic 
acid remaining in the medium (Egan et al., 2014a).  
In the aforementioned study (Ward et al., 2007), five bifidobacterial strains 
(representing four bifidobacterial species) namely B. longum subsp. longum 
ATCC15707, B. longum subsp. infantis ATCC15697, B. breve ATCC27539, B. 
bifidum ATCC29521 and B. adolescentis ATCC15703, were tested for their ability 
to utilise HMOs. B. longum subsp. infantis ATCC15697 achieved three times the cell 
density compared to that of the other strains during growth on HMOs as a sole 
carbon source. Interestingly, B. longum subsp. infantis ATCC15697 and B. breve 
ATCC27539 were shown to utilise the five monosaccharide components of HMOs, 
namely glucose, galactose, GlcNAc, fucose and sialic acid, whereas B. bifidum 
ATCC29521, B. adolescentis ATCC15703 and B. longum subsp. longum 
ATCC15707 were shown to only utilise glucose and galactose (Ward et al., 2007). 
Another study showed that B. longum subsp. infantis ATCC15697 consumed a 
significantly larger proportion of available HMOs, compared to B. longum subsp. 
longum DJO10A and B. breve ATCC15700 (63.9 %, 35.2 % and 24.4 %, 
respectively) (LoCascio et al., 2007). These authors furthermore showed that crude 
cell extract of the B. longum subsp. infantis ATCC15697 strain grown on HMOs 
contains sialidase and fucosidase activity, which was absent from the crude cell 
extract of the other tested bifidobacterial strains, indicative of the presence of 
intracellular fucosidase and sialidase enzymes in B. longum subsp. infantis 
ATCC15697 (LoCascio et al., 2007). When the genome of B. longum subsp. infantis 
ATCC15697 was first sequenced, it was noted that it contains a 43 kb gene cluster, 
comprised of 30 genes, dedicated to the metabolism of HMO (Sela et al., 2008). This 
cluster is conserved among B. longum subsp. infantis strains, yet interestingly, is 
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absent in the genomes of B. longum subsp. longum strains, which consequently 
cannot utilise HMOs as a sole carbon source (LoCascio et al., 2010; Schell et al., 
2002; Sela et al., 2008). Instead, B. longum subsp. longum strains possess gene 
clusters required for the metabolism of the plant-derived pentose sugars, xylose and 
arabinose, genes which are absent or partially present as remnants in B. longum 
subsp. infantis (Schell et al., 2002; Sela & Mills, 2010).  
Some of the GHs involved in HMO metabolism in B. longum subsp. infantis 
ATCC15697 include an α1-2 fucosidase, an α1-3/4 fucosidase, two β-galactosidases, 
three N-acetylhexosaminidases and an α2-3/6 sialidase, all of which lack a signal 
sequence at the N-terminal and are therefore presumed to be intracellular (Sela et al., 
2008; Sela et al., 2011; Sela et al., 2012; Yoshida et al., 2012). These findings 
suggest that B. longum subsp. infantis ATCC15697 internalises particular intact 
HMOs, which are then degraded sequentially by intracellular GHs (Sela & Mills, 
2010) (Fig. 1.5). For this purpose, B. longum subsp. infantis ATCC15697 encodes 
twenty genes predicted to be Family 1 solute binding proteins (associated with 
fourteen predicted ABC-type transport systems) for the transport of oligosaccharides, 
twice as many as other bifidobacterial genomes (Garrido et al., 2011; Sela et al., 
2008; Tam & Saier, 1993). Of these, the solute binding proteins corresponding to 
locus tags Blon_0883 and Blon_2177 recognise the type I glycans LNB and GNB, 
while that specified by Blon_2177 also recognises the abundant HMO structures 
LNT, lacto-N-hexaose (LNH) and lacto-N-octaose (Garrido et al., 2011; Kogelberg 
et al., 2004). The predicted solute binding proteins specified by Blon_2344 and 
Blon_2347, which are located within the previously mentioned HMO cluster on the 
genome of B. longum subsp. infantis ATCC15697, recognise type II glycans such as 







Figure 1.5: Schematic representation of the degradation of sialylated Type I and Type II HMO by B. longum subsp. infantis ATCC15697 and B. 
bifidum JCM1254. (A) B. longum subsp. infantis ATCC15697 degrades sialylated-LNT and sialylated-LNnT sequentially, beginning with the 
removal of sialic acid by NanH2 activity, followed by the removal of Gal from the non-reducing end by the β-galactosidases, Bga42A (LNT) or 
Bga2A (LNnT). The resulting lacto-N-triose is hydrolysed to lactose and GlcNAc by N-acetylglucosaminidase (Blon_2355) activity. B. bifidum 
JCM1254 extracellularly degrades Type II HMO in a similar manner. (B) B. bifidum JCM 1254 extraceullularly cleaves Type I HMO through 
lacto-N-biosidase (LnbB) activity, producing lactose and GNB which are assimilated into the cell. Glycosyl hydrolases characterised from B. 
longum subsp. infantis ATCC15697 and B. bifidum JCM1254 are indicated in blue and red, respectively. The monosaccharide key is shown at 
the bottom of the figure.  
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Thus, this strain can assimilate a substantial number of different HMOs and degrade 
them intracellularly to their monosaccharide components for further metabolic 
processing. The limitation to this strategy is that only HMOs of a certain degree of 
depolymerisation (DP ≤ 8) can be consumed by the strain (LoCascio et al., 2007), 
due to transporter specificity or the steric factors which inhibit the transport of high 
molecular weight substrates across the cell membrane (Sela & Mills, 2010). This is 
in contrast to the strategy of extracellular hydrolysis employed by B. bifidum, which 
allows it to depolymerise the high molecular weight HMOs that are inaccessible to 
other bifidobacterial species. 
B. longum subsp. infantis and B. bifidum have therefore adopted divergent strategies 
in the utilisation of similar host-derived carbohydrates. A third possible strategy 
employed by certain bifidobacterial species is cross-feeding on the mucin and HMO 
components released by the extracellular activity of another (bifido)bacterial species. 
It has long been hypothesised that extracellular degradation of large polysaccharides 
such as mucin may provide nutritional support to other enteric bacteria (Hoskins et 
al., 1985), while it was later suggested that cross-feeding on HMO may occur 
between bifidobacterial species, with particular reference to B. bifidum and B. breve 
(Ward et al., 2007). Certain strains of B. breve can metabolise fucosylated HMOs, 
although the overall utilisation of HMOs is moderate compared to B. longum subsp. 
infantis ATCC15697 (Ruiz-Moyano et al., 2013). However, as mentioned above, it 
was previously shown that B. breve ATCC15700 can utilise all monosaccharide 
components of HMO, as well as LNT and LNnT (LoCascio et al., 2007; LoCascio et 
al., 2009; Ward et al., 2007). The metabolic pathway by which B. breve UCC2003 
utilises sialic acid has been described (Egan et al., 2014a). It is possible that B. breve 
relies on its ability to utilise a broad range of mono- and oligosaccharides 
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(Pokusaeva et al., 2011a) to scavenge the mucin and HMO components released by 
the extracellular mucin and HMO-degrading activities of B. bifidum and perhaps 
other (bifido)bacteria. Such cross-feeding between bifidobacterial species was shown 
for α2-3 linked sialyllactose: B. breve UCC2003 was shown to metabolise sialic acid 
released by the exo-sialidase activity of B. bifidum PRL2010 (Egan et al., 2014a). 
Similarly, B. breve UCC2003 was shown to exhibit growth and sustain viability in 
medium containing mucin, yet only in the presence of B. bifidum PRL2010 (Egan et 
al., 2014b). Therefore, cross-feeding represents a third strategy by which certain 








Figure 1.5: Schematic representation of the strategies employed by three bifidobacterial species to utilise host derived glycans using 
lacto-N-difucosylhexaose (LNDH) and extended mucin core 1 structures as examples. (A) B. longum subsp. infantis internalises intact 
HMO through a considerable number of ABC transporters, followed by intracellular hydrolysis of the HMO to its constituent parts. (B) 
B. bifidum hydrolyses large HMO and mucin oligosaccharides using a number of extracellular GHs. The resulting disaccharides such as 
GNB and LNB are internalised, but many monosaccharides are not. (C) B. breve internalises the monosaccharides released by B. 
bifidum (and other intestinal mucin-degrading bacteria). B. breve may also internalise a small number of HMOs such as LNT and LNnT. 
The monosaccharide key is shown at the bottom of the figure. GNB, galacto-N-biose; LNB, lacto-N-biose. 
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1.6.3 Metabolism of N-linked glycoproteins 
Proteins are the fourth most abundant component of human milk, behind lactose, 
lipids and HMO (Table 1.3), and it is estimated that 70 % of the most abundant 
proteins in milk are glycosylated (Froehlich et al., 2010). Like mucin, glycosylation 
can be O-linked to a serine or threonine residue, or N-linked to an asparagine residue 
via a GlcNAc monomer (Froehlich et al., 2010; Picariello et al., 2008). All N-linked 
glycans contain the core pentasaccharide Man3GlcNAc2, which can be further 
modified to produce one of three structures. In high mannose structures, the core 
pentasaccharide is extended by another two to six mannose residues. Complex 
structures contain no additional mannose residues but may have up to five antennae 
consisting of GlcNAc, galactose and fucose, and are often decorated with sialic acid 
residues. Hybrid glycans comprise of a combination of high mannose and complex 
branches (Morelle & Michalski, 2007). Bacterial metabolism of N-glycans has 
primarily been associated with pathogens such as Enterococcus faecalis, which 
utilises the high mannose-type N-glycan RNaseB (Roberts et al., 2000), and 
Capnocytophaga canimorsus, which utilises the complex-type N-glycans fetuin and 
IgG (Renzi et al., 2011). The ability to utilise N-glycans is associated with the 
presence of an extracellular enzyme, endo-β-N-acetylglucosaminidase, which 
cleaves the pentasaccharide core between the GlcNAc residues, releasing the 
oligosaccharide chain (Roberts et al., 2001; Varki et al., 2009).  
Recent research has shown that some bifidobacterial species also display 
extracellular endo-β-N-acetylglucosaminidase activity (Garrido et al., 2012). B. 
longum subsp. infantis ATCC15697 was shown to degrade the high mannose-
containing glycoprotein RNaseB, yet interestingly, other B. longum subsp. infantis 
strains were shown to exhibit very little hydrolytic activity towards this substrate, 
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suggesting that this is a strain-specific characteristic (Garrido et al., 2012). Of the 
nine B. longum subsp. longum strains tested, only four demonstrated endo-β-N-
acetylglucosaminidase activity, an observation that is consistent with this 
subspecies’ preference for plant-derived polysaccharides (Schell et al., 2002), while 
members of the B. bifidum species display no activity towards this substrate (Garrido 
et al., 2012). In contrast, the B. breve strains JCM 7019 and KA179 were shown to 
display high activity towards this substrate, completely deglycosylating RNaseB and 
consistent with this it was shown that heavily N-glycosylated cell wall proteins from 
Saccharomyces cerevisiae can support growth of B. breve strains SC139 and KA179 
(Garrido et al., 2012). This presents an interesting scenario where B. bifidum and B. 
breve may collaborate to access N-glycans, whereby the endo-β-N-
acetylglucosaminidase activity of B. breve liberates the oligosaccharide chain, which 
is then further degraded by the sialidase and fucosidase activities of B. bifidum to 
remove sialic acid and fucose residues, thus introducing a mutually beneficial 
partnership between these two species of bifidobacteria. Characterisation of two 
endo-β-N-acetylglucosaminidases, EndoBl-1 and EndoBl-2, from B. longum subsp. 
infantis ATCC15697 and B. longum subsp. infantis SC142, respectively, revealed 
activity against both high mannose and complex glycans, while Endo-BL1 was also 
active on lactoferrin from human milk, another example of this strain’s adaptation to 






Table 1.3: Abundance of the four primary components of human milk. 
Milk Component Quantity (g L-1) References 
Lactose 43-70 (Fusch et al., 2011; Mitoulas et al., 2002; Silvestre et al., 2014; Thurl et al., 2010) 
Lipids 36-43 (Mitoulas et al., 2002; Silvestre et al., 2014) 
HMOs 5-23 (Coppa et al., 1993; Kunz et al., 2000; Thurl et al., 2010) 




1.6.4 Sulfatase activity in bacteria 
Host-derived glycoproteins such as mucin, as well as proteoglycans such as 
chondroitin sulfate and heparan sulfate which are found in the colonic mucosa and 
human milk (Eliakim et al., 1986; Newburg et al., 1995; Oshiro et al., 2001), are 
often highly sulfated (Fig. 1.7). Three sulfated oligosaccharide structures have also 
been isolated from human milk, although they are present only in minute quantities 
(>100 µg ml-1) (Guérardel et al., 1999). As described above, the O-linked glycans of 
human colonic mucin have four distinct core structures bound to a serine or 
threonine residue, namely Galβ1-3GalNAc (Core 1, GNB), GlcNAcβ1-6(Galβ1-
3)GalNAc (Core 2), GlcNAcβ1-3GalNAc (Core 3) and GlcNAcβ1-6(GlcNAcβ1-
3)GalNAc (Core 4) (Fig. 1.2). In human colonic mucin, these structures can carry 
sulfate residues, a potential purpose of which is to protect the mucin against bacterial 
glycosidases (Brockhausen, 2003). However, glycosulfatase activity has been 
identified in enteric bacteria. Bacteroides thetaiotaomicron and Bacteroides ovatus 
were initially predicted to produce sulfatases due to their ability to utilise the highly 
sulfated sugars, chondroitin sulfate and heparan (Salyers et al., 1977b). 
Subsequently, a glycosulfatase purified from Prevotella strain RS2 was shown to 





Figure 1.7: Representative examples of the structures of heparan sulfate and chondroitin sulfate (modified from Varki et al., 2009). 
Heparan sulfate is a linear polysaccharide consisting of repeating disaccharide units of D-glucosamine and β-D-glucuronic acid. The D-
glucosamine monomer can be N-acetylated or N-sulfated (represented by NS), both of which can subsequently 6-O-sulfated. The 
glucuronic acid monomer can be 2-O-sulfated. Chondroitin sulfate is a linear polysaccharide consisting of repeating disaccharide units 
of D-glucuronic acid and GalNAc. The GalNAc monomers can be 4 or 6-O-sulfated. The monosaccharide key is shown on the right.
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Sulfatases constitute a family of hydrolases that are highly conserved between 
prokaryotes and eukaryotes, and whose substrate specificity can range from 
glycoproteins and glycolipids to hydroxysteroids (von Figura et al., 1998). In both 
prokaryotes and eukaryotes, sulfatases are unique in that they require a 3-oxoalanine 
(typically called Cα-formylglycine or FGly) residue at the active site (Bond et al., 
1997; Lukatela et al., 1998). The absence of this modification results in severely 
decreased sulfatase activity (Schmidt et al., 1995). Eukaryotic sulfatases carry a 
conserved cysteine (Cys) residue, which is post-translationally modified to FGly in 
the endoplasmic reticulum (Dierks et al., 1997; Schmidt et al., 1995). Prokaryotic 
sulfatases carry either a Cys or a serine (Ser) residue which requires post-
translational conversion to FGly in the cytosol in order to activate the enzyme (Beil 
et al., 1995; Marquordt et al., 2003; Miech et al., 1998; Szameit et al., 1999).  
Initially, modification of Ser-type or Cys-type sulfatases in bacteria was thought to 
follow one of two pathways. In Klebsiella pneumoniae DSM 681, the conversion of 
the Ser72 residue to FGly was found to be catalysed by an iron-sulfur protein 
encoded by the atsB gene (Szameit et al., 1999). The atsB gene is a homolog of the 
chuR gene from Ba. thetaiotaomicron BT4001 which was previously implicated in 
the metabolism of chondroitin sulfate and heparan sulfate in this species, although at 
the time it was predicted to encode a regulatory protein (Cheng & Salyers, 1995). 
AtsB is a member of the S-adenosyl-L-methionine (AdoMet)-dependent family of 
radical enzymes, whose activity was believed to be limited to the maturation of Ser-
type sulfatases (Fang et al., 2004). In humans and certain prokaryotes such as 
Mycobacterium tuberculosis H37Rv, modification of Cys-type sulfatases was shown 
to require a formylglycine-generating enzyme (FGE), an enzyme which is strictly 
dependent on oxygen (Carlson et al., 2008; Cosma et al., 2003; Dierks et al., 2003; 
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Roeser et al., 2006). However, it was notable that anaerobic bacteria encoding Cys-
type sulfatases do not possess FGE-encoding genes, but, rather, astB-related genes 
(Berteau et al., 2006). Since then, a prokaryotic maturase, which is active on Cys-
type sulfatases under anaerobic conditions, has been characterised from Clostridium 
perfringens ATCC13124, a discovery which explained the absence of FGE-related 
genes in anaerobic bacteria (Berteau et al., 2006). The authors of this study proposed 
that AtsB and the characterised maturase from C. perfrigens ATCC13124 belong to 
a new family named anSMEs (anaerobic sulfatase maturation enzymes), being 
separate from the oxygen-dependent FGE family (Berteau et al., 2006). Subsequent 
research has shown that the anSME from C. perfringens ATCC13124, as well as the 
ChuR protein from Ba. thetaiotaomicron VPI-5481, were active on both Ser-type 
and Cys-type sulfatases (Benjdia et al., 2008).  
Metagenomic sequence analysis has revealed that genes that encode homologues of 
anSME enzymes are enriched in the gut microbiomes of humans compared to non-
gut microbial communities (Kurokawa et al., 2007), suggesting an important role in 
bacterial colonisation of the gut. Ba. thetaiotaomicron type strain VPI-5481 
possesses 28 predicted sulfatase-encoding genes, but only a single gene for a 
predicted anSME (Benjdia et al., 2011). Nevertheless, this anSME was shown to 
have significant importance in this strain’s colonisation of the gut, as an isogenic 
derivative of this strain (designated ∆anSME) carrying a deletion in the anSME-
encoding gene displayed reduced fitness in vivo even in the presence of dietary 
glycans (Benjdia et al., 2011). As expected, growth of the ∆anSME strain was also 
impaired on sulfated carbohydrates, such as mucin, chondroitin sulphate and heparin, 
thus demonstrating the importance of sulfatase activity to carbohydrate metabolism 
in the gut (Benjdia et al., 2011).  
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1.7 Carbon catabolite repression in bacteria 
Carbon catabolite repression (CCR) is a regulatory process whereby, when presented 
with a number of carbon sources, bacteria will preferentially utilise the substrate that 
most effectively yields (the highest amount of) energy, while inhibiting the 
expression or activity of proteins involved in the uptake and catabolism of other 
substrates (Gorke & Stülke, 2008; Stülke & Hillen, 1999). The two main forms of 
CCR are (i) the inhibition of expression of genes involved in the uptake or utilisation 
of secondary substrates (Cohn & Horibata, 1959), and (ii) the inhibition of proteins 
involved in the uptake of secondary substrates, also known as inducer exclusion 
(Dills et al., 1980; Gorke & Stulke, 2008). CCR is defined as “a regulatory 
phenomenon by which the expression of functions for the use of secondary carbon 
sources and the activities of the corresponding enzymes are reduced in the presence 
of a preferred carbon source” (Gorke & Stulke, 2008).  
The methods by which CCR operates in the Gram negative bacterium Escherichia 
coli and the low-GC, Gram positive bacterium Bacillus subtilis have been studied 
extensively and have been shown to be hugely dependent on the PEP-PTS transport 
system (Postma et al., 1993; Saier Jr & Ramseier, 1996). In E. coli, the key factor for 
CCR is the phosphorylation state of the IIA component of the glucose specific-PTS, 
EIIAGlc. In times of high flux through glycolysis, the ratio of PEP (the high energy 
phosphate donor) to pyruvate in the cell is low, resulting in dephosphorylated 
EIIAGlc. Concurrently, the availability of a PTS sugar, such as glucose, results in a 
phosphate group being transferred from EIIAGlc to the sugar. Therefore, during times 
of growth on a PTS sugar, EIIAGlc is dephosphorylated. In this form, the protein 
binds and inactivates enzymes and transporters involved in the metabolism of 
secondary metabolites, such as the LacY permease which transports lactose into the 
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cell, in an example of inducer exclusion as defined above. In the absence of a PTS 
sugar and when the PEP to pyruvate ratio is high, EIIAGlc is phosphorylated, and in 
this form EIIAGlc binds and activates adenylate cyclase, which leads to cyclic AMP 
(cAMP) synthesis. This triggers the formation of the cAMP-CRP complex, which in 
turn binds and activates the promoters of many catabolic genes and operons 
(Bettenbrock et al., 2007; Feucht & Saier, 1980; Harwood et al., 1976; Hogema et 
al., 1998).  
In B. subtilis the key player of CCR is the phosphorylation state of the histidine 
protein (HPr) of the PTS. Phosphorylated HPr, HPr-(Ser-P), binds to carbon 
catabolite protein A (CcpA) to promote its binding to cre sites on the DNA, in turn 
leading to the repression of transcription of other catabolic gene clusters, although in 
certain cases binding of CcpA to the cre site may also lead to transcriptional 
activation. This was observed for the ackA and pta genes of B. subtilis which are 
required for the excretion of acetate (Gorke & Stulke, 2008; Grundy et al., 1993; 
Presecan-Siedel et al., 1999). The phosphorylation of HPr is catalysed by the HprK 
protein. In times of high glycolytic activity, the levels of fructose-1,6-biphosphate in 
the cell are high, inducing HPrK kinase activity. However, when nutrients are 
limited, inorganic phosphate (Pi) accumulates, inducing HPrK phosphorylase 
activity, resulting in dephosphorylated HPr which cannot interact with CcpA, thus 
transcription of other catabolic gene clusters can proceed (Deutscher et al., 1995; 






1.8 CCR-type phenomena and LacI type repression in bifidobacteria 
CCR systems comparable to those described in E. coli and B. subtilis have so far not 
been identified in bifidobacteria, although phenomena reminiscent of CCR have 
been described in a number of bifidobacterial species. In B. breve UCC2003, 
expression of an operon involved in the metabolism of FOS was shown to be 
induced in the presence of sucrose and Actilight (a commercial source of short chain 
FOS), yet repressed when the strain was grown in a medium containing a mixture of 
glucose and sucrose, or fructose and sucrose, indicating the preferred utilisation of 
glucose or fructose (Ryan et al., 2005). Similarly, when this strain was grown in a 
medium containing ribose or a combination of ribose and glucose, genes encoding 
the predicted fructose-specific PEP-PTS, as well as other carbohydrate-related ABC 
transport systems, were down-regulated (Pokusaeva et al., 2010). The B. longum 
subsp. longum strain NCC2705 was shown to preferentially utilise lactose over 
glucose, a phenomenon previously only observed in Streptococcus thermophilus 
CNRZ302 and another B. longum strain, SH2 (Kim et al., 2003; Parche et al., 2006; 
van den Bogaard et al., 2000). The preferential utilisation of lactose over glucose, 
was achieved by transcriptional down-regulation of the glcP gene, a glucose-specific 
permease of the major facilitator superfamily, in the presence of lactose (Parche et 
al., 2006). In B. animalis subsp. lactis, sucrose metabolising activity was induced in 
the presence of sucrose, raffinose or oligofructose, but repressed in the presence of 
glucose (Trindade et al., 2003). Another CCR-related metabolic phenomenon was 
observed when B. longum subsp. infantis ATCC15697 was grown on a complex 
mixture of HMOs. It was observed that of the five fucosidase-encoding genes 
identified on the B. longum subsp. infantis ATCC15697 genome, one was up-
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regulated, two were down-regulated and two showed no change in transcription, 
compared to when the strain was grown in lactose (Sela et al., 2012). 
Transcriptional repressors are DNA binding proteins which physically interact with 
an operator sequence in the vicinity of a regulated promoter, thereby preventing the 
binding of RNA polymerase and transcription initiation. Perhaps the best 
characterised transcriptional repressor in bacteria is the LacI protein of E. coli, which 
represses transcription of the lac operon, required for the uptake and utilisation of 
lactose (Gilbert & Müller-Hill, 1966; Jacob & Monod, 1961). LacI monomers are 
divided into three distinct domains. The N-terminus contains a helix-turn-helix DNA 
binding domain and a short hinge region, both of which are involved in specific 
binding to an operator sequence upstream of the lac operon, thereby preventing 
transcription. The core domain, or effector binding domain, binds a sugar ligand, 
while at the C-terminal, the multi-merisation domain is essential for the formation of 
the LacI dimer (the native form of LacI) or the LacI tetramer (Lewis et al., 1996). In 
the case of the lac operon, the effector molecule is allolactose, produced from lactose 
by β-galactosidase activity. Binding of allolactose to the core domain of the LacI 
repressor results in a conformational change that prevents binding of the protein to 
the operator sequence, thus permitting transcription of the lac operon (Jacob & 
Monod, 1961). Members of the LacI/GalR family of transcriptional regulators all 
function in the same manner as the LacI protein from E. coli, yet have specific 
effectors and DNA binding properties (Swint-Kruse & Matthews, 2009; Weickert & 
Adhya, 1992).  
In a recent study on the comparative genomics of LacI-family transcription factors 
(LacI-TFs), the largest average number of such transcription factors per genome was 
found in lineages of the Actinobacteria phylum, including the Bifidobacteriaceae 
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family (Ravcheev et al., 2014). Bifidobacterial genomes have been shown to encode 
a particularly high number of repressor proteins, a characteristic believed to allow 
the bacteria to adapt faster to fluctuations in carbohydrate sources (Schell et al., 
2002). For example, the genome of B. longum subsp. longum NCC2705 encodes 22 
predicted LacI-type transcriptional repressors, all of which contain a sugar-binding 
motif, suggesting their involvement in the regulation of carbohydrate metabolism 
(Schell et al., 2002). Just one carbohydrate-responsive transcriptional activator has 
so far been characterised in a bifidobacterial species: the ROK (Repressor open 
reading frame kinase)-type regulator RafR, which was shown to activate 
transcription of the raffinose utilisation cluster in B. breve UCC2003 (O'Connell et 
al., 2014).  
Six predicted LacI-type regulators encoded by B. breve UCC2003 have so far been 
characterised, including LacIfos, which regulates transcription of the fos operon 
(Ryan et al., 2005), GalR, which controls transcription of a galactan utilisation 
cluster (O'Connell Motherway et al., 2011a), CldR which controls cellodextrin 
utilisation (Pokusaeva et al., 2011b) and RbsR, which controls transcription of the 
rbsACBDK cluster for ribose utilisation (Pokusaeva et al., 2010). Recently, two 
LacI-type regulators, designated MelR1 and MelR2, were shown to control 
transcription of the melezitose utilisation cluster in B. breve UCC2003 (O'Connell et 
al., 2014). The characterised LacI-family transcriptional regulators from B. breve 
UCC2003 and their predicted or experimentally determined operator sequences are 
presented in Table 1.4. These repressors demonstrate the typical characteristics of 
LacI-TFs as reviewed recently (Ravcheev et al., 2014). The latter review found that 
the majority of LacI-TFs (69 % of those studied) regulate one or two gene operons, 
and that 90 % of the investigated LacI-TFs are local regulators, as they control a 
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single metabolic pathway, usually involved in the catabolism of carbohydrates. This 
is in agreement with the characterised LacI-family repressors from B. breve 
UCC2003. In terms of the DNA binding motifs of the operators, the identified DNA 
binding sequences of LacI-family repressors from B. breve UCC2003 share the 
characteristic CG pair in the centre of the binding sites of other LacI-TFs, with the 
exception of the predicted binding site of LacIfos (Ryan et al., 2005). Approximately 
20 % of operons regulated by LacI-TFs contain more than one upstream binding site, 
similar to what was observed in the gal and cld operons of B. breve UCC2003 
(O'Connell Motherway et al., 2011a; Pokusaeva et al., 2011b). Finally, 75 % of the 
binding motifs of LacI-TFs are located within 30 and 140 bp upstream of the closest 
regulated gene. This is in agreement with the LacI-binding sites identified in B. 
breve UCC2003, where only in one case the binding site is present at a distance of 










Binding site Gene cluster 
regulated 





CldR Bbr_0105 xTxxTGGAAACGxTxCCAxxAA cldEFGC (4) 2 (Pokusaeva et al., 2011b) 
AtsR1 Bbr_0351 xxGTxTxACGTTAxxxTx Bbr_0349-0355 (7) 2 Chapter V of this thesis 
GalR Bbr_0421 xxxxTGxTACACxGxTxxAxCA galCDEGRA (6) 4 (O'Connell Motherway et al., 2011a) 
LacIfos Bbr_1321 GGCCTCCGTTCAGCACGGAGGCC fosABC (3) 1 (Ryan et al., 2005) 
RbsR Bbr_1420 TGATTAAACGTTTAAATCA rbsACBDK  (5) 1 (Pokusaeva et al., 2010) 
MelR1 Bbr_1863 TGCATAAGCGCTTAGCAA melABCDE (5) 1 (O'Connell et al., 2014) 





1.9 Conclusion  
As the number of complete bifidobacterial genome sequences continues to grow, so 
too does our understanding of the species and strain-specific attributes responsible 
for the metabolic diversity described in this review. An understanding of 
bifidobacterial HMO metabolism, as well as that of the structurally related 
oligosaccharides in mucin, will provide insights into how bifidobacterial species, 
such as B. breve and B. bifidum, can be effective and abundant colonisers of the 
infant gut, yet can also be present in significant numbers in the adult microbiota 
(Turroni et al., 2012b), despite the dramatic shift in carbohydrate sources that occurs 
during weaning. Knowledge concerning the factors that contribute to bifidobacterial 
utilisation of mucin is also of increasing importance as questions are raised on the 
potential harm caused by degradation of the protective mucus layer and the effect of 
the Western-style diet and its associated microbiota on mucin degradation 
(Mahowald et al., 2009; Marcobal et al., 2013). Furthermore, an understanding of 
the characteristic metabolic traits of the various species of bifidobacteria, and their 
effects on other members of the gut microbiota is of crucial importance in the 





1.10 Thesis outline 
Chapter I (above) is a general introduction of this thesis which covers carbohydrate 
metabolism in bifidobacteria with particular emphasis on host-derived 
carbohydrates. 
Chapter II describes the metabolism of sialic acid by B. breve UCC2003. 
Chapter III reports on the regulation of sialic acid metabolism in B. breve UCC2003 
by the transcriptional repressor, NanR. 
Chapter IV describes the co-cultivation of B. breve UCC2003 and B. bifidum 
PRL2010 on a mucin-based medium. 
Chapter V reports on the identification two sulfatase gene clusters in B. breve 
UCC2003, their transcriptional regulation and their role in the metabolism of 
sulfated monosaccharides. 
Chapter VI contains a general discussion and the overall conclusions of the work 
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2.1 ABSTRACT  
Bifidobacteria constitute a specific group of commensal bacteria, which inhabit the 
gastrointestinal tract of humans and other mammals. Bifidobacterium breve 
UCC2003 has previously been shown to utilise several plant-derived carbohydrates 
that include cellodextrins, starch and galactan. In the current study, we investigated 
the ability of this strain to utilise the mucin- and human milk oligosaccharide 
(HMO)-derived carbohydrate, sialic acid. Using a combination of transcriptomic and 
functional genomic approaches, we identified a gene cluster dedicated to the uptake 
and metabolism of sialic acid. Furthermore, we demonstrate that B. breve UCC2003 
can cross-feed on sialic acid derived from the metabolism of 3’ sialyllactose, an 






Bifidobacteria are Gram positive, anaerobic, typically Y-shaped bacteria which are 
members of the Bifidobacteriaceae family and the Actinobacteria phylum. 
Discovered in 1900 (Tissier, 1900), bifidobacteria are naturally found in the 
digestive tract of mammals and insects, while they have also been isolated from the 
human oral cavity and sewage (Ventura et al., 2007). The large intestine is the 
natural habitat for a large and diverse bacterial community, which is known to 
significantly contribute to the well-being of humans. This positive contribution 
includes metabolic activities to provide energy and nutrients to the host (LeBlanc et 
al., 2013; Vaughan et al., 2005), development of the immune system (Round & 
Mazmanian, 2009; Ventura et al., 2012) and protection against pathogenic bacteria 
(Servin, 2004).  
Bifidobacteria are saccharolytic organisms and their survival and growth in the large 
intestine requires a variety of extracellular and cytoplasmic glycosyl hydrolases, 
which they employ to metabolise carbohydrates prevalent in this environment. The 
characteristic central metabolic pathway in bifidobacteria is the fructose-6-phosphate 
phosphoketolase pathway, also known as the bifid-shunt (Scardovi & Trovatelli, 
1965). Because of the diversity of carbohydrate sources present in the 
gastrointestinal tract and the dependence of bifidobacteria on such carbon and energy 
sources, it is not surprising that an estimated 8 % of the typical bifidobacterial 
genome is devoted to carbohydrate metabolism (Schell et al., 2002; Ventura et al., 
2007).  
Bifidobacterium breve UCC2003 has already been shown to utilise quite a variety of 
plant-derived poly-, oligo-, and mono-saccharides, including cellodextrins, galactan, 
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starch, raffinose and melezitose (O'Connell et al., 2013; O'Connell Motherway et al., 
2008; O'Connell Motherway et al., 2011a; Pokusaeva et al., 2011; Ryan et al., 
2006), which reflects the apparent flexibility of the carbohydrate utilisation profile of 
this strain. Interestingly, B. breve strains are numerically prevalent among the gut 
microbiota of healthy breast-fed infants (Turroni et al., 2012b), although the ability 
of members of this bifidobacterial species to utilise human milk- and host-derived 
carbohydrates is relatively unexplored. 
Sialic acids comprise a large family of nine-carbon monosaccharides called 
neuraminic acids, the most common of which is N-acetylneuraminic acid (Neu5Ac), 
for which the name of sialic acid is also used. Approximately 16 % of human milk 
oligosaccharides (HMOs) are sialylated (Ninonuevo et al., 2006), with 3’ 
sialyllactose and 6’ sialyllactose being abundant sialylated HMO components (Bao 
et al., 2007; Kunz et al., 2000; Martin-Sosa et al., 2003). Total sialic acid 
concentrations are highest in colostrum, reaching levels of 5.04 mmol L-1, though 
this level will then decrease by almost 80 % after 3 months (Wang et al., 2001). 
Sialic acid also features prominently at the surface-exposed end of human colonic 
mucin (Podolsky, 1985) and in healthy adults approximately 300 µg of sialic acid is 
present per mg of colonic mucin (Corfield et al., 1999).  
Representative Clostridium perfringens strains were the first bacteria shown to be 
capable of utilising sialic acid as the sole carbon source (Nees & Schauer, 1974; 
Nees et al., 1976). Nevertheless, sialic acid metabolism was first explored in 1983 in 
Escherichia coli, with the identification of a transporter, designated nanT, and an N-
acetylneuraminate lyase, designated nanA (Vimr & Troy, 1985a; Vimr & Troy, 
1985b), followed by the description of the complete, five-step metabolic pathway in 
1999 (Fig. 2.1) (Plumbridge & Vimr, 1999). Other gut inhabitants, including the 
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pathogen Vibrio cholerae (Almagro-Moreno & Boyd, 2009) and the commensals 
Bacteroides fragilis (Brigham et al., 2009) and Lactobacillus sakei (Anba-
Mondoloni et al., 2013) have since been shown to utilise sialic acid as a carbon 
source.  
The ability of Bifidobacterium species to metabolise sialic acid has not been widely 
studied. Genes predicted to be involved in the breakdown of sialic acid, which 
correspond with those outlined in Figure 2.1, were identified on the genome of 
Bifidobacterium longum subsp. infantis ATCC15697 and in accordance this strain 
was shown to be capable of utilising sialic acid (Sela et al., 2008) or the HMO 
sialylated lacto-N-tetraose as a sole carbon source (Sela et al., 2011). A recent study 
on the consumption of HMOs by strains of B. breve revealed that all B. breve strains 
tested can utilise sialylated lacto-N-tetraose (Ruiz-Moyano et al., 2013). Another 
study examined the utilisation of the monosaccharide constituents of HMO by five 
bifidobacterial strains, representing four bifidobacterial species (B. longum, B. breve, 
Bifidobacterium bifidum and Bifidobacterium adolescentis), and found that, of the 
strains examined, only B. longum subsp. infantis ATCC15697 and B. breve 
ATCC15700 are capable of utilising sialic acid (Ward et al., 2007). This suggests 
that the ability to utilise sialic acid and/or sialylated-HMOs is a species/strain-
specific attribute. 
The aim of this study was to investigate how B. breve UCC2003 utilises sialic acid, a 
characteristic which is likely to support particular bifidobacterial species in their 
ability to colonise the infant gut. Furthermore, the manner by which B. breve 
UCC2003 can cross-feed on sialic acid, when derived from the metabolism of 3’ 
sialyllactose by B. bifidum PRL2010, was characterised. 
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2.3 MATERIALS AND METHODS  
Bacterial strains, plasmids, media and culture conditions. Bacterial strains and 
plasmids used in this study are listed in Table 2.1. B. breve UCC2003 was routinely 
cultured in Reinforced Clostridial Medium (RCM; Oxoid Ltd., Basingstoke, 
Hampshire, United Kingdom). B. bifidum PRL2010 was cultured in modified deMan 
Rogosa Sharpe (mMRS) medium made from first principles (De Man et al., 1960), 
though excluding a carbohydrate source, and supplemented with 0.05 % (wt/vol) L-
cysteine HCl and 1 % (wt/vol) lactose (unless otherwise specified). Carbohydrate 
utilisation by bifidobacteria was examined in mMRS medium supplemented with 
0.05 % (wt/vol) L-cysteine HCl and a particular carbohydrate source (0.5 % wt/vol). 
It was previously shown that without the addition of a carbohydrate, mMRS does not 
support growth of B. breve (Watson et al., 2013). The carbohydrates used were 
lactose (Sigma Aldrich, Steinheim, Germany), sialic acid and 3’ and 6’ sialyllactose 
(Carbosynth, Compton, Berkshire, United Kingdom). Addition of sialic acid at this 
concentration to the mMRS resulted in a decrease in pH to 6.0, hence the pH was re-
adjusted to 6.8 following addition of the sugar and the medium was subsequently 
filter sterilised. Bifidobacterial cultures were incubated under anaerobic conditions in 
a modular atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 
37°C. E. coli was cultured in Luria Bertani broth (LB) at 37°C with agitation 
(Sambrook, 1989). Lactococcus lactis strains were grown in M17 medium 
supplemented with 0.5 % (wt/vol) glucose at 30°C (Terzaghi & Sandine, 1975). 
Where appropriate, growth media contained tetracycline (Tet; 10 µg ml-1), 
chloramphenicol (Cm; 5 µg ml-1 for L. lactis and E. coli, 2.5 µg ml-1 for B. breve), 
erythromycin (Em; 100 µg ml-1) or kanamycin (Kan; 50 µg ml-1). Recombinant E. 
coli cells containing pORI19 were selected on LB agar containing Em and Kan, and 
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supplemented with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (40 
µg ml-1) and 1 mM IPTG (isopropyl-β-D-galactopyranoside). 
In order to determine bacterial growth profiles and final optical densities, 10 ml of a 
freshly prepared mMRS medium, including a particular carbohydrate source (see 
above), was inoculated with 100 µl (1 %) of a stationary-phase culture of a particular 
strain. Un-inoculated mMRS was used as a negative control. Cultures were 
incubated anaerobically for 24-36 h. Optical density (OD600nm) measurements were 
recorded unless otherwise stated. 
 
Nucleotide sequence analysis. Sequence data were obtained from the Artemis-
mediated genome annotations of B. breve UCC2003 (O'Connell Motherway et al., 
2011b; Rutherford et al., 2000). Database searches were performed using the non-
redundant sequence database accessible at the National Centre for Biotechnology 
Information website (http://www.ncbi.nlm.nih.gov) using BLAST (Altschul et al., 
1990). Sequence analysis was performed using the Seqbuilder and Seqman programs 
of the DNASTAR software package (DNASTAR, Madison, WI, USA). 
 
DNA manipulations. Chromosomal DNA was isolated from B. breve UCC2003 as 
previously described (Riordan, 1998). Plasmid DNA was isolated from E. coli, L. 
lactis and B. breve using the Roche High Pure plasmid isolation kit (Roche 
Diagnostics, Basel, Switzerland). An initial lysis step was performed using 30 mg 
ml-1 of lysozyme for 30 min at 37°C prior to plasmid isolation from L. lactis or B. 
breve. Single stranded oligonucleotide primers used in this study were synthesised 
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by Eurofins (Ebersberg, Germany) (Supplementary table 2.1). Standard PCRs were 
performed using Taq master mix (Qiagen GmBH, Hilden, Germany). B. breve 
colony PCRs were carried out as described previously (O'Connell Motherway et al., 
2009). PCR fragments were purified using the Roche High Pure PCR purification kit 
(Roche Diagnostics). Electroporation of plasmid DNA into E. coli, L. lactis or B. 
breve was performed as previously described (Maze et al., 2007; Sambrook, 1989; 
Wells et al., 1993). 
 
Analysis of global gene expression using B. breve DNA microarrays. Global gene 
expression was determined during log-phase growth of B. breve UCC2003 in mMRS 
supplemented with 0.5 % (wt/vol) sialic acid. The obtained transcriptome was 
compared to that obtained from log-phase B. breve UCC2003 cells when grown in 
mMRS supplemented with 0.5 % (wt/vol) ribose. DNA microarrays containing 
oligonucleotide primers representing each of the 1864 identified open reading frames 
on the genome of B. breve UCC2003 were designed and obtained from Agilent 
Technologies (Palo Alto, Ca., USA). Methods for cell disruption, RNA isolation, 
RNA quality control, complementary DNA (cDNA) synthesis and labelling were 
performed as described previously (Zomer et al., 2009). Labelled cDNA was 
hybridised using the Agilent Gene Expression hybridisation kit (part number 5188-
5242) as described in the Agilent Two-Colour Microarray-Based Gene Expression 
Analysis v4.0 manual (publication number G4140-90050). Following hybridisation, 
microarrays were washed in accordance with Agilent’s standard procedures and 
scanned using an Agilent DNA microarray scanner (model G2565A). Generated 
scans were converted to data files with Agilent's Feature Extraction software 
(Version 9.5). DNA-microarray data were processed as previously described (García 
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de la Nava et al., 2003; van Hijum et al., 2003; van Hijum et al., 2005). Differential 
expression tests were performed with the Cyber-T implementation of a variant of the 
t-test (Long et al., 2001).  
 
Construction of B. breve UCC2003 insertion mutants. An internal fragment of 
Bbr_0161, designated nanK (370 base pairs (bp), representing codon numbers 148 
through to 271 of the 336 codons of this gene), Bbr_0164, designated nanB (504 bp, 
representing codon numbers 226 through to 394 of the 521 codons of this gene), 
Bbr_0165, designated nanC (355 bp, representing codon numbers 27 through to 145 
of the 319 codons of this gene), Bbr_0168, designated nanA (301 bp, representing 
codon numbers 116 through to 216 of the 321 codons of this gene), and Bbr_1247, 
designated nagA2 (402 bp, representing codon numbers 107 through to 241 of the 
426 codons of this gene) were amplified by PCR using B. breve UCC2003 
chromosomal DNA as a template and primer pairs NanKF and NanKR, NanBF and 
NanBR, NanCF and NanCR, NanAF and NanAR, or NagA2F and NagA2R, 
respectively. The insertion mutants were constructed as described previously 
(O'Connell Motherway et al., 2009). Site-specific recombination of potential Tet-
resistant mutant isolates was confirmed by colony PCR using primer combinations 
TetWF and TetWR to verify tetW gene integration, and primers NanKconfirm, 
NanBconfirm, NanCconfirm, NanAconfirm and NagA2confirm (positioned 
upstream of the selected internal fragments of nanK, nanB, nanC, nanA and nagA2, 
respectively) in combination with primer TetWF to confirm integration at the correct 




Complementation of B. breve UCC2003-nanA. A DNA fragment encompassing 
nanA was generated by PCR amplification from B. breve UCC2003 chromosomal 
DNA using PFUII DNA polymerase and the primer pair NanApNZ44F and 
NanApNZ44R. The resulting fragment was digested with PstI and XbaI, and ligated 
to the similarly digested pNZ44 (McGrath et al., 2001). The ligation mixture was 
introduced into L. lactis NZ9000 by electrotransformation and transformants selected 
based on Cm resistance. The plasmid content of a number of Cmr transformants was 
screened by restriction analysis. The integrity of the cloned insert of one of the 
recombinant plasmids, designated pNZ44-nanA, was confirmed by sequencing. The 
nanA coding sequence, together with the constitutive p44 lactococcal promoter, 
specified by pNZ44, was amplified by PCR from a representative pNZ44-nanA 
plasmid using PFUII DNA polymerase and the primer combination P44FORWARD 
and NanApNZ44R. The resulting DNA fragment was digested with BamHI and 
XbaI and ligated to the similarly digested pBC1.2 (Álvarez-Martín et al., 2007). The 
ligation mixture was introduced into E. coli XL1-blue by electrotransformation and 
transformants were selected based on Tet and Cm resistance. Transformants were 
checked for plasmid content using colony PCR and restriction analysis of plasmid 
DNA. Positively identified clones were verified by sequencing and one of the thus 
identified plasmids was designated pBC1.2-nanA. Plasmid pBC1.2-nanA was 
introduced into B. breve UCC2003-nanA by electrotransformation and transformants 
were selected based on Tet and Cm resistance. 
 
Plasmid Constructions. For the construction of the plasmids pNZ-nanK, pNZ-nanE, 
pNZ-nanA, pNZ-nagB1 and pNZ-nagA2, DNA fragments encompassing the 
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predicted N-acetylmannosamine kinase-encoding gene nanK (Bbr_0161), N-
acetylmannosamine-6-phosphate epimerase-encoding gene nanE (Bbr_0162), N-
acetylneuraminate lyase-encoding gene nanA (Bbr_0168), glucosamine-6-phosphate 
deaminase-encoding gene nagB1 (Bbr_0169) and N-acetylglucosamine-6-phosphate 
deacetylase-encoding gene nagA2 (Bbr_1247) were generated by PCR amplification 
from chromosomal DNA of B. breve UCC2003 using PFUII DNA polymerase and 
the primer combinations nanKFOR and nanKREV, nanEFOR and nanEREV, 
nanAFOR and nanAREV, nagB1FOR and nagB1REV, or nagA2FOR and 
nagA2REV, respectively. An in-frame His10-encoding sequence was incorporated 
into the forward primers nanKFOR, nanEFOR and nagA2FOR and the reverse 
primers nanAREV and nagB1REV, to facilitate downstream protein purification. 
The generated amplicons were digested with EcoRV and XbaI, and ligated into the 
ScaI and XbaI digested, nisin-inducible translational fusion plasmid pNZ8150 
(Mierau & Kleerebezem, 2005). The ligation mixtures were introduced into L. lactis 
NZ9000 by electrotransformation and transformants were selected based on Cm 
resistance. The plasmid content of a number of Cmr transformants was screened by 
restriction analysis and the integrity of positively identified clones was verified by 
sequencing. 
 
Protein overproduction and purification. In order to (over)express and purify 
proteins, 400 ml of M17 broth supplemented with 0.5 % (wt/vol) glucose was 
inoculated with a 2 % inoculum of a particular L. lactis NZ9000 strain, followed by 
incubation at 30°C until an OD600nm of 0.5 was reached, at which point protein 
expression was induced by addition of cell-free supernatant of a nisin-producing 
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strain (de Ruyter et al., 1996), followed by continued incubation for a further 2 h. 
Cells were harvested by centrifugation and protein purification achieved using the 
PrepEase histidine-tagged protein purification maxi kit (USB, Germany) according 
to the manufacturer’s instructions. Elution fractions were analysed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After 
electrophoresis the gels were fixed and stained with Coomassie Brilliant blue to 
identify fractions containing the purified protein. The molecular weights of the 
proteins were estimated by comparison with rainbow-prestained, low molecular 
weight protein markers (New England BioLabs, Herefordshire, United Kingdom). 
Protein concentrations were determined using the Bradford method (Bradford, 
1976). 
 
High Performance Thin Layer Chromatography (HPTLC). HPTLC analysis was 
used for the qualitative determination of the activity of each of the purified enzymes. 
Purified NanAHis, NanKHis, NanEHis, NagA2His or NagB1His (final concentration 20 
µg ml-1), or combinations thereof, were incubated with sialic acid, N-
acetylmannosamine, N-acetylmannosamine-6-phosphate, N-acetylglucosamine-6-
phosphate or glucosamine-6-phosphate, respectively. Enzymatic assays were 
performed at 37°C in a total volume of 1 ml in a reaction buffer containing 20 mM 
Tris-HCl pH8.0, 10 mM KCl and 5 mM MgSO4.7H2O with a 5 mg ml-1 
concentration of a particular carbohydrate substrate. In reactions including NanKHis, 
100 µl of 100 mM ATP was added to the reaction mixture. The reactions were 
terminated after 24 h by incubation at 65°C for 10 min. HPTLC analysis was 
performed as previously described (O'Connell Motherway et al., 2011a). An aliquot 
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(1 µl) of the reaction mixture was spotted onto a Silica Gel 60 plate (10 x 10 cm, 
Merck) with a Nanomat 4 (Camag, Switzerland). The chromatogram was developed 
with a butanol-isopropanol-water (3:12:4, vol/vol/vol) solvent system in a horizontal 
developing chamber. Ascending development was repeated twice at room 
temperature. The plate was allowed to dry in a fume hood and then sprayed evenly 
with 20 % (vol/vol) sulfuric acid in ethanol. The plate was dried and heated to 120°C 
for 10 min to visualise sugar-representing spots. Reaction products were identified 
by comparison with relevant carbohydrate standards. 
 
Growth of B. bifidum PRL2010 and B. breve UCC2003 or B. breve UCC2003-
nanA on 3’ sialyllactose. An overnight culture of B. bifidum PRL2010 (1 %) was 
used to inoculate mMRS broth supplemented with 0.05 % (wt/vol) L-cysteine HCl 
and 0.5 % (wt/vol) 3’ sialyllactose and cultivated for 24 h at 37°C under anaerobic 
conditions. The cells were removed by centrifugation at 9,000 x g for 5 min. Growth 
of B. bifidum PRL2010 resulted in a pH decrease to 5.1, therefore the pH of cell free 
supernatant (CFS) was re-adjusted to 6.8 and the CFS was filter sterilised. This 
medium was supplemented with 0.01 % (wt/vol) lactose and 0.05 % (wt/vol) L- 
cysteine-HCl, prior to inoculation with an overnight culture (0.01 %) of either B. 
breve UCC2003 or B. breve UCC2003-nanA. Growth was monitored over 72 h, with 
samples taken at 6 or 12 h intervals. All samples collected were serially diluted in 
sterile Ringers solution and plated on Reinforced Clostridial Agar (RCA). Viable 
counts were determined by counting colonies on agar plates using dilutions that 




High-Performance Anion Exchange Chromatography with Pulsed Amperometric 
Detection (HPAEC-PAD). Carbohydrate analysis by HPAEC-PAD was performed 
on CFS samples taken at 6 or 12 h intervals during the 72 h growth experiment, 
using a Dionex ICS-3000 system (Dionex, Sunnyvale, CA). Oligosaccharide 
fractions (25 µl aliquots) were separated on a CarboPac PA1 analytical-exchange 
column (250 mm x 4 mm) with a CarboPac PA1 guard column (50 mm x 4 mm) and 
a pulsed electrochemical detector in the pulsed amperometric detection (PAD) mode. 
The elution was performed at a constant flow-rate of 1.0 ml min-1 at 30°C using the 
following eluents for the analysis (A) 200 mM NaOH, (B) 100 mM NaOH, 550 mM 
sodium acetate (NaAC), and (C) Milli-Q water. The following linear gradient of 
NaAC was used: 100 mM NaOH: 0-50 min, 0 mM; 50-51 min, 16 mM; 51-56 min, 
100 mM; 56.1-61 min, 0 mM. Detection was achieved using a Dionex ED40 detector 
in PAD mode. The Chromeleon software-version 6.70 (Dionex Corporation) was 
used for the integration and evaluation of the chromatograms obtained. The 
chromatographic profiles corresponding to 3’ sialyllactose, sialic acid and lactose 
were qualitatively examined to evaluate 3’ sialyllactose hydrolysis, and subsequent 
metabolism of lactose and/or sialic acid.  
  
Microarray data accession number. The microarray data obtained in this study have 
been deposited in NCBI’s Gene Expression Omnibus database and are accessible 




2.4 RESULTS  
Growth of B. breve strains on sialic acid. In order to determine if B. breve strains 
are capable of sialic acid metabolism, growth in mMRS supplemented with either 0.5 
% (wt/vol) lactose or sialic acid was assessed for fourteen B. breve strains by 
measuring the OD600nm following 24 h of anaerobic growth at 37°C. All B. breve 
strains were shown to grow well on lactose (OD600nm >1.2). Eleven out of the 
fourteen examined B. breve strains, including the prototypical strain B. breve 
UCC2003, were capable of moderate growth on sialic acid, reaching OD600nm values 
between 0.6-0.9, while the three remaining strains were unable to metabolise sialic 
acid (Fig. 2.2).  
 
Genome response of B. breve UCC2003 to growth on sialic acid. In order to 
investigate which genes are involved in sialic acid metabolism by B. breve 
UCC2003, global gene expression was determined by microarray analysis during 
growth of the strain in mMRS supplemented with sialic acid and compared with 
gene expression when grown in mMRS supplemented with ribose. The pentose sugar 
ribose was considered an appropriate carbohydrate for comparative transcriptome 
analysis as the genes involved in ribose metabolism are known (Pokusaeva et al., 
2010), and it has been used in several transcriptome studies in B. breve UCC2003 
(O'Connell et al., 2013; O'Connell et al., 2014; O'Connell Motherway et al., 2011a; 
O'Connell Motherway et al., 2013). Analysis of the DNA microarray data revealed 
that the expression of a gene cluster, comprising of twelve open reading frames, 
corresponding to locus tags Bbr_0160 to Bbr_0172, was significantly up-regulated 
when B. breve UCC2003 was grown on sialic acid relative to when the strain was 
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grown on ribose (fold change >3.0, P<0.001). In addition, two adjacent genes, 
corresponding to Bbr_1247 (nagA2) and Bbr_1248 (nagB3), were also up-regulated 
(see below; Table 2.2). 
 
Genetic organisation of the predicted nan/nag gene clusters. Our presumption, 
based on the microarray results, was that the proteins encoded by the Bbr_0160-0172 
gene cluster, and those of Bbr_1247-1248, schematically outlined in Figure 2.3, are 
involved in the metabolism of sialic acid in B. breve UCC2003. The first gene of this 
up-regulated cluster, Bbr_0160, encodes a hypothetical protein of unknown function. 
Bbr_0161, designated nanK here, encodes a putative N-acetylmannosamine kinase 
and is predicted to be a member of the ROK protein family. Members of this family 
include transcriptional regulators and sugar kinases (Titgemeyer et al., 1994). 
Predicted ROK kinases possess a conserved N-terminal ATP-binding motif, DxGxT, 
which can be identified in the nanK gene of B. breve UCC2003 and which is absent 
in ROK transcriptional regulators (Conejo et al., 2010). The predicted function of 
NanK is to phosphorylate N-acetylmannosamine, producing N-acetylmannosamine-
6-phosphate. Bbr_0162, designated here as nanE, is predicted to encode an N-
acetylmannosamine-6-phosphate epimerase, the predicted function of which is the 
conversion of N-acetylmannosamine-6-phosphate to N-acetylglucosamine-6-
phosphate. Bbr_0163 encodes a putative hydrolase protein, the function of which, if 
any, in relation to sialic acid metabolism is unknown. The deduced protein products 
of Bbr_0164-0167 are predicted to represent an ABC transport system, including a 
putative solute-binding protein, permease and two ATP-binding proteins, and were 
designated nanB, nanC, nanD and nanF, respectively. Bbr_0168, designated nanA, 
encodes a putative N-acetylneuraminate lyase. The predicted function of NanA is the 
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cleavage of sialic acid, producing N-acetylmannosamine and pyruvate. Bbr_0169, 
designated nagB1, encodes a putative glucosamine-6-phosphate deaminase, the 
predicted function of which is the conversion of glucosamine-6-phosphate to 
fructose-6-phosphate, with the concomitant release of ammonia. Bbr_0170 is a 
pseudogene which is predicted to encode a truncated, non-functional NagA protein. 
Bbr_0171 encodes a predicted sialidase, designated nanH, which due to the lack of a 
signal sequence at the N-terminal is presumed to be intracellular. Sialidases are 
responsible for the removal of sialic acid residues from glycans. The nanH gene is 
followed by Bbr_0172, a putative ATPase from the AAA+ superfamily of ATPases, 
a large and diverse family of enzymes which are found in all kingdoms of living 
organisms where they are essential in various cellular processes such as proteolysis 
and DNA replication (Ogura & Wilkinson, 2001). Its function, if any, regarding 
sialic acid metabolism in B. breve UCC2003 is obscure. The Bbr_0160-0172 gene 
cluster was renamed as the nan/nag cluster, as it includes a complete nan system, as 
defined in 2004 as “one that minimally includes orthologues of genes encoding 
NanA, NanE and NanK” (Vimr et al., 2004), as well as a predicted transport system 
and the nagB1-encoded glucosamine-6-phosphate deaminase. In addition to the 
nan/nag cluster, the Bbr_1247/Bbr_1248 locus is also predicted to be involved in 
sialic acid metabolism. Bbr_1247 (designated nagA2), encodes a putative N-
acetylglucosamine-6-phosphate deacetylase, the predicted function of which is the 
removal of acetate from N-acetylglucosamine-6-phosphate, producing glucosamine-
6-phosphate. Bbr_1248 (designated nagB3), encodes an additional glucosamine-6-
phosphate deaminase (see above). Therefore, within these two loci, whose 
encompassing genes are transcriptionally induced when B. breve UCC2003 is grown 
on sialic acid, we can identify elements of a complete sialic acid catabolic pathway 
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corresponding to that previously outlined in E. coli (Fig. 2.1), with the sole 
difference being a nanBCDF-encoded ABC-type transport system instead of a nanT 
encoded transporter in E. coli (Plumbridge & Vimr, 1999). Interestingly, the genome 
of B. breve UCC2003 contains two adjacent genes, corresponding to locus tags 
Bbr_0846 and Bbr_0847, designated here as nagA1 and nagB2, which are predicted 
to encode additional N-acetylglucosamine-6-phosphate deacetylase and 
glucosamine-6-phosphate deaminase activities respectively, although these genes 
were not shown to be significantly up-regulated when B. breve UCC2003 was grown 
on sialic acid. The NagA1 protein shares a 74 % identity with NagA2, while the 
NagB1 protein shares an 84 % identity with NagB2 and an 89 % identity with 
NagB3. Based on the comparative genome analysis presented in Figure 2.3, the 
nan/nag cluster is highly conserved among the B. breve strains whose genomes were 
recently published (Bottacini et al., 2014). The same genes can also be identified in 
B. longum subsp. infantis ATCC15697, another Bifidobacterium which can utilise 
sialic acid, although the order of the genes of this particular nan/nag cluster has been 
slightly rearranged relative to that of B. breve UCC2003 (Sela et al., 2008) (Fig. 2.3). 
There are no other homologs of this cluster within the completed bifidobacterial 
genomes currently available. 
 
Disruption of the nanK, nanB, nanC, nanA and nagA2 genes in B. breve 
UCC2003. In order to investigate if disruption of individual genes from the nan 
cluster would affect the ability of B. breve UCC2003 to utilise sialic acid, insertion 
mutants were constructed in the nanK, nanB, nanC, nanA and nagA2 genes, resulting 
in strains B. breve UCC2003-nanK, B. breve UCC2003-nanB, B. breve UCC2003-
nanC, B. breve UCC2003-nanA and B. breve UCC2003-nagA2, respectively. These 
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strains were analysed for their ability to grow in mMRS supplemented with sialic 
acid as compared to B. breve UCC2003. As expected, and in contrast to the wild 
type, there was a complete lack of growth of B. breve UCC2003-nanA in media 
containing sialic acid (Fig. 2.4A). In order to demonstrate that the protein product of 
nanA is uniquely required for sialic acid metabolism in B. breve UCC2003, a 
complementation experiment was performed. The nanA gene was cloned into 
pBC1.2 under the control of the constitutive p44 promoter (Alvarez-Martin et al., 
2012) and introduced into B. breve UCC2003-nanA. Expression of NanA in B. breve 
UCC2003-nanA-pBC1.2-nanA allowed this strain to regain its ability to grow on 
sialic acid to an OD600nm level comparable to that reached by the wild type (Fig. 
2.4B). The insertion mutants, B. breve UCC2003-nanK, B. breve UCC2003-nanB 
and B. breve UCC2003-nanC also failed to grow in media containing sialic acid. 
However, the insertion mutant B. breve UCC2003-nagA2 reached OD600nm levels 
comparable to the wild type strain during growth on sialic acid. Growth of the 
insertion mutants was not impaired on lactose, where all strains reached final 
OD600nm levels comparable to that reached by the wild type strain (Fig. 2.4A).  
 
Purification and biochemical characterisation of NanA, NanK, NanE, NagA2 and 
NagB1. In order to investigate the predicted enzymatic activities of NanA, NanK, 
NanE, NagA2 and NagB1, the genes encoding the respective enzymes were cloned 
into L. lactis NZ9000 and subsequently overproduced and purified. The thus 
produced NanAHis, NanKHis, NanEHis, NagA2His and NagB1His proteins exhibited 
their expected molecular masses of 34 kDa, 33 kDa, 23 kDa, 45 kDa and 29 kDa, 
respectively (results not shown). Biochemical characterisation was performed by 
incubating an individual enzyme or combination of enzymes with a particular 
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substrate and resulting products were analysed by HPTLC. The results are consistent 
with the predicted sialic acid breakdown pathway as outlined above (Fig. 2.1) 
(Plumbridge & Vimr, 1999). Under the HPTLC conditions used, it was not possible 
to visualise sialic acid, however, as expected, NanAHis, when incubated with its 
assumed substrate, was shown to produce a product with similar mobility properties 
as N-acetylmannosamine. The expected by-product of the reaction, pyruvate, was not 
visible under these conditions. NanKHis was, only in the presence of ATP, shown to 
use N-acetylmannosamine as a substrate, generating a product with HPTLC mobility 
properties consistent with its expected product N-acetylmannosamine-6-phosphate. 
Furthermore, when both NanAHis and NanKHis were incubated with sialic acid and 
ATP, this also allowed the production of presumed N-acetylmannosamine-6-
phosphate. Since it was not possible to visualise N-acetylglucosamine-6-phosphate 
or glucosamine-6-phosphate under the HPTLC conditions used, NanEHis, NagB1His 
and NagA2His were incubated together with N-acetylmannosamine-6-phosphate and, 
as expected, the combined activities of these three enzymes generated a product 
exhibiting HPTLC mobility properties consistent with fructose-6-phosphate. If any 
one or two of these enzymes was not included, this product was not generated, thus 
demonstrating the contribution of each of these three enzymes to this biochemical 
conversion (results not shown). Finally, when the five enzymes, NanAHis, NanKHis, 
NanEHis, NagA2His and NagB1His, were incubated with only sialic acid as the 
substrate (plus ATP), a product was generated having HPTLC mobility properties 
consistent with the expected end product fructose-6-phosphate (Fig. 2.5). 
 
Growth of B. bifidum PRL2010 and B. breve UCC2003 or B. breve UCC2003-
nanA on 3’ sialyllactose. Growth of B. bifidum PRL2010 and B. breve UCC2003 in 
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mMRS supplemented with 0.5 % (wt/vol) 3’ sialyllactose, a trisaccharide consisting 
of sialic acid and lactose bound by an α2-3 linkage, was first assessed by measuring 
the OD600nm for 36 h under anaerobic conditions. 3’ sialyllactose was found to 
support growth of B. bifidum PRL2010, reaching OD600nm values of approximately 
0.8 (Fig. 2.6A). Analysis of the CFS after 24 h growth by HPAEC-PAD and 
comparison with non-fermented standards of 3’ sialyllactose, sialic acid and lactose, 
showed that 3’ sialyllactose was consumed from the medium, yet that consumption 
of this trisaccharide coincided with the accumulation of a carbohydrate with 
HPAEC-PAD properties consistent with sialic acid in the medium. It has previously 
been shown that B. bifidum PRL2010 encodes two putative extracellular exo-
sialidases on its genome, each presumed to be specific for α2-3 or α2-6 linkages 
(Turroni et al., 2010). From this information, we assumed that the extracellular 
sialidase of B. bifidum PRL2010 cleaves 3’ sialyllactose to produce sialic acid and 
lactose, of which it can utilise lactose, but not sialic acid (i.e. B. bifidum PRL2010 
does not exhibit growth in a medium containing sialic acid as a sole carbon source 
(Turroni et al., 2012a)), resulting in an accumulation of sialic acid in the media. 
Consistent with this observation, the genome of B. bifidum PRL2010 lacks a sialic 
acid utilisation cluster (Turroni et al., 2010). In contrast, it was found that 3’ 
sialyllactose, and its α2-6 linked counterpart, 6’ sialyllactose, were unable to support 
growth of B. breve UCC2003 (results not shown). In order to establish if B. breve 
UCC2003 could grow in the 3’ sialyllactose-supplemented mMRS medium in which 
B. bifidum PRL2010 was previously grown for 24 h (spent medium), a small amount 
of lactose, 0.01 % (wt/vol), was added to the spent medium prior to inoculation to 
initiate growth . A low inoculum (0.01 %) of B. breve UCC2003 was used to allow 
the strain to undergo multiple growth generations. Growth on lactose was required 
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for the initial increase in cell numbers during the first 12 h, however, HPAEC-PAD 
analysis confirmed that lactose was fully utilised by B. breve UCC2003 after 12 h of 
incubation, after which growth and viability was dependent on the ability to utilise 
the sialic acid in the spent medium. Between 12 and 30 h, B. breve UCC2003 was 
able to reach a viable count of almost 109 CFU ml-1 from a starting point of 108 CFU 
ml-1, and was able to maintain these viable cell numbers until 72 h (Fig. 2.6B). 
HPAEC-PAD analysis of the CFS after 30 h of growth shows the absence of the 
sialic acid-associated peak, implying that the sialic acid released as a result of the 
exo-sialidase activity of B. bifidum PRL2010 was entirely utilised to support growth 
of B. breve UCC2003 (Fig. 2.6C). Consistent with this scenario, B. breve UCC2003-
nanA (which is incapable of growth in sialic acid, see above) was shown to be 
incapable of growth in this spent medium with viable counts dropping from their 
initial inoculation number of 105 CFU ml-1 after 72 h (Fig. 2.6B). As expected, 
HPAEC-PAD analysis demonstrated that sialic acid is not metabolised by B. breve 




B. breve strains represent a dominant commensal group in the breast-fed infant gut 
microbiota, but it is only recently that the factors that contribute to this dominance 
have become a subject of scientific scrutiny. It has already been shown that B. breve 
strains can liberate N-glycans from host glycoproteins (Garrido et al., 2012) and a 
more recent study has demonstrated that B. breve strains can grow on the HMOs 
lacto-N-tetraose, lacto-N-neotetraose and sialylated lacto-N-tetraose (Ruiz-Moyano 
et al., 2013). In the current study, we describe the functional characterisation of a 
locus dedicated to the uptake and utilisation of sialic acid. To our knowledge, this is 
the first study to adopt a functional genomic approach to gain an understanding of 
sialic acid metabolism by a Bifidobacterium species. 
A range of B. breve strains were tested for growth on sialic acid as a sole carbon 
source and of the fourteen strains tested, eleven were shown to be capable of growth. 
DNA microarray analysis of B. breve UCC2003 grown on sialic acid revealed a 
locus of twelve genes predicted to be involved in sialic acid uptake and catabolism, 
as well as two genes specifying a putative N-acetylglucosamine-6-phosphate 
deacetylase and glucosamine-6-phosphate deaminase, designated nagA2 and nagB3 
respectively, located at an unlinked position on the genome. The genome of B. breve 
UCC2003 also contains additional nagA and nagB genes at the Bbr_0846-0847 
locus, which were designated nagA1 and nagB2, respectively. Since the enzymatic 
activities encoded by nagAB genes are also required for the metabolism of amino 
sugars such as N-acetylglucosamine and N-acetylgalactosamine (Reizer et al., 1996; 
White, 1968), the presence of multiple nagAB copies on the B. breve UCC2003 
genome may reflect its metabolic versatility to utilise such amino sugars when they 
are released from host-derived carbohydrates such as mucin and HMO (Kunz et al., 
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2000; Podolsky, 1985). Previously performed comparative genomic hybridisation 
(CGH) analysis revealed that all tested B. breve strains harbour the nan/nag genes on 
their genome, thus indicating that the ability to utilise sialic acid is well conserved in 
the B. breve species (O'Connell Motherway et al., 2011b). An apparent inconsistency 
is the presence of these genes on the genomes of B. breve NIZO 658, B. breve 
LMG13208 and B. breve UCC2007, yet exhibiting an inability to grow on sialic 
acid; however, it must be considered that the nature of CGH analysis means that only 
the presence or absence of genes is revealed, but not any mutations in a gene or 
promoter which may result in loss of function.  
The uptake of sialic acid is likely to be facilitated by an ABC transport system, 
encoded by the nanBCDF genes. Disruption of nanB or nanC in B. breve UCC2003 
was shown to result in an impairment of growth on sialic acid, thus proving that this 
predicted transport system is solely responsible for sialic acid uptake. Previous 
studies have shown that transport of sialic acid into bacterial cells can be achieved by 
ABC transport systems, as seen in Haemophilus ducreyi (Post et al., 2005), 
transporters of the major facilitator superfamily of proteins, as in E. coli (Martinez et 
al., 1995; Vimr & Troy, 1985b) and Ba. fragilis (Brigham et al., 2009) or a tripartite 
ATP-independent periplasmic (TRAP) transporter, as seen in Haemophilus 
influenzae (Allen et al., 2005) and V. cholerae (Chowdhury et al., 2012). ABC 
transport systems have previously been shown to be involved in carbohydrate uptake 
in B. breve UCC2003 (O'Connell et al., 2013; O'Connell Motherway et al., 2011a;  
Pokusaeva et al., 2010; Pokusaeva et al., 2011). 
Mutations in nanA and nanK were also shown to cause impaired growth on sialic 
acid, implying that the enzymes encoded by these genes are essential for sialic acid 
metabolism. In contrast, the insertion mutant, B. breve UCC2003-nagA2, did not 
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display impaired growth on sialic acid, suggesting that either this gene is not 
involved in sialic acid metabolism or that another gene is able to compensate for the 
mutation, a possible candidate for which would be the nagA1 gene mentioned above. 
Analysis of the substrate specificities of the enzymes NanA, NanK, NanE, NagA2 
and NagB1 indicates that sialic acid metabolism by B. breve UCC2003 occurs by 
means of a five-step pathway, similar to that previously characterised in E. coli (Fig. 
2.1) (Plumbridge & Vimr, 1999). An analogous pathway has been described in H. 
influenzae (Vimr et al., 2000), Staphylococcus aureus (Olson et al., 2013) and Lb. 
sakei (Anba-Mondoloni et al., 2013), yet it differs slightly from that found in Ba. 
fragilis. It was shown that Ba. fragilis does not encode a nanK gene, but instead 
encodes a novel N-acetylmannosamine epimerase, designated nanE, which converts 
N-acetylmannosamine to N-acetylglucosamine, which is then phosphorylated by a 
rokA-encoded kinase (Brigham et al., 2009). While individual enzymes of this 
pathway have been purified and characterised previously, such as NanA from C. 
perfringens (Krüger et al., 2001), H. influenzae (Lilley et al., 1998) and 
Lactobacillus plantarum (Sánchez-Carrón et al., 2011) and the previously mentioned 
NanE from Ba. fragilis (Brigham et al., 2009), to our knowledge this is the first time 
that the full catabolic pathway of sialic acid has been reconstituted in vitro. 
In order for B. breve UCC2003 to utilise sialic acid, it must first be released from 
glyconjugates such as mucin or HMO, in which it is most commonly found. 
Sialidases, which release sialic acid from glycans, have previously been described 
for infant-derived bifidobacteria, including two intracellular sialidases from B. 
longum subsp. infantis ATCC15697 (Sela et al., 2011) and an extracellular sialidase 
from B. bifidum JCM1254 (Kiyohara et al., 2011). Two predicted extracellular exo-
α-sialidases were also identified on the genome of B. bifidum PRL2010 (Turroni et 
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al., 2010). A putative intracellular sialidase is located in the nan/nag locus of B. 
breve UCC2003, but as yet its substrate is unknown. Its cognate substrate may be 
sialylated lacto-N-tetraose, which has previously been shown to support growth of 
various B. breve strains (Ruiz-Moyano et al., 2013).  
Interestingly, growth experiments of B. breve UCC2003 in spent medium in which 
B. bifidum PRL2010 had previously grown on 3’ sialyllactose (as the sole carbon 
source) showed that B. breve UCC2003 can cross feed on the sialic acid released by 
the exo-sialidase activity of B. bifidum PRL2010. These results suggest that B. 
bifidum PRL2010 uses its sialidase activity to gain access to the lactose component 
of this HMO and leaving the sialic acid for B. breve UCC2003 (and others) to 
forage. These results show that a lack of sialidase activity would not necessarily 
disadvantage the proliferation of a cross-feeding bifidobacterial strain such as B. 
breve UCC2003 in the infant gut. Similarly, a recent study showed that two 
pathogens, Salmonella enterica serovar Typhimurium (S. typhimurium) and 
Clostridium difficile can scavenge sialic acid released by the sialidase activity of 
Bacteroides thetaiotaomicron in a gnotobiotic mouse (Ng et al., 2013). Within the 
same study, it was shown that antibiotic-treated mice had elevated levels of free 
sialic acid in the caecum, as compared to their untreated counterparts. The authors 
proposed that in the untreated gut, sialic acid is utilised by members of the gut 
microbiota. Antibiotic treatment causes acute disturbance in this complex 
microbiota, yet enough sialidase-producing bacteria remain, resulting in elevated 
levels of sialic acid, which can be exploited by a sialic acid-utilising pathogen, such 
as C. difficile (Ng et al., 2013).  
Our results, combined with previous knowledge on the utilisation of sialic acid by 
pathogens, e.g. C. difficile, suggest that the metabolism of sialic acid by certain 
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bifidobacterial strains such as B. breve UCC2003 may provide competition for 
opportunistic pathogens in a healthy gut environment, thus inhibiting or moderating 
their proliferation. It also suggests a role for sialic acid-utilising B. breve strains as 
probiotic prophylaxis, particularly during antibiotic treatment, or in probiotic 
treatment of C. difficile infection, as recently suggested (Ley, 2014). Recently, B. 
breve strains were identified as suitable probiotics for the treatment of enteric 
disorders in infants (Aloisio et al., 2012). Our results suggest that a combination of 
(extracellular) sialidase-encoding B. bifidum strains and sialic acid-utilising B. breve 
strains can improve colonisation and persistence of B. breve strains in the infant gut, 
thus potentially conferring the aforementioned benefits to its infant host.  
Previous research has shown that B. breve UCC2003, as well as other B. breve 
strains, are capable of utilising a number of constituents of an adult, plant-based diet 
(O'Connell et al., 2013; O'Connell Motherway et al., 2008; O'Connell Motherway et 
al., 2011a; O'Connell Motherway et al., 2013; Pokusaeva et al., 2011; Ryan et al., 
2006), yet this data did not explain the prevalence of this species in the infant gut. 
The current study, which demonstrates how B. breve UCC2003 can utilise sialic 
acid, advances our understanding on the prevalence of B. breve in the infant gut, 
where cross-feeding may play an important role in the establishment of a microbiota 








The Alimentary Pharmabiotic Centre is a research centre funded by Science 
Foundation Ireland (SFI), through the Irish Government's National Development 
Plan. The authors and their work were supported by SFI (Grant Nos. 07/CE/B1368 
and SFI/12/RC/2273) and a HRB postdoctoral fellowship (Grant No. 




2.7 TABLES AND FIGURES 
Table 2.1: Bacterial strains and plasmids used in this study. 
Strains and plasmids Relevant features Reference or source 
Strains   
Escherichia coli strains   
E.coli XL1-blue (supE44 hsdR17 recA1 gyrA96 thi relA1 lac F′ [proAB+ laclq lacZΔM15 Tn10(Tetr)]) Stratagene 
E.coli XL1-blue-pBC1.2-nanA XL1-blue containing pBC1.2-nanA This study 
E.coli EC101 Cloning host; repA+ kmr (Law et al., 1995) 
E.coli EC101-pNZ-M.Bbrll+Bbr11 EC101 harboring a pNZ8048 derivative containing bbrllM and bbrlllM (O'Connell Motherway et al., 2009) 
Lactococcus lactis strains   
L. lactis NZ9000 MG1363, pepN::nisRK, nisin inducible overexpression host (de Ruyter et al., 1996) 
L. lactis NZ9000-pNZ-nanA NZ9000 containing pNZ-nanA This study 
L. lactis NZ9000-pNZ-nanK NZ9000 containing pNZ-nanK This study 
L. lactis NZ9000-pNZ-nanE NZ9000 containing pNZ-nanE This study 
L. lactis NZ9000-pNZ-nagA2 NZ9000 containing pNZ-nagA2 This study 
L. lactis NZ9000-pNZ-nagB1 NZ9000 containing pNZ-nagB1 This study 
L. lactis NZ9000-pNZ44-nanA NZ9000 containing pNZ44-nanA This study 
               L. lactis NZ97000 Nisin-A producing strain (de Ruyter et al., 1996) 
Bifidobacterium sp. strains   
B. breve UCC2003 Isolate from a nursling stool (Maze et al., 2007) 
B. breve UCC2003-nanA pORI19-tetW-nanA insertion mutant of UCC2003 This study 
B. breve UCC2003-nanK pORI19-tetW-nanK insertion mutant of UCC2003 This study 
B. breve UCC2003-nanB pORI19-tetW-nanB insertion mutant of UCC2003 This study 
B. breve UCC2003-nanC pORI19-tetW-nanC insertion mutant of UCC2003 This study 
B. breve UCC2003-nagA2 pORI19-tetW-nagA2 insertion mutant of UCC2003 This study 
B. breve UCC2003-nanA-pBC1.2-
nanA 
pORI19-tetW-nanA insertion mutant of UCC2003 harbouring complementation 
construct pBC1.2-nanA 
This study 
B. breve JCM7017 Isolate from human faeces JCM 
B. breve JCM7019 Isolate from adult faeces JCM 
B. breve NCFB2257 Isolate from infant intestine  NCFB 
B. breve NCFB2258 Isolate from infant intestine NCFB 
B. breve NCIMB8815 Isolate from human faeces NCIMB 
B. breve NIZO658 Isolate from human faeces NIZO 
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B. breve LMG13208 Isolate from infant intestine LMG 
B. breve UCC2007 Isolate from nursling stool UCC 
B. breve UCC2005 Isolate from infant intestine UCC 
B. breve NCTC11815 Isolate from infant intestine NCTC 
B. breve 461B Isolate from infant/adult faeces PRL 
B. breve 689B Isolate from infant faeces (Bottacini et al., 2014) 
B. breve 12L Mother’s milk (Bottacini et al., 2014) 
B. bifidum PRL2010 Isolate from infant faeces (Turroni et al., 2010) 
   
Plasmids   
pAM5 pBC1-puC19-Tetr (Álvarez-Martín et al., 2007) 
pNZ44 pNZ8048 containing constitutive p44 promoter from Lactococcal chromosome (McGrath et al., 2001) 
pNZ44-nanA pNZ44 harbouring nanA downstream of p44 promoter This study 
pBC1.2 pBC1-pSC101-Cmr (Álvarez-Martín et al., 2007) 
pBC1.2-nanA pBC1-pSC101-Cmr harbouring nanA downstream of p44 promoter This study 
pORI19 Emr, repA-, ori+, cloning vector (Law et al., 1995) 
pORI19-tetW-nanA Internal 301 bp fragment of nanA and tetW cloned in pORI19 This study 
pORI19-tetW-nank Internal 370 bp fragment of nanK and tetW cloned in pORI19 This study 
pORI19-tetW-nanB Internal 504 bp fragment of nanB and tetW cloned in pORI19 This study 
pORI19-tetW-nanC Internal 355 bp fragment of nanC and tetW cloned in pORI19 This study 
pORI19-tetW-nagA2 Internal 402 bp fragment of nagA2 and tetW cloned in pORI19 This study 
pNZ8150 Cmr, nisin-inducible translational fusion vector (Mierau & Kleerebezem, 2005) 
pNZ-nanA nanA cloned downstream of nisin-inducible promoter on pNZ8150  This study 
pNZ-nanK nanK cloned downstream of nisin-inducible promoter on pNZ8150 This study 
pNZ-nanE nanE cloned downstream of nisin-inducible promoter on pNZ8150 This study 
pNZ-nagA2 nagA2 cloned downstream of nisin-inducible promoter on pNZ8150 This study 
pNZ-nagB1 nagB1 cloned downstream of nisin-inducible promoter on pNZ8150 This study 
JCM: Japanese Collection of Microorganisms; NCFB: National Collection of Food Bacteria; NCIMB: National Collection of Industrial and 
Marine Bacteria; NIZO: Netherlands Institute for Dairy Research; LMG: Belgian Co-ordinated Collection of Microorganisms; UCC: University 
College Cork, Ireland; NCTC: National Collection of Type Cultures; PRL: Culture collection of probiogenomics, University of Parma.
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Table 2.2: Effect of sialic acid on the transcriptome of B. breve UCC2003 
Locus tag  
(Gene name) 
Predicted Function Level of 
upregulation 
Bbr_0160 Conserved hypothetical protein 37.32 
Bbr_0161 (nanK) ROK family kinase 59.01 
Bbr_0162 (nanE) N-acetylmannosamine-6-P 2-epimerase  49.91 
Bbr_0163 Hydrolase 51.55 
Bbr_0164 (nanB) Substrate binding protein 367.68 
Bbr_0165 (nanC) ABC transport system permease protein 451.08 
Bbr_0166 (nanD) ABC transport system ATP-binding protein 453.7 
Bbr_0167 (nanF) ABC transport system ATP-binding protein 435.43 
Bbr_0168 (nanA) N-acetylneuraminate lyase 435.04 
Bbr_0169 (nagB1) Glucosamine-6-P deaminase 275.38 
Bbr_0171 (nanH) Sialidase A 204.69 
Bbr_0172 ATPase 6.7 
Bbr_1247 (nagA2) N-acetylglucosamine-6-P deacetylase 3.07 
Bbr_1248 (nagB3) Glucosamine-6-P deaminase 4.11 





Figure 2.1: Metabolism of sialic acid by E. coli, as previously described 
(Plumbridge & Vimr, 1999). Sialic acid enters the cell through a transporter, 
encoded by the nanT gene. Intracellular sialic acid is cleaved by the nanA- encoded 
N-acetylneuraminate lyase, producing pyruvate and N-acetylmannosamine. N-
acetylmannosamine is phosphorylated by the nanK-encoded N-acetylmannosamine 
kinase forming N-acetylmannosamine-6-phosphate, which is in turn converted to N-
acetylglucosamine-6-phosphate by the nanE-encoded N-acetylmannosamine-6-
phosphate epimerase. N-acetylglucosamine-6-phosphate then enters the amino sugar 
degradation pathway, where this compound is first deacetylated by a nagA-encoded 
N-acetylglucosamine-6-phosphate deacetylase, and subsequently converted to 
fructose-6-phosphate with the concomitant release of ammonia by the nagB-encoded 





Figure 2.2: Final OD600nm values obtained following 24 h growth of 14 different B. 
breve strains in mMRS containing 0.5 % (wt/vol) lactose or sialic acid as the sole 






Figure 2.3: Comparison of the sialic acid gene cluster of B. breve UCC2003 with corresponding putative sialic acid utilisation loci of other 
bifidobacteria. Each solid arrow represents an open reading frame. The length of the arrows (which contain the locus tag number) is proportional 
to the size of the open reading frame and the gene locus name, which is indicative of its putative function, is given at the top. Orthologs are 
marked with the same colour. The amino acid identity of each predicted protein to its equivalent protein encoded by B. breve UCC2003, 








Figure 2.4: (A) Final OD600nm values after 24 h of growth of B. breve UCC2003 and 
the insertion mutants, B. breve UCC2003-nanA, B. breve UCC2003-nanK, B. breve 
UCC2003-nanB, B. breve UCC2003-nanC and B. breve UCC2003-nagA2 in mMRS 
containing 0.5 % (wt/vol) lactose or sialic acid as the sole carbon source. (B) Final 
OD600nm values after 24 h of growth of B. breve UCC2003, the insertion mutants B. 
breve UCC2003-nanA and B. breve UCC2003-nanA-pBC1.2, and the complemented 
insertion mutant B. breve UCC2003-nanA-pBC1.2-nanA in mMRS containing 0.5 % 
(wt/vol) lactose or sialic acid as the sole carbon source. The results are the mean 









Figure 2.5: Hydrolysis of sialic acid to fructose-6-phosphate by the combined 
activities of purified NanAHis, NanKHis, NanEHis, NagA2His and NagB1His. Lane 1: 5 
mg ml-1 (wt/vol) standards in kinase buffer: (A) N-acetylmannosamine, (B) N-
acetylmannosamine-6-phosphate, (C) fructose-6-phosphate. Lane 2: NanAHis + sialic 
acid. Lane 3: NanKHis + N-acetylmannosamine. Lane 4: NanAHis and NanKHis + 
sialic acid. Lane 5: NanEHis, NagA2His and NagB1His + N-acetylmannosamine-6-
phosphate. Lane 6: NanAHis, NanKHis, NanEHis, NagA2His and NagB1His + sialic 
acid. 








Figure 2.6: (A) Growth profiles of B. bifidum PRL2010 in mMRS containing 0.5 % 
(wt/vol) lactose or 3’ sialyllactose for 36 h. The results are the mean values obtained 
from two separate experiments. Error bars represent the standard deviation. (B) 
Growth profiles of B. breve UCC2003 and B. breve UCC2003-nanA in mMRS 
containing 0.5 % (wt/vol) 3’sialyllactose (previously fermented by B. bifidum 
PRL2010 for 24 h). The results are the mean values obtained from two separate 
experiments. Error bars represent the standard deviation. (C) HPAEC profiles of (I) 
mMRS + 0.5 % (wt/vol) 3’ sialyllactose; (II) mMRS + 0.5 % (wt/vol) sialic acid; 
(III) mMRS + 0.5 % (wt/vol) 3’sialyllactose after 24 h growth of B. bifidum 
PRL2010; (IV) the media from (III) after 30 h growth of B. breve UCC2003 (V) the 




Table S2.1: Oligonucleotide primers used in this study. 
Purpose Primer Sequence 
Cloning of 301 bp fragment of nanA in pORI19 NanAF TAGCATCTGCAGGAGATCGAGCGCCACTTC 
 NanAR TGGCATTCTAGACACGTTGGCGAGTCCCGGC 
Cloning of 370 bp fragment of nanK in pORI19 NanKF GCTATTAAGCTTGTAGTGCTCTCGATCGGCGTG 
 NanKR GATCTATCTAGACGTCCGGGTCGATGAGGTTG 
Cloning of 504 bp fragment of nanB in pORI19 NanBF TACGCTGCATGCGTGGAACGTGAATGTGGATGAC 
 NanBR GTATGCTCTAGAGGGCGGAGGACTTCATGGAC 
Cloning of 355 bp fragment of nanC in pORI19 NanCF TAGCATAAGCTTCTTCCTGATGTCGTTCTCCC 
 NanCR GACTAGTCTAGAGGTAGCGATGGCGATGATG 
Cloning of 402 bp fragment of nagA2 in pORI19 NagA2F TAGCTACTGCAGGCATTGATGTGGCTCGTG 
 NagA2R GCATCGTCTAGACCTTGGCGGTCTCGTAGTC 
Amplification of tetW TetWF TCAGCTGTCGACATGCTCATGTACGGTAAG 
 TetWR GCGACGGTCGACCATTACCTTCTGAAACATA 
Confirmation of site-specific homologous recombination NanAconfirm ACCGTCATGGAGATTGTCGA 
 NanKconfirm GTGACCGACCTGCCAGTGC 
 NanBconfirm GCGGACCTCAAGAAGATGCC 
 NanCconfirm CACAAGTCATTCGCCATCAC 
 NagA2confirm CCGTAATGCAGTGGTGGATG 
Cloning of nanA into pNZ44 NanApNZ44F TAGCATTCTAGAGATGTCAGGCCTCGGTGGA 
 NanApNZ44R TAGCATTCTAGACAACGAAGGGAACCGGGAC 
Cloning of p44-nanA in pBC1.2 P44FORWARD TCAGCAGGATCCGAGATAATGCCGACTGTAC 
Cloning of nanA into pNZ8150 NanAFOR TAGCATGATATCATGACAACACAATTCCGCG 
 NanAREV CATTAGTCTAGATCAATGGTGATGGTGATGGTGATGGTGATGGTGGGTGGAG
GCGGAGACTTC 
Cloning of nanK into pNZ8150 NanKFOR TAGCGTGATATCATGCACCATCACCATCACCATCACCATCACCATCCCACCTA
CCTCGCCTTCGACATC 
 NanKREV TAACGTTCTAGACTTGTCTATCGCGCGTCGTCCGGC 
Cloning of nanE into pNZ8150 NanEFOR TAGCATGATATCATGCACCATCACCATCACCATCACCATCACCATCATCAGGC
AATCGAGAAGATC 
 NanEREV CGTTCATCTAGACTCACAGCTTCGCCTCG 
Cloning of nagA2 in pNZ8150 NagA2FOR TAGCATGATATCATGCACCATCACCATCACCATCACCATCACCATTCTGATAG
GGAAGAAATTGTCTC 
 NagA2REV CGTTCATCTAGAGCCATTGCAGCTATTTC 
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Cloning of nagB1 in pNZ8150 NagB1FOR TAGCATGATATCATGGCAGAAGTCATCATCGTCAAG 
 NagB1REV TGCACGTCTAGATCAATGGTGATGGTGATGGTGATGGTGATGGTGGATCGTC
TGCCAGGCCGG  
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Bifidobacterium breve strains are numerically prevalent among the gut microbiota of 
healthy, breast-fed infants. The metabolism of sialic acid, a ubiquitous 
monosaccharide in the infant and adult gut, by B. breve UCC2003 is dependent on a 
large gene cluster, designated the nan/nag cluster. The aim of this study was to 
analyse the transcriptional regulation of the nan/nag cluster and thus sialic acid 
metabolism in B. breve UCC2003. Insertion mutagenesis and transcriptome analysis 
revealed that the nan/nag cluster is regulated by a GntR family transcriptional 
repressor, designated NanR. NanR was shown to bind to two promoter regions 
within this cluster, each of which containing an imperfect inverted repeat that is 
believed to act as the operator sequence. Formation of the DNA-NanR complex is 
prevented in the presence of sialic acid, which we had previously shown to induce 
transcription of this gene cluster. NanR represents the first GntR-type transcriptional 




Bifidobacteria are Gram-positive, strictly anaerobic, non-motile, non-sporulating 
bacteria, which are members of the Actinobacteria phylum and the 
Bifidobacteriaceae family. They were first isolated in 1900 by Henri Tissier, who 
recommended the administration of bifidobacteria to infants for the treatment of 
diarrhoea (Tissier, 1900). Bifidobacteria are typically found in the large intestine of 
humans and other mammals and represent the dominant bacterial group among the 
intestinal microbiota of breast-fed infants (Turroni et al., 2012; Ventura et al., 2007). 
Bifidobacteria have been implicated in a number of health-promoting activities 
including vitamin provision (LeBlanc et al., 2013), serum cholesterol reduction 
(Bordoni et al., 2013), the development and modulation of the immune system 
(Round & Mazmanian, 2009; Ventura et al., 2012), and protection against 
pathogenic bacteria (Servin, 2004). For this reason bifidobacteria have been used as 
probiotic bacterial ingredients in certain foods (Stanton et al., 2005). 
Bifidobacteria are saccharolytic bacteria whose survival and colonisation of the large 
intestine requires the ability to utilise some of the complex diet- and host-derived 
carbohydrates present in this environment. Approximately 8 % of the predicted 
proteins in a typical bifidobacterial genome are assigned to the so-called 
carbohydrate-transport and metabolism COG (Cluster of Orthologous Groups) 
category, with this proportion rising to as high as 12 % in certain bifidobacterial 
genomes (Milani et al., 2014; Schell et al., 2002; Ventura et al., 2007).  
When bacteria are presented with a number of carbon sources, they will want to 
utilise the substrate that yields the highest amount of energy, while inhibiting the 
expression or activity of proteins involved in the uptake and catabolism of other 
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substrates (Gorke & Stulke, 2008). This preferential carbon source utilisation has 
also been described in various bifidobacteria, such as Bifidobacterium animalis 
subsp. lactis (Trindade et al., 2003), Bifidobacterium breve UCC2003 (Pokusaeva et 
al., 2010; Ryan et al., 2005) and Bifidobacterium longum subsp. longum NCC2705 
(Parche et al., 2006). 
One of the primary methods of regulation of carbohydrate utilisation pathways 
employed by bacteria is the transcriptional control of genes involved in the uptake or 
utilisation of less-favoured substrates (Cohn & Horibata, 1959). This involves 
transcriptional regulators, the best known of which is the LacI repressor from 
Escherichia coli (Jacob & Monod, 1961; Lewis, 2005 ; Matthews & Nichols, 1998; 
Wilson et al., 2007). The characterised bifidobacterial transcriptional regulators have 
typically been LacI-family repressors, with the sole exception being RafR, a ROK-
family transcriptional activator from B. breve UCC2003 (O'Connell et al., 2014). 
Among the LacI-family transcriptional repressors characterised from B. breve 
UCC2003 are GalR which controls transcription of the galactan utilisation cluster 
(O'Connell Motherway et al., 2011a), RbsR which regulates transcription of the 
rbsACBDK cluster for ribose utilisation (Pokusaeva et al., 2010), CldR which 
controls transcription of the cldEFGC cluster for cellodextrin metabolism 
(Pokusaeva et al., 2011), and MelR1 and MelR2 which regulate transcription of the 
melezitose utilisation cluster (O'Connell et al., 2014).  
The first characterised GntR-type transcriptional regulator, GntR from Bacillus 
subtilis, represses transcription of the gnt operon required for gluconate metabolism 
(Fujita & Fujita, 1987). In 1991, Haydon and Guest presented the GntR family as 
transcription factors that possess a conserved N-terminal DNA binding domain, yet 
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exhibit considerable divergence in their C-terminal effector binding and 
oligomerisation domains (Haydon & Guest, 1991). Binding of the effector molecule 
to the C-terminal domain causes a conformational change of the N-terminal domain 
and thereby its associated DNA-binding properties (Haydon & Guest, 1991). The 
variable C-terminal portion is used to define the GntR subfamilies, of which the 
FadR subfamily is the largest (Rigali et al., 2002). GntR-type regulators are typically 
found in Actinobacteria, Proteobacteria and Firmicutes (Hoskisson & Rigali, 2009), 
and can regulate various cellular processes, including, but not limited to, mobility in 
Vibrio parahaemolyticus (Jaques & McCarter, 2006), virulence in Mycobacterium 
tuberculosis (Casali et al., 2006) and citrate metabolism in Enterococcus faecalis 
(Blancato et al., 2008). 
A GntR-type transcriptional repressor was previously shown to control sialic acid 
metabolism in E. coli (Kalivoda et al., 2003). Sialic acid metabolism in B. breve 
UCC2003 requires a gene cluster comprising of twelve genes (Bbr_0160-0172), 
designated the nan/nag cluster, as well as two additional genes, nagA2 and nagB3 
(Bbr_1247-1248), located elsewhere on the genome (Egan et al., 2014). The current 
study describes the characterisation of NanR, the transcriptional regulator of the 
nan/nag cluster in B. breve UCC2003, and the first bifidobacterial GntR-type 
regulator to be characterised. 
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3.3 MATERIALS AND METHODS 
Bacterial strains, plasmids, media and culture conditions. Bacterial strains and 
plasmids used in this study are listed in Table 3.1. B. breve UCC2003 was routinely 
cultured in Reinforced Clostridial Medium (RCM; Oxoid Ltd., Basingstoke, 
Hampshire, United Kingdom). Carbohydrate utilisation by bifidobacteria was 
examined in modified deMan Rogosa Sharpe (mMRS) medium made from first 
principles (De Man et al., 1960), without the inclusion of the standard carbohydrate 
source, and supplemented with 0.05 % (wt/vol) L-cysteine HCl and a particular 
carbohydrate source (0.5 % wt/vol). The carbohydrates used were lactose (Sigma 
Aldrich, Steinheim, Germany) and sialic acid (Carbosynth, Compton, Berkshire, 
United Kingdom). Addition of sialic acid to mMRS resulted in a decrease in pH to 
6.0, and hence, the pH was re-adjusted to 6.8 following addition of the sugar and 
subsequently filter sterilised. In order to determine bacterial growth profiles and final 
optical densities, 10 ml of freshly prepared mMRS medium, including a particular 
carbohydrate source, was inoculated with 100 µl (1 %) of a stationary-phase culture 
of a particular strain. Un-inoculated mMRS was used as a negative control. Cultures 
were incubated anaerobically for 24 h and the optical density (OD600nm) was 
recorded. Bifidobacterial cultures were incubated under anaerobic conditions in a 
modular atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 
37°C. E. coli was cultured in Luria Bertani (LB) broth at 37°C with agitation 
(Sambrook, 1989). Where appropriate, growth media contained tetracycline (Tet; 10 
µg ml-1), chloramphenicol (Cm; 5 µg ml-1 for E. coli, 2.5 µg ml-1 for B. breve), 
ampicillin (Amp; 100 µg ml-1), erythromycin (Em; 100 µg ml-1) or kanamycin (Kan; 
50 µg ml-1). Recombinant E. coli cells containing pORI19 were selected on LB agar 
containing Em and Kan, and supplemented with 40 µg ml-1 X-gal (5-bromo-4-
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chloro-3-indolyl-β-D-galactopyranoside) and 1 mM IPTG (isopropyl-β-D-
galactopyranoside). 
  
Nucleotide sequence analysis. Sequence data were obtained from the Artemis-
mediated genome annotations of B. breve UCC2003 (O'Connell Motherway et al., 
2011b; Rutherford et al., 2000). Database searches were performed using the non-
redundant sequence database accessible at the National Centre for Biotechnology 
Information website (http://www.ncbi.nlm.nih.gov) using BLAST (Altschul et al., 
1990). Sequence analysis was performed using the Seqbuilder and Seqman programs 
of the DNASTAR software package (DNASTAR, Madison, WI, USA). Inverted 
repeats in the Bbr_0160 and nanB promoter regions were identified using the 
PrimerSelect program of the DNASTAR software package and a graphical 
representation of the putative NanR-binding motif was obtained using WebLogo 
software (Crooks et al., 2004). Multiple sequence alignments were performed using 
CLUSTAL W (Goujon et al., 2010). 
 
DNA manipulations. Chromosomal DNA was isolated from B. breve UCC2003 as 
previously described (Riordan, 1998). Plasmid DNA was isolated from E. coli and B. 
breve using the Roche High Pure plasmid isolation kit (Roche Diagnostics, Basel, 
Switzerland). An initial lysis step was performed using 30 mg ml-1 of lysozyme for 
30 min at 37°C prior to plasmid isolation from B. breve. Single stranded 
oligonucleotide primers used in this study were synthesised by Eurofins (Ebersberg, 
Germany) (Table 3.2). Standard PCRs were performed using Taq master mix 
(Qiagen GmBH, Hilden, Germany). B. breve colony PCRs were carried out as 
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described previously (O'Connell Motherway et al., 2009). PCR fragments were 
purified using the Roche High Pure PCR purification kit (Roche Diagnostics). 
Electrotransformation of E. coli or B. breve was performed as previously described 
(Maze et al., 2007; Sambrook, 1989). 
 
Construction of B. breve UCC2003-nanR. An internal fragment of 347 base pairs 
(bp), representing codon numbers 102 through to 217 of the 284 codons of gene 
Bbr_0173 (designated nanR), was amplified by PCR using B. breve UCC2003 
chromosomal DNA as a template and the primer pair NanRIMF and NanRIMR. The 
insertion mutant was constructed as described previously (O'Connell Motherway et 
al., 2009). Site-specific recombination of potential Tet-resistant mutant isolates was 
confirmed by colony PCR using primer combinations TetWF and TetWR to verify 
tetW gene integration, and the primer NanRconfirm (positioned upstream of the 
selected internal fragment of nanR) in combination with primer TetWF to confirm 
integration at the correct chromosomal location. 
 
Analysis of global gene expression using B. breve UCC2003 DNA microarrays. 
Global gene expression was determined during log-phase growth of B. breve 
UCC2003-nanR in mMRS supplemented with 0.5 % ribose and the obtained 
transcriptome was compared to that obtained from log-phase B. breve UCC2003 
cells that had also been grown on ribose as the sole carbon source. DNA microarrays 
containing oligonucleotide primers representing each of the 1864 identified open 
reading frames on the genome of B. breve UCC2003 were designed and obtained 
from Agilent Technologies (Palo Alto, Ca., USA). Methods for cell disruption, RNA 
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isolation, RNA quality control, complementary DNA (cDNA) synthesis and 
labelling were performed as described previously (Zomer et al., 2009). Labelled 
cDNA was hybridised using the Agilent Gene Expression hybridisation kit (part 
number 5188-5242) as described in the Agilent Two-Colour Microarray-Based Gene 
Expression Analysis v4.0 manual (publication number G4140-90050). Following 
hybridisation, microarrays were washed in accordance with Agilent’s standard 
procedures and scanned using an Agilent DNA microarray scanner (model G2565A). 
Generated scans were converted to data files with Agilent's Feature Extraction 
software (Version 9.5). DNA-microarray data were processed as previously 
described (García de la Nava et al., 2003; van Hijum et al., 2003; van Hijum et al., 
2005). Differential expression tests were performed with the Cyber-T 
implementation of a variant of the t-test (Long et al., 2001). 
 
Plasmid constructions. For the construction of the plasmid pQE-60-nanR, a DNA 
fragment encompassing the predicted transcriptional repressor-encoding gene, nanR 
(Bbr_0173), was amplified by PCR using PFUII DNA polymerase and the primers 
NanRFORWARD and NanRREVERSE. Plasmid pQE-60 includes a C-terminal 
His6-tag on the plasmid to facilitate downstream purification, to prevent the addition 
of this His6-tag to the protein, a stop codon was included on the reverse primer. The 
generated amplicon was digested with AflIII and BglII, and ligated to NcoI and 
BglII-digested pQE-60. The ligated mixture was introduced into E. coli EC101 (Law 
et al., 1995) by electrotransformation and transformants were selected based on 
ampicillin resistance (Ampr). The plasmid content of a number of Ampr 
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transformants was screened by restriction analysis and the integrity of positively 
identified clones was verified by sequencing. 
In order to clone the Bbr_0160 promoter region, a DNA fragment encompassing the 
intergenic region between the Bbr_0159-0160 genes was generated by PCR 
amplification from B. breve UCC2003 chromosomal DNA using PFUII DNA 
polymerase and the primer pair, nanP1F and nanP1R. The PCR product was digested 
with HindIII and XbaI, and ligated to the similarly digested pBC1.2 (Álvarez-Martín 
et al., 2007). The ligation mixture was introduced into E. coli XL1-blue by 
electrotransformation and transformants were selected based on Tet and Cm 
resistance. Transformants were checked for plasmid content by restriction analysis 
and the integrity of positively identified clones was verified by sequencing. Plasmid 
pBC1.2-nanP1 was introduced into B. breve UCC2003 by electrotransformation and 
transformants were selected based on Cm resistance. 
   
Induced protein production. 25 ml of LB broth was inoculated with a 2 % inoculum 
of E. coli EC101 harboring either pQE-60-nanR or the empty vector, pQE-60 (used 
as a negative control), followed by incubation at 37°C with agitation until an 
OD600nm of 0.5 was reached, at which point protein expression was induced by the 
addition of 1 mM IPTG, followed by further incubation for 2 h. Cells were harvested 
by centrifugation, resuspended in Tris-HCl (pH 8.0) and disrupted with glass beads 
in a mini-bead beater (BioSpec Products, Bartlesville, OK). Cellular debris was 




Electrophoretic mobility shift assays (EMSAs). DNA fragments representing the 
promoter regions upstream of the Bbr_0160 and nanB genes were prepared by PCR 
using Extensor DNA polymerase and IRD-labelled primer pairs (Table 3.3). EMSAs 
were essentially performed as described previously (Hamoen et al., 1998). In all 
cases, the binding reactions were performed in a final reaction volume of 20 μl in the 
presence of poly (dI-dC) in binding buffer (25 mM HEPES, 50 mM sodium 
glutamate, 50 mM KCl, 1 mM phenylmethanesulfonyl fluoride and 10 % glycerol at 
pH 7.0). Various amounts of crude cell extract containing pQE-60-nanR or pQE-60 
were mixed on ice with a fixed amount of DNA probe (0.1 pmol) and subsequently 
incubated for 30 min at 37°C. To determine the effector molecule of NanR, sialic 
acid or N-acetylmannosamine was added to the binding reaction in concentrations 
ranging from 1 mM to 10 mM. Following addition of sialic acid to the binding 
buffer, the pH was re-adjusted to 7.0. Samples were loaded on a 6 % non-denaturing 
polyacrylamide (PAA) gel prepared in TAE buffer (40 mM Tris acetate [pH 8.0], 2 
mM EDTA) and run in a 0.5 to 2.0 x gradient of TAE at 100 V for 2 h in an Atto 
Mini PAGE system (Atto Bioscience and Biotechnology, Tokyo, Japan). Signals 
were detected using an Odyssey Infrared Imaging System (Li-Cor Biosciences, 
United Kingdom Ltd., Cambridge, United Kingdom) and images were captured 
using the supplied Odyssey software v3.0. 
 
Primer extension analysis. Total RNA was isolated from exponentially growing 
cells of B. breve UCC2003 and B. breve UCC2003-pBC1.2-nanP1 in mMRS 
supplemented with 0.5 % sialic acid. Primer extension was performed by annealing 1 
pmol of an IRD-labelled synthetic oligonucleotide to 20 µg of RNA as previously 
161 
 
described (Ventura et al., 2005), using the primers 0160-R1Rev and nanB-B1Rev 
(Table 3.3). Sequence ladders of the presumed Bbr_0160 and nanB promoter regions 
were produced using the same primer as in the primer extension reaction and a DNA 
cycle-sequencing kit (Jena Bioscience, Germany) and were run alongside the primer 
extension products to allow precise alignment of the transcriptional start site with the 
corresponding DNA sequence. Separation was achieved on a 6.5 % Li-Cor Matrix 
KB Plus acrylamide gel. Signal detection and image capture were performed with a 
Li-Cor sequencing instrument (Li-Cor Biosciences).  
 
RT-PCR. 10 μg of RNA isolated from log phase B. breve UCC2003 cells grown in 
mMRS with 0.5 % sialic acid were treated with DNase (Roche) according to the 
manufacturer’s instructions and used as a template in a 100 µl reaction mixture 
containing 20 ng of random primers, 0.5 mM of each deoxyribonucleoside 
triphosphate and Superscript III reverse transcriptase (Invitrogen, Paisley, United 
Kingdom) to produce cDNA. The generated cDNA was then used as a template for 
reverse transcription (RT)-PCRs using Extensor DNA polymerase and the primers 
listed in Table 3.2 in a 20 μl PCR reaction. PCRs were performed under the 
following conditions: initial denaturation at 95°C for 2 min was followed by 30 
cycles of denaturation at 95°C for 30 s, primer annealing at 52°C for 30 s and 
elongation at 68°C for 30 s. The PCR reactions were terminated with a final 




 Microarray data accession number. The microarray data obtained in this study 
have been deposited in NCBI’s Gene Expression Omnibus database and are 




3.4 RESULTS AND DISCUSSION. 
Identification of a GntR-type regulator in B. breve UCC2003. We previously 
demonstrated that transcription of the nan/nag cluster (corresponding to locus tags 
Bbr_0160 through to Bbr_0172), as well as the nagA2 and nagB3 genes, 
corresponding to Bbr_1247 and Bbr_1248, are induced in the presence of sialic acid, 
indicative of the presence of carbohydrate-dependent transcriptional regulation 
(Egan et al., 2014). Bbr_0173, designated here as nanR and located immediately 
downstream of the nan/nag cluster, specifies a 283 amino acid protein (~31 kDa) 
that belongs to the FadR subfamily of the GntR-type transcriptional regulators (Pfam 
family: PF00392) (Finn et al., 2010; Rigali et al., 2002). BLASTP analysis revealed 
that the NanR protein is highly conserved among other sequenced members of the B. 
breve species, perhaps unsurprisingly given that the nan/nag cluster is also highly 
conserved within the species (Egan et al., 2014). NanR also shares high identity with 
predicted GntR-type regulators in Bifidobacterium longum subsp. infantis 
ATCC15697 and Bifidobacterium dentium ATCC27679. Analysis of the genes 
flanking these predicted GntR-type regulators in B. longum subsp. infantis 
ATCC15697 and B. dentium ATCC27679 revealed the presence of genes predicted 
to be involved in the metabolism of sialic acid, suggesting that all of these identified 
bifidobacterial GntR-type regulators are associated with the control of sialic acid 
metabolism. The previously characterised NanR protein from E. coli, also from the 
FadR subfamily (Kalivoda et al., 2003; Rigali et al., 2002), shares 43 % similarity 
with the B. breve UCC2003 NanR protein. This can be considered significant (P < 
0.001) considering that Bifidobacterium species and E. coli represent very different 
bacteria, on both a phylogenetic and phenotypic level. Multiple sequence alignment 
of the aforementioned NanR proteins, as well as the FadR sequence from E. coli is 
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presented in Figure 3.1. The winged helix-turn-helix (HTH) DNA-binding domain of 
NanR (57 amino acids) is similar in size to that of the average DNA-binding domain 
of GntR-type regulators (62 amino acids) (Hoskisson & Rigali, 2009). Within this 
domain some of the residues found to be involved in DNA-binding of FadR could 
also be identified in B. breve UCC2003 (Fig. 3.1) (van Aalten et al., 2000; Xu et al., 
2001). The deduced ligand binding domain of NanR (124 amino acids) appears to be 
smaller than the average length of other C-terminal domains of members of the FadR 
subfamily (150-170 amino acids) (Rigali et al., 2002).  
 
Transcriptome of B. breve UCC2003-nanR. In order to determine if the protein 
product of nanR is responsible for the transcriptional regulation of the nan/nag 
cluster, and/or nagA2 and nagB3, an insertion mutant was constructed and the 
transcriptome was analysed. It was hypothesised that if NanR was to act as a 
repressor, mutation of the corresponding gene should lead to increased transcription 
of the genes it controls, even in the absence of sialic acid. Microarray data revealed 
that, as compared to B. breve UCC2003, the nan/nag locus (with the exception of 
Bbr_0172), was significantly up-regulated (>2.5 fold change; P <0.001) in the 
mutant strain (Table 3.4). These data are consistent with our prediction that nanR 
acts as a transcriptional repressor of the nan/nag cluster. Interestingly, the nagA2 and 
nagB3 genes were not up-regulated in B. breve UCC2003-nanR. As speculated in 
Chapter VI this thesis, these genes may also be involved in the degradation of other 
N-acetylglucosamine and/or N-acetylgalactosamine-containing oligosaccharides, and 




B. breve UCC2003-nanR was also investigated for the ability to utilise sialic acid. As 
expected, the mutant did not display impaired growth on sialic acid as it attained 
final OD600nm values comparable to the wild type strain (Fig. 3.2). This is consistent 
with the notion of NanR being a transcriptional repressor. 
  
Electrophoretic mobility shift assays. In order to determine if the NanR protein 
directly interacts with operator sequences within the nan/nag cluster, the nanR gene 
product was overexpressed in E. coli EC101 using the pQE-60 protein 
overexpression system. The recombinant protein NanR-His lacked binding ability 
(data not shown) and it was hypothesised that the His-tag interferes with the folding 
or binding of the protein. For this reason, nanR was cloned into the pQE-60 vector, 
heterologously expressed without a His-tag and crude cell extracts were used to 
perform EMSAs. Unfortunately, due to the apparent intrinsic instability of the 
protein, it was not possible to produce enough active protein to attain a full shift of 
the DNA fragment. Further extensive efforts were made to improve the activity of 
hetorologously expressed NanR, including cloning the gene into Lactococcus lactis 
NZ9000 with an N-terminal or C-terminal His-tag as previously described for other 
bifidobacterial transcriptional regulators (O'Connell et al., 2014; O'Connell 
Motherway et al., 2011a; Pokusaeva et al., 2010) and cloning the gene under the 
constitutive p44 promoter in B. breve UCC2003 (Alvarez-Martin et al., 2012), yet 
only a partial mobility shift of the target DNA fragment could ever be achieved. 
However, the results obtained with crude cell extract overexpressing NanR 
demonstrate that NanR specifically binds to DNA fragments encompassing the 
intergenic regions upstream of Bbr_0160 and Bbr_0164 (nanB) (Fig. 3.3A and 
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3.3B). NanR failed to bind to the fragments encompassing the intergenic regions 
upstream of nanC, nanA or nanH (data not shown). Crude cell extracts of E. coli 
EC101 containing empty pQE-60 was used as a negative control and, as expected, 
did not alter the electrophoretic behaviour of the DNA fragments (Fig. 3.3B). 
Dissection of the Bbr_0160 promoter region showed that NanR binding required a 
211 bp region, within which a 21 bp imperfect inverted repeat was identified (5’-
ATTAGACATC>A<GACGTCTGAT-3’) Similarly, dissection of the nanB 
promoter region showed that NanR binding required a 196 bp region which also 
includes a 21 bp imperfect inverted repeat (5’-
ATCAGACATC>A<GATGTCATAT-3’), and which is similar to the imperfect 
inverted repeat identified upstream of Bbr_0160 (Fig. 3.3A, 3.3B). Further 
fragmentation of both promoter regions to the point where the inverted repeats were 
excluded resulted in the absence of binding, consistent with the notion that these 
inverted repeats indeed represent operator sequences of NanR (Fig. 3.3A, 3.3B). This 
conserved inverted repeat was also identified upstream of homologues of the 
Bbr_0160 and nanB genes in of all the currently available complete B. breve 
genomes (Bottacini et al., 2014) and the genome of B. longum subsp. infantis 
ATCC15697 (Sela et al., 2008), although it could not be identified at the expected 
locations on the genome of B. dentium ATCC27679.  
Operator binding sequences of GntR-type regulators can be in the form of inverted 
or direct repeats (Rigali et al., 2002). A consensus palindromic operator sequence for 
members of the GntR-type family has been described, comprising 5’- 
(N)yGT(N)xAC(N)y-3’, with the number of residues (y) and the nature of the central 
residues (x) varying (Rigali et al., 2002). The operator sequence of NanR as deduced 
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in this study includes the conserved GT and AC residues, although in the opposite 
order as in the described consensus sequence.  
Sialic acid is the effector molecule for the NanR repressor from E. coli (Kalivoda et 
al., 2003), whereas in Vibrio vulnificus and Staphylococcus aureus, RpiR-type 
regulators control transcription of sialic acid-utilising gene clusters and the effector 
molecule is N-acetylmannosamine, an intermediate of the sialic acid breakdown 
pathway (Hwang et al., 2013; Kim et al., 2011; Olson et al., 2013; Plumbridge & 
Vimr, 1999). At a concentration of 1 mM sialic acid, a significant reduction of 
binding of NanR to the nanB promoter region was observed, whereas N-
acetylmannosamine had no effect on the binding ability of NanR. A similar effect 
was observed for the Bbr_0160 promoter region (Fig. 3.3C). 
 
Identification of the transcription start sites of Bbr_0160 and nanB. In order to 
determine the transcription start site of the presumed promoters upstream of 
Bbr_0160 and nanB, primer extension analysis was performed using RNA extracted 
from B. breve UCC2003 and B. breve UCC2003-pBC1.2-nanP1 grown in mMRS 
containing 0.5 % sialic acid. For the Bbr_0160 promoter region, initial attempts to 
attain a primer extension product from mRNA isolated from B. breve UCC2003 wild 
type cells during growth on sialic acid were unsuccessful, therefore to increase the 
amount of mRNA transcripts of this promoter region, a DNA fragment 
encompassing the promoter region was cloned into pBC1.2 and introduced into B. 
breve UCC2003. Single extension products were identified upstream of the 
Bbr_0160 and nanB genes, and in both cases potential promoter recognition 
sequences resembling consensus -10 and -35 hexamers could be identified upstream 
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of the transcription start sites (Fig. 3.4A). Hence, these two promoters were 
designated nanP1 and nanP2. In both cases, the predicted NanR operator sequence 
overlaps the -35 sequence, a location consistent with the characterisation of NanR as 
a transcriptional repressor (Fig. 3.4A). Binding of NanR is expected to interfere with 
the interaction of RNA polymerase with the -10 and -35 promoter sequences, thus 
preventing transcription of the operon.  
 
RT-PCRs. In order to determine if the nan/nag locus exists as a single or multiple 
transcriptional unit, transcriptional analysis by RT-PCR was performed using cDNA 
templates derived from mRNA transcripts isolated from B. breve UCC2003 during 
growth on sialic acid. The obtained cDNA was used as a template in various PCR 
reactions that targeted the intergenic regions between each gene of the nan/nag 
cluster (NB. some genes of the cluster overlap or are separated by a single base pair 
and were therefore not assessed). As expected, when chromosomal DNA isolated 
from B. breve UCC2003 was used as a positive control, PCR products were obtained 
for each intergenic region. Using cDNA as a template, PCR products were obtained 
for each intergenic region, with the exception of that upstream of Bbr_0160, being 
the first gene of the nan/nag cluster (Fig. 3.4B). Using these results, in combination 
with data obtained from EMSAs and primer extension analysis, we deduce that the 
nan/nag cluster consists of two transcriptional units. The first transcriptional unit, 
driven by the nanP1 promoter upstream of the Bbr_0160 gene, overlaps with the 
second transcriptional unit, which is driven by the nanP2 promoter upstream of the 
nanB gene. Bbr_0173, the gene encoding NanR, is oriented in the opposite direction 
and is therefore not co-transcribed with the nan/nag gene cluster. Accordingly, a 
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predicted rho-independent terminator sequence was identified downstream of the 
Bbr_0172 gene.  
At over fifteen thousand base pairs, the sialic acid utilisation cluster is the largest 
carbohydrate metabolic cluster to be characterised from B. breve UCC2003, 
followed by the galactan utilisation cluster at almost ten thousand base pairs 
(O'Connell Motherway et al., 2011a). That such a large gene cluster can be driven by 
just two promoters reflects the tightly organised nature of the gene cluster, 
particularly between the Bbr_0160-0169 genes. Interestingly, despite the presence of 
a pseudogene (Bbr_0170) between Bbr_0169 (nagB1) and Bbr_0171 (nanH), RT-
PCR and EMSA results indicated the absence of a promoter in this region, thus 
indicating that either or both of the nanP1 and nanP2-driven transcripts terminates at 
the terminator sequence (mentioned above) downstrean of Bbr_0172.  
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3.5 CONCLUDING REMARKS 
The current study investigated the regulation of sialic acid metabolism in B. breve 
UCC2003 by NanR, a GntR-type transcriptional repressor. To our knowledge, NanR 
is the first GntR-family regulator characterised from bifidobacteria, and thus 
represents a diversion from the customary LacI-mediated regulation of carbohydrate 
metabolism in this genus (Lee & O'Sullivan, 2010; O'Connell et al., 2014; O'Connell 
Motherway et al., 2011a; Pokusaeva et al., 2010; Pokusaeva et al., 2011; Schell et 
al., 2002). Although GntR-type regulators are commonly found in the Actinobacteria 
phylum (Hoskisson & Rigali, 2009), it was previously noted that the number of such 
regulators on the genome of B. longum subsp. longum NCC2705 is rather low 
compared to other bacterial genomes (Schell et al., 2002). The genome of B. longum 
subsp. longum NCC2705 encodes just one predicted GntR-family transcriptional 
regulator (Schell et al., 2002), while the B. breve UCC2003 genome is predicted to 
encode three members of this regulator family, including NanR (O'Connell 
Motherway et al., 2011b). We identified homologues of NanR in all currently 
available complete B. breve genome sequences, as well as B. longum subsp. infantis 
ATCC15697 and B. dentium ATCC27679. Each of the NanR-encoding genes was 
located adjacent to genes predicted to be involved in the uptake and metabolism of 
sialic acid. 
The nan/nag cluster was previously identified as required for the uptake and 
metabolism of sialic acid (Egan et al., 2014). The data assembled in this study 
provides significant information on the remarkably efficient method by which B. 
breve UCC2003 regulates this particularly large gene cluster. It was previously 
hypothesised that negative regulation allows bifidobacteria to react faster to 
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fluctuations in the carbohydrate availability in the large intestine (Schell et al., 
2002), and the NanR-mediated control of the nan/nag cluster represents another 
example of such adaptation. 
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3.7 TABLES AND FIGURES 
Table 3.1: Bacterial strains and plasmids used in this study. 
Strains and plasmids Relevant features Reference or source 
Strains   
Escherichia coli strains   
E.coli EC101 Cloning host; repA+ kmr (Law et al., 1995) 
E.coli EC101-pNZ-M.Bbrll+Bbr11 EC101 harboring a pNZ8048 derivative containing bbrllM and bbrlllM (O'Connell Motherway et al., 2009) 
E. coli EC101-pQE-60 EC101 containing pQE-60 This study 
E. coli EC101-pQE-60-nanR EC101 containing pQE-60-nanR This study 
E. coli XL1-blue (supE44 hsdR17 recA1 gyrA96 thi relA1 lac F′ [proAB+ laclq lacZΔM15 Tn10(Tetr)]) Stratagene 
E. coli XL1-blue-pBC1.2-nanP1 XL1-blue containing pBC1.2-nanP1 This study 
Bifidobacterium sp. strains   
B. breve UCC2003 Isolate from a nursling stool (Maze et al., 2007) 
B. breve UCC2003-nanR pORI19-tetW-nanR insertion mutant of UCC2003 This study 
B. breve UCC2003-pBC1.2-nanP1 B. breve UCC2003 containing pBC1.2-nanP1 This study 
   
Plasmids   
pORI19 Emr, repA-, ori+, cloning vector (Law et al., 1995) 
pORI19-tetW-nanR Internal 347 bp fragment of nanR and tetW cloned in pORI19 This study 
pQE-60 Ampr, IPTG inducible vector Qiagen 
pQE-60-nanR nanR cloned into the IPTG inducible vector, pQE-60 This study 
pBC1.2 pBC1-pSC101-Cmr (Álvarez-Martín et al., 2007) 




Table 3.2: Oligonucleotide primers used in this study. 
Purpose Primer Sequence 
Cloning of 347 bp fragment of nanR in pORI19 NanRIMF GCTATTAAGCTTGAAGCGCTCAACATCGTCAAAG 
 NanRIMR GATCTATCTAGAGAACGGACCATCTGCTTGACG 
Amplification of tetW TetWF TCAGCTGTCGACATGCTCATGTACGGTAAG 
 TetWR GCGACGGTCGACCATTACCTTCTGAAACATA 
Confirmation of site-specific homologous recombination NanRconfirm CGCTGTGACGAGACGATGG 
Cloning of nanR in pQE-60 NanRFORWARD GACTAGACATGTGCAACCTATCCGACTCG 
 NanRREVERSE GCATGCAGATCTTCACTCGGTACCTCCCTGAATG 
Cloning of nanP1 in pBC1.2 nanP1F TCGATCAAGCTTCGAGCTGCCTGATACGCC  
 nanP1R TCAGCTTCTAGACTCGCGCAGCTGCTTCATG 
RT-PCRs 0160FOR-RT-PCR CGAGCTGCCTGATACGCC 
 0160REV-RT-PCR CTCGCGCAGCTGCTTCATG 
 0162FOR-RT-PCR CCTCATCGACCCGGACGTG 
 0162REV-RT-PCR CGCTCACCTGGCCCTTG 
 0163FOR-RT-PCR GTCGCATCCACACGCCTG 
 0163REV-RT-PCR GAATGGATGTCGGAGTTGAGC 
 0164FOR-RT-PCR CGGTTACGCCCATACTGC 
 0164REV-RT-PCR CTCCCTTGGCGTTCGTCG 
 0165FOR-RT-PCR CCACCGCCGTCAAGAAGAAC 
 0165REV-RT-PCR GACGCCGAATGCCACAAAC 
 0168FOR-RT-PCR CATTGTGGAGCGCGGAGC 
 0168REV-RT-PCR GCGTCGATCATGCGGTTG 
 0169FOR-RT-PCR CACCAACCAGATGCCCAAC 
 0169REV-RT-PCR GAGTCCCAGCACCGCGTTC 
 0171FOR-RT-PCR CTCGTGCTGCTCGCGTTC 
 0171REV-RT-PCR GCGCACTGTTCCATGTCTG 
 0172FOR-RT-PCR CATTGGCCTGTCTTGGGAG 
 0172REV-RT-PCR GCCATCATCGTCTTGCCTAC 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in italics.
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Table 3.3: IRD-labelled primers used to generate PCR products and primer 



















Table 3.4: Transcriptome analysis of B. breve UCC2003-nanR compared to B. 
breve UCC2003 grown on 0.5 % ribose 
Locus tag  
(gene name) 
Predicted Function Level of 
upregulation 
Bbr_0160 Conserved hypothetical protein 6.58 
Bbr_0161 (nanK) ROK family kinase 3.08 
Bbr_0162 (nanE) N-acetylmannosamine-6-phosphate 
epimerase  
2.74 
Bbr_0163 Hydrolase 4.66 
Bbr_0164 (nanB) Substrate binding protein 14.27 
Bbr_0165 (nanC) ABC transport system permease protein 8.21 
Bbr_0166 (nanD) ABC transport system ATP-binding protein 3.46 
Bbr_0167 (nanF) ABC transport system ATP-binding protein 3.27 
Bbr_0168 (nanA) N-acetylneuraminate lyase 6.85 
Bbr_0169 (nagB1) Glucosamine-6-phosphate deaminase 4.83 
Bbr_0171 (nanH) Sialidase A 4.25 





Figure 3.1: Multiple sequence alignment of the NanR protein from B. breve 
UCC2003 compared to predicted GntR-type regulators from B. dentium 
ATCC27679 and B. longum subsp. infantis ATCC15697, the previously 
characterised NanR protein from E. coli (Kalivoda et al., 2003) and the FadR 
transcriptional regulator from E. coli (Xu et al., 2001) using CLUSTAL X (Goujon 
et al., 2010). Conserved residues are shaded based on conservation in 60 % or more 
of the sequences used. The predicted N-terminal DNA binding domain of NanR is 
indicated by a black box. Arrows below the sequence point at residues previously 
shown to be involved in DNA-binding of FadR that are conserved in B. breve 
sequences (van Aalten et al., 2000; Xu et al., 2001). The predicted C-terminal 





Figure 3.2: Final OD600nm values obtained following 24 h growth of B. breve 
UCC2003 and B. breve UCC2003-nanR in mMRS containing 0.5 % (wt/vol) lactose 
or sialic acid as the sole carbon source. The results are the mean values obtained 









Figure 3.3: (A) Schematic representation of the sialic acid utilisation cluster of B. 
breve UCC2003 and DNA fragments used in electrophoretic mobility shift assays 
(EMSAs) for the Bbr_0160 and nanB promoter regions together with Weblogo 
representation of the predicted operator of NanR. Plus or minus signs indicate ability 
or inability of NanR to bind to the DNA fragment. The bent arrows represent the 
proven promoter regions and the lollipop sign represents a putative rho-independent 
terminator region. (B) EMSAs showing the interactions of (I) crude cell extract 
containing pQE-60-NanR with the DNA fragments R1, R2 and R3 and B1, B2 and 
B3 and (II) the interactions of crude cell extract containing pQE-60 (negative 
control) with the DNA fragments R1 and B1. The minus symbol indicates reactions 
to which no crude cell extract was added, while the remaining lanes represent 
binding reactions with the respective DNA probes incubated with increasing 
amounts of crude cell extract. Each successive lane from right to left represents a 
doubling of the amount of crude cell extract.  (C) EMSAs showing NanR interaction 
with the R1 and B1 DNA fragments with the addition of sialic acid or N-











Figure 3.4: (A) Schematic representation of the (I) Bbr_0160 and (II) nanB 
promoter regions. Boldface type and underlining indicate -10 and -35 hexamers (as 
deduced from the primer extension results) and ribosomal binding site (RBS); the 
transcriptional start site is indicated by an asterisk. The arrows under sequences 
indicate the inverted repeat that represents the putative NanR-binding sequence. The 
arrows in the right panels indicate the primer extension products. (B) PCR products 
obtained using (I) B. breve UCC2003 chromosomal DNA and (II) cDNA obtained 
from mRNA isolated from log-phase B. breve UCC2003 cells during growth in sialic 
acid using oligonucleotide primers spanning the intergenic regions between the 
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Bifidobacteria constitute a specific group of commensal bacteria that commonly 
inhabit the mammalian gastrointestinal tract. Bifidobacterium breve UCC2003 is 
known to utilise a variety of plant/diet/host-derived carbohydrates, including 
cellodextrins, starch and galactan, as well as the mucin and HMO-derived, 
monosaccharide, sialic acid. In the current study, we investigated the ability of this 
strain to utilise parts of a host-derived source of carbohydrate, namely the mucin 
glycoprotein, when grown in co-culture with the mucin-degrading Bifidobacterium 
bifidum PRL2010. B. breve UCC2003 was shown to exhibit growth properties in a 
mucin-based medium, but only when grown in the presence of B. bifidum PRL2010, 
which is known to metabolise mucin. A combination of HPAEC-PAD and 
transcriptome analyses identified some of the possible monosaccharides and 
oligosaccharides which support this enhanced co-cultivation growth/viability 
phenotype. This study provides evidence of a gut commensal relationship between 
two bifidobacterial species, thus advancing our knowledge on the metabolic 
adaptability which allows the former strain to colonise the (infant) gut by its 




Bifidobacteria are Gram positive, anaerobic, Y-shaped bacteria that have been found 
in the gastrointestinal tract (GIT) of mammals, birds and insects and have also been 
isolated from the human oral cavity and sewage (Ventura et al., 2007). In recent 
years, bifidobacteria have attracted attention due to the purported health benefits 
associated with their presence in the gut, including development of the immune 
system (Round & Mazmanian, 2009), provision of vitamins (LeBlanc et al., 2013), 
and protection against pathogenic bacteria (Servin, 2004). Bifidobacteria rapidly 
colonise the infant gut in the first days and weeks of life. In a recent study on the 
microbial diversity of the infant gut, it was found that members of the Actinobacteria 
phylum were dominant, with various bifidobacterial species present in high 
abundance, in particular Bifidobacterium longum, Bifidobacterium bifidum, 
Bifidobacterium breve and Bifidobacterium catenulatum (Turroni et al., 2012b).  
Survival and growth of bifidobacteria in the gastrointestinal tract requires them to 
employ an arsenal of enzymes to metabolise the complex carbohydrates prevalent in 
this environment (Pokusaeva et al., 2011a). B. breve UCC2003 is well-adapted to 
utilise various diet/plant-derived oligo- and poly-saccharides, including melezitose, 
raffinose, cellodextrins, GOS, starch and galactan (O'Connell et al., 2013; O'Connell 
Motherway et al., 2011a; O'Connell Motherway et al., 2013; O'Connell Motherway 
et al., 2008; Pokusaeva et al., 2011b; Ryan et al., 2006). B. breve UCC2003 also 
metabolises the mucin- and human milk oligosaccharide (HMO)-derived 
monosaccharide sialic acid (Egan et al., 2014), which is more consistent with this 
strain’s origin as a nursling stool isolate from a breast-fed infant, where it would be 
expected to metabolise HMOs and/or the structurally similar oligosaccharides found 
in mucin glycoproteins. Along with dietary components, host-derived 
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oligosaccharides are believed to form part of the nutrient resource for certain 
intestinal bacteria.  
The original investigations on the (bio)chemical composition of human colonic 
mucin described twenty-one discrete oligosaccharide structures (Podolsky, 1985). 
Since then, it has been estimated that carbohydrate constitutes approximately 80 % 
of the total mucin mass, and that MUC2, the prominent secretory mucin in the colon, 
may contain more than 100 different O-linked glycans (Larsson et al., 2009; Tytgat 
et al., 1994). Glycosylation of the peptide backbone can be N-linked to an asparagine 
residue or O-linked to serine or threonine residues via N-acetylgalactosamine 
(GalNAc). Subsequent elongation of this structure results in a number of distinct 
core structures. While eight mucin type core structures are known, only four 
regularly occur in human mucins. Core 1 is formed by the addition of galactose (Gal) 
in a β1-3 linkage to GalNAc to produce galacto-N-biose (GNB, also known as the T 
antigen). Core 3, the most common core structure in the human colon, is formed by 
the addition of N-acetylglucosamine (GlcNAc) in a β1-3 linkage to GalNAc. Core 2 
and core 4 structures are formed by the addition of GlcNAc in a β1-6 linkage to core 
1 and core 3, respectively. Each of the core structures can be further elongated by the 
addition of Gal, GalNAc and GlcNAc. The oligosaccharide chains can also be 
substituted with sialic acid, fucose (Fuc) or sulfate residues in terminal or branched 
positions (Capon et al., 2001; Larsson et al., 2009; Podolsky, 1985; Robbe et al., 
2004). 
Due to the high complexity and variability of the mucin oligosaccharide chains, only 
a small proportion of the culturable intestinal microbiota is believed to encode 
enzymes required for (partial) degradation of mucin into free sugars. These include 
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members of the Bifidobacterium, Bacteroides and Ruminococcus genera, as well as a 
more recently characterised bacterium isolated from human faeces, Akkermansia 
muciniphila (Crost et al., 2013; Derrien et al., 2004; Sonnenburg et al., 2005; 
Turroni et al., 2010b). As mentioned previously, B. bifidum is one of the most 
abundant species in the infant intestine (Turroni et al., 2012b). A study in 2010 
revealed that some 60 % of the glycosyl hydrolases identified on the genome of B. 
bifidum PRL2010 are linked to the degradation of mucin, many of which are 
predicted to be extracellular (Turroni et al., 2010a; Turroni et al., 2010b). 
Comparative genome hybridisation analysis revealed that most of these genes 
encoding these glycosyl hydrolases are conserved within the examined members of 
the B. bifidum species (Turroni et al., 2010a; Turroni et al., 2010b).  
It has been suggested that the degradation of mucin by a small number of 
extracellular glycosidase-producing bacteria may provide nutritional support to other 
enteric bacteria (Hoskins et al., 1985). It has been shown that a number of HMO-
derived degradation products remain in the media during vegetative growth of B. 
bifidum (Asakuma et al., 2011). B. breve UCC2003 can cross-feed on sialic acid 
derived from the metabolism of 3’ sialyllactose, an abundant HMO, by B. bifidum 
PRL2010 (Egan et al., 2014). The aim of the current study was to establish if B. 
breve UCC2003 is able to cross-feed on the oligosaccharides released by B. bifidum 
PRL2010 extracellular activity on mucin, and secondly, to investigate which, if any, 




4.3 MATERIALS AND METHODS  
Bacterial strains, plasmids, media and culture conditions. Bacterial strains and 
plasmids used in this study are listed in Table 4.1. B. breve UCC2003 and its 
derivatives were routinely cultured in Reinforced Clostridial Medium (RCM; Oxoid 
Ltd, Basingstoke, Hampshire, United Kingdom). B. bifidum PRL2010 was routinely 
cultured in modified deMan Rogosa Sharpe (mMRS) medium made from first 
principles (but excluding a carbohydrate source) (De Man et al., 1960), and 
supplemented with 0.05 % (wt/vol) L-cysteine HCl and 1 % (wt/vol) lactose (unless 
otherwise stated). All carbohydrates used in this study were purchased from Sigma 
Aldrich and were of the highest purity available. To prepare mucin-containing 
media, a 0.8 % (wt/vol) concentration of mucin from porcine stomach (Type III) was 
prepared in water and autoclaved at 115°C for 10 minutes, in order to optimise 
mucin dissolution, yet minimising glycosidic hydrolysis. This was added to an equal 
volume of twice-concentrated mMRS, resulting in a final concentration of 0.4 % 
mucin in mMRS. Bifidobacterial cultures were incubated under anaerobic conditions 
in a modular atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 
37°C. Escherichia coli was cultured in Luria Bertani (LB) broth at 37 °C with 
agitation (Sambrook, 1989). Where appropriate, growth media contained tetracycline 
(Tet; 10 µg ml-1), chloramphenicol (Cm; 5 µg ml-1 for E. coli, 2.5 µg ml-1 for B. 
bifidum), erythromycin (Em; 100 µg ml-1) or kanamycin (Kan; 50 µg ml-1). 
Recombinant E. coli cells containing pORI19 were selected on LB agar containing 
Em and Kan, and supplemented with X-gal (5-bromo-4-chloro-3-indolyl-β-D-




Nucleotide sequence analysis. Sequence data were obtained from the Artemis-
mediated genome annotations of B. breve UCC2003 (O'Connell Motherway et al., 
2011b; Rutherford et al., 2000). Database searches were performed using non-
redundant sequences available at the National Centre for Biotechnology Information 
internet site (http://www.ncbi.nlm.nih.gov) using BLAST (Altschul et al., 1990). 
Sequence analysis was performed using the Seqbuilder and Seqman programs of the 
DNASTAR software package (DNASTAR, Madison, WI, USA). 
 
DNA manipulations. Chromosomal DNA was isolated from B. breve UCC2003 as 
previously described (Riordan, 1998). Plasmid DNA was isolated from E. coli, B. 
breve and B. bifidum using the Roche High Pure plasmid isolation kit (Roche 
Diagnostics, Basel, Switzerland). An initial lysis step was performed using 30 mg 
ml-1 of lysozyme for 30 min at 37°C prior to plasmid isolation from bifidobacteria. 
Single stranded oligonucleotide primers used in this study were synthesised by 
Eurofins (Ebersberg, Germany) (Table 4.2). Standard PCRs were performed using 
Taq PCR master mix (Qiagen GmbH, Hilden, Germany). B. breve colony PCRs 
were carried out as described previously (O'Connell Motherway et al., 2009). PCR 
products were purified using the Roche High Pure PCR purification kit (Roche 
Diagnostics). Electroporation of plasmid DNA into E. coli or bifidobacteria was 
performed as described previously (Maze et al., 2007; Sambrook, 1989).  
 
Construction of B. breve UCC2003 insertion mutants. An internal fragment of 
Bbr_1742, designated here as fucP (400 base pairs (bp), representing codon numbers 
137 through to 270 out of the 421 codons of fucP), Bbr_1587, designated here as 
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lnbP (479 bp, representing codon numbers 108 through to 267 of the 751 codons of 
lnbP) and Bbr_1833, designated here as lacZ7 (568 bp, representing codon numbers 
123 through 312 of the 699 codons of lacZ7), were amplified by PCR using B. breve 
UCC2003 chromosomal DNA as a template and primer pair FucPF and FucPR, 
LnbPF and LnbPR and LacZ7F and LacZ7R, respectively. The insertion mutants 
were constructed as described previously (O'Connell Motherway et al., 2009). Site-
specific recombination in potential Tet-resistant mutant isolates was confirmed by 
colony PCR using primer combinations TetWF and TetWR to confirm tetW gene 
integration, and the primers FucPconfirm, LnbPconfirm and LacZ7confirm 
(positioned upstream of the selected internal fragment of fucP, lnbP and lacZ7, 
respectively) and TetWF to confirm integration at the correct chromosomal location. 
 
Evaluation of B. breve UCC2003 growth on mucin. Growth of B. breve UCC2003 
using mucin as the sole carbon source was determined both independently and in co-
culture with B. bifidum PRL2010. Plasmid-containing derivatives of the wild type 
strains were used, namely B. breve UCC2003-pAM5, which contains the pAM5 
plasmid and is therefore Tet resistant (Álvarez-Martín et al., 2007) and B. bifidum 
PRL2010-pPKCM7, which contains the pPKCM7 plasmid and is Cm resistant 
(Cronin et al., 2007). Use of plasmid-containing derivatives allowed for selection 
and enumeration of either B. breve UCC2003 or B. bifidum PRL2010 colonies on 
RCA containing the appropriate antibiotic. All B. breve UCC2003 mutant strains 
were also Tet resistant. A 0.001 % inoculum of a stationary phase culture of B. breve 
UCC2003 strains (see Table 1; B. breve UCC2003-pAM5, or the mutant strains, B. 
breve UCC2003-nanA (Egan et al., 2014), B. breve UCC2003-fucP, B. breve 
UCC2003-lnbP, B. breve UCC2003-lacZ7 or B. breve UCC2003-galT (Ruiz et al., 
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2013)) and/or a 0.01 % inoculum of B. bifidum PRL2010-pPKCM7, were added to 
mMRS medium supplemented with 0.05 % (wt/vol) L-cysteine HCl and 0.4 % 
(wt/vol) mucin (see above). Growth of the cultures was measured over 72 h, with 
samples taken every 6 or 12 h. All samples collected were serially 10-fold diluted in 
sterile Ringers solution and plated onto RCA supplemented with 1 % (wt/vol) 
lactose and the appropriate antibiotic. Viable counts were determined by counting 
colonies on agar plates using dilutions that yielded between 30 and 300 colony 
forming units (CFU). 
  
Transcriptome analysis using B. breve UCC2003-based microarrays. B. breve 
UCC2003-pAM5 was grown in mMRS medium supplemented with 0.05 % (wt/vol) 
L-cysteine HCl and 0.4 % ribose to an OD600nm of 0.5 and then harvested by 
centrifugation at 9,000 x g for 2 min at room temperature. B. breve UCC2003-pAM5 
grown in mucin in co-culture with B. bifidum PRL2010-pPKCM7 (see above) was 
similarly harvested after 30 h of growth. DNA microarrays containing 
oligonucleotide primers representing each of the 1864 annotated genes on the 
genome of B. breve UCC2003 were designed by and obtained from Agilent 
Technologies (Palo Alto, CA, USA). Methods for cell disruption, RNA isolation, 
RNA quality control, complementary DNA (cDNA) synthesis and labelling were 
performed as described previously (Zomer et al., 2009). Labelled cDNA was 
hybridised using the Agilent Gene Expression hybridisation kit (part number 5188-
5242) as described in the Agilent Two-Color Microarray-Based Gene Expression 
Analysis (v4.0) manual (publication number G4140-90050). Following 
hybridisation, microarrays were washed as described in the manual and scanned 
using Agilent's DNA microarray scanner G2565A. The scanning results were 
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converted to data files with Agilent's Feature Extraction software (version 9.5). 
DNA-microarray data were processed as previously described (García de la Nava et 
al., 2003; van Hijum et al., 2005; van Hijum et al., 2003). Differential expression 
tests were performed with the Cyber-T implementation of a variant of the t-test 
(Long et al., 2001).  
 
Analysis of the monosaccharide composition of fermented and non-fermented 
mucin. Identification and quantification of the free monosaccharides in non-
fermented mMRS supplemented with 0.4 % mucin and the media following 30 h 
fermentation by B. bifidum PRL2010-pPKCM7 was performed according to Dionex 
technical note 40 (http://www.dionex.com/en-us/webdocs/5052-TN40-IC-
Glycoprotein-Monosaccharide-23May2012-LPN1632-01.pdf) and as previously 
described (Kilcoyne et al., 2009), using high performance anion exchange 
chromatography with pulsed amperometric detection (HPAEC-PAD). In brief, media 
was pelleted, sterilised through a 0.2 µm filter and then lyophilised to dryness. The 
lyophilised powder was dissolved at 1 mg ml-1 in purified water. Dilutions were 
injected on to a Dionex ICS 3000 system (Dionex, Sunnyvale, CA) equipped with a 
CarboPac PA20 analytical column (150 mm x 3 mm) with an Amino-trap column 
(30 mm x 3 mm) and separated as previously described (Kilcoyne et al., 2012). 
Resulting peaks were identified and quantified by comparison to a standard curve 
with a mixture containing the common mammalian residues Fuc, glucosamine 
(GlcN), galactosamine (GalN), Gal, glucose (Glc) and mannose (Man). Samples 
were injected three times and the average value is reported for the concentration. 
Samples were then spiked with a known concentration of Fuc and Gal standards and 
re-injected to confirm the identification of these residues in the sample.  
202 
 
To confirm the identity of Fuc in spent medium, samples were labelled with 2-
aminobenzamide (2-AB) according to the published method (Bigge et al., 1995). The 
2-AB labelled samples were cleaned on Glycoclean S cartridges (Prozyme) 
according to manufacturer’s instructions and vacuum centrifuged dry. Samples were 
analysed by reverse phase-high performance liquid chromatography (RP-HPLC) 
injected onto a Waters Alliance 2695 instrument and separated on a Phenomenex 
Luna 3u C18(2) (150 mm x 4.6 mm) column using previously described conditions 
(Hardy, 1997).  
During co-culture experiments samples of cell free supernatants were taken every 6 
or 12 h to qualitatively analyse the carbohydrate composition of the media by 
HPAEC-PAD. Samples (25 μl aliquots) were separated on a CarboPac PA1 
analytical-exchange column (250 mm x 4 mm) with a CarboPac PA1 guard column 
(50 mm x 4 mm). Elution was performed at a constant flow-rate of 1.0 ml min-1 at 30 
°C using the following eluents for the analysis (A) 200 mM NaOH, (B) 100 mM 
NaOH, 550 mM sodium acetate, and (C) purified water. The following linear 
gradient of sodium acetate was used with 100 mM NaOH: from 0 to 50 min, 0 mM; 
from 50 to 51 min, 16 mM; from 51 to 56 min, 100 mM; from 56 to 61 min, 0 mM. 
Eluate was monitored with a Dionex ED40 detector in the PAD mode. The 
chromatogram of non-fermented mucin was used to evaluate mucin utilisation by B. 
bifidum PRL2010-pPKCM7 and B. breve UCC2003-pAM5, and the Chromeleon 
software v. 6.70 (Dionex Corporation) was used for the integration and evaluation of 




Microarray data accession number. The microarray data obtained in this study have 
been deposited in NCBI’s Gene Expression Omnibus database and are accessible 




Growth of B. breve UCC2003 on mucin. Growth of B. breve UCC2003-pAM5 and 
B. bifidum PRL2010-pPKCM7 in mMRS supplemented with 0.4 % (wt/vol) mucin, 
independently or in co-culture, was measured by viable plate counts over 72 h. 
Monitoring of growth in co-culture required the use of plasmid-containing 
derivatives of the wild type strains. The plasmids used, pAM5 for B. breve 
UCC2003 or pPKCM7 for B. bifidum PRL2010, conferred Tet or Cm resistance to 
the respective strains, thus allowing selection and enumeration of each strain by 
viable plate count on RCA containing the corresponding antibiotic. Both B. breve 
UCC2003-pAM5 and B. bifidum PRL2010-pPKCM7 were also cultured in mMRS 
supplemented with 0.5 % lactose, a substrate on which both strains achieve a high 
level of growth (Turroni et al., 2012a; Watson et al., 2013), and it was found that 
presence of the plasmid did not impair growth of the strain on this substrate (results 
not shown). A low inoculum of 0.001 % and/or 0.01 % of B. breve UCC2003-pAM5 
and B. bifidum PRL2010-pPKCM7, respectively, was used to allow the strains to 
undergo multiple generations of growth. In the absence of an added carbohydrate, no 
growth was observed for either B. breve UCC2003-pAM5 or B. bifidum PRL2010-
pPKCM7 in mMRS medium (results not shown). As expected, the positive control, 
B. bifidum PRL2010-pPKCM7, was capable of growth in mucin-containing mMRS 
medium, from a low inoculum of 104 CFU ml-1 it attained cell numbers of 
approximately 108 CFU ml-1 following 30 h of incubation (Turroni et al., 2010b) 
(Fig. 4.1). However, a notably different growth profile was observed for B. breve 
UCC2003-pAM5 on this medium. During the first 12 h of incubation in this 
medium, B. breve UCC2003-pAM5 viable cell numbers increased from 104 CFU ml-
1 to almost 107 CFU ml-1, followed by a decline in viable cells to below 104 CFU ml-
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1 (Fig. 4.1). HPAEC-PAD analysis (see below) revealed the presence of 
contaminating monosaccharides, namely Glc and Gal, in the non-fermented mucin 
preparation. It is unknown whether these carbohydrates were released from partial 
degradation of the mucin during autoclaving, despite efforts made to reduce such 
degradation (see above), or were present as contaminating monosaccharides in the 
mucin preparation.  Given that B. breve UCC2003 can utilise both of these 
contaminants as a sole carbon source (Ruiz et al., 2013; Watson et al., 2013), it is 
hypothesised that they are responsible for the observed growth during the first 12 h 
following inoculation. Once these carbon sources were utilised, and as B. breve 
UCC2003-pAM5 apparently does not have the required enzymes to degrade intact 
mucin, a substantial drop in viable count was observed. Interestingly, when B. 
bifidum PRL2010-pPKCM7 was included as a potential carbohydrate-releasing 
bacterium in co-culture with B. breve UCC2003-pAM5, an improvement in growth 
and survival abilities of B. breve UCC2003-pAM5 was observed. In co-culture, B. 
breve UCC2003-pAM5 reached cell numbers of almost 108 CFU ml-1 after 24 h and 
maintained a viable count of over 106 CFU ml-1 after 72 h (Fig. 4.1). This suggests 
that B. breve UCC2003-pAM5 is cross-feeding on (some of) the sugars released 
following mucin breakdown by B. bifidum PRL2010-pPKCM7. The cell numbers of 
B. bifidum PRL2010-pPKCM7 were moderately lower in co-culture as compared to 
when the strain was grown independently in this medium and this was attributed to 
the presence of another acid-producing in the culture. However, the growth profile of 
B. bifidum PRL2010-pPKCM7 in co-culture followed a similar trend to that of the 
strain growing individually, suggesting that the two strains do not compete for 




Gene expression analysis using B. breve UCC2003 DNA microarrays. In order to 
investigate how the transcriptome of B. breve UCC2003-pAM5 is affected by growth 
in co-culture with B. bifidum PRL2010-pPKCM7 in mucin-containing mMRS, 
global gene expression was determined by microarray analysis during growth of the 
strain in co-culture and compared with gene expression when grown on ribose as the 
sole carbon source. Ribose was considered an appropriate carbohydrate for 
comparative transcriptome analysis as the genes involved in ribose metabolism are 
unique to this sugar (Pokusaeva et al., 2010), thus making it an ideal substrate for 
gene expression analysis on other carbohydrates. It has previously been used as a 
reference condition in several transcriptome studies in B. breve UCC2003 (Egan et 
al., 2014; O'Connell et al., 2013; O'Connell et al., 2014; O'Connell Motherway et 
al., 2011a; O'Connell Motherway et al., 2013). Furthermore, as a pentose sugar, 
ribose is suitable for gene expression analysis in mucin, given that the 
monosaccharide components of mucin are all hexose sugars (Glc, Gal, GalNAc, 
GlcNAc or Fuc), except sialic acid which is a nine-carbon monosaccharide. In the 
current study, gene expression was determined following 30 h growth in co-culture. 
This was to ensure that any observed changes in the transcriptome of B. breve 
UCC2003-pAM5 could be attributed solely to growth in co-culture with B. bifidum 
PRL2010-pPKCM7, as opposed to growth on free monosaccharides in the mucin 
preparation which appeared to be responsible for the initial 12 h of growth of B. 
breve UCC2003-pAM5 in mucin (see above). Analysis of DNA microarray data 
showed that a number of stress-related genes were up-regulated, which was 
attributed to the cells being in co-culture with another bacterium or to the possibility 
that the cells had entered the stationary phase. Nonetheless, the majority of genes 
that were shown to be significantly up-regulated (fold change >2.5, P<0.001) in co-
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culture are predicted to be involved in the transport and metabolism of carbohydrates 
(Table 4.3). One such cluster, Bbr_1740-1742, is believed to be involved in Fuc 
metabolism and includes genes predicted to encode a dihydrodipicolinate synthase 
(Bbr_1740), an enzyme which was previously shown to be involved in Fuc 
metabolism in Campylobacter jejuni (Stahl et al., 2011), a hypothetical protein 
(Bbr_1741) and a Fuc permease (fucP, Bbr_1742). Transcription of a predicted β-
galactosidase-encoding gene (Bbr_1833, designated lacZ7) was also significantly 
increased, this enzyme is possibly involved in the removal of Gal from mucin 
oligosaccharides, suggesting that B. breve UCC2003 may utilise one or more Gal-
containing fractions of mucin. The Bbr_1585-1590 gene cluster was also up-
regulated during growth in co-culture. Bbr_1585 encodes a predicted UDP-Glc-4-
epimerase, designated galE. Previously, UDP-Glc-4-epimerase enzymes have been 
shown to be involved in the Leloir pathway for Gal metabolism (Frey, 1996), as well 
as the GNB/LNB pathway for the metabolism of (ga)lacto-N-biose (GNB/LNB) 
derived from HMO or mucin (Kitaoka et al., 2005; Nishimoto & Kitaoka, 2007). 
Bbr_1586 encodes a predicted N-acetylhexosamine-1-kinase, designated nahK. In B. 
longum JCM 1217, an N-acetylhexosamine-1-kinase, which shares 90 % identity to 
NahK, was shown to have a role in the previously mentioned GNB/LNB pathway 
(Nishimoto & Kitaoka, 2007). Bbr_1587 encodes a predicted LNB phosphorylase, 
designated lnbP, an enzyme which is also involved in the GNB/LNB pathway 
(Derensy-Dron et al., 1999; Kitaoka et al., 2005; Nishimoto & Kitaoka, 2007). The 
LnbP protein from B. breve UCC2003 shares 90 % identity with the previously 
characterised LnbP protein from B. bifidum JCM 1254 (Kitaoka et al., 2005). 
Finally, as regards to this upregulated cluster, Bbr_1588-1590 encode a predicted 
ABC transport system, including two predicted permease proteins (represented by 
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Bbr_1588 and Bbr_1589), and a solute binding protein (Bbr_1590), which shares 98 
% identity with the GNB/LNB-specific binding protein of B. longum JCM1217 
(Suzuki et al., 2008). Bbr_1884 (designated galT2), encoding a predicted Gal-1-
phosphate uridyltransferase, another enzyme required for the Leloir pathway and the 
GNB/LNB pathway (Frey, 1996; Kitaoka et al., 2005; Nishimoto & Kitaoka, 2007), 
was also up-regulated when B. breve  UCC2003 was grown in mucin in co-culture 
with B. bifidum PRL2010. Finally, two gene clusters responsible for the transport 
and metabolism of sialic acid were significantly up-regulated under these growth 
conditions (Bbr_0160-0171 and Bbr_1247-1248) (Egan et al., 2014) (Table 4.3). 
  
Analysis of the monosaccharide composition of fermented and non-fermented 
mucin. HPAEC-PAD was used to quantitatively analyse the carbohydrate profile of 
non-fermented mucin, compared to the cell free supernatant (CFS) of B. bifidum 
PRL2010-pPKCM7 grown in mucin for 30 h. Non-fermented mucin was shown to 
contain 0.13 nmol mg-1 of free Gal and 3.96 nmol mg-1 of free Glc, both of which 
support growth of B. breve UCC2003 (Ruiz et al., 2013; Watson et al., 2013), thus 
presenting a plausible explanation for the initial increase in B. breve UCC2003-
pAM5 cell numbers during the first 12 h of incubation in mucin-containing medium 
(Table 4.4). However, after 30 h growth of B. bifidum PRL2010-pPKCM7, the 
carbohydrate profile of the medium was significantly altered. Glc was no longer 
detected, indicating its uptake by B. bifidum PRL2010-pPKCM7, but the amount of 
free Gal increased to 51.73 nmol mg-1, while 34.94 nmol mg-1 of free Fuc was also 
detected, indicative of the extracellular glycosidase activity of B. bifidum PRL2010-
pPKCM7 (Table 4.4). The presence of Fuc was further verified by fluorescent 
labelling of the CFS samples and analysis by RP-HPLC (Fig. 4.2A). RP-HPLC 
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analysis also confirmed that free Fuc was absent in non-fermented mMRS 
supplemented with 0.4 % mucin, which indicated that its presence was a result of B. 
bifidum PRL2010-pPKCM7 extracellular activity (Fig. 4.2A). To investigate 
whether these released monosaccharides from mucin support the observed growth 
and viability of B. breve UCC2003-pAM5 in co-culture, the carbohydrate profile of 
the CFS of the co-culture was compared to that of B. bifidum PRL2010-pPKCM7 
grown independently in mucin (hence any difference observed could be attributed to 
the presence of B. breve UCC2003-pAM5). The results support the hypothesis that 
B. breve UCC2003-pAM5 is cross-feeding on at least one carbohydrate released 
following degradation of mucin by B. bifidum PRL2010-pPKCM7. After 30 h Fuc 
was present in the carbohydrate profile of B. bifidum PRL2010-pPKCM7, but absent 
(or at least below the detection level) in that of the co-culture, indicative of its uptake 
and utilisation by B. breve UCC2003-pAM5 (Fig. 4.2B).  
  
Growth of B. breve UCC2003 insertion mutants in co-culture in mucin with B. 
bifidum PRL2010-pPKCM7. HPAEC-PAD and transcriptome data suggested that 
the improved growth and viability of B. breve UCC2003-pAM5 in co-culture was a 
result of the strain cross-feeding on Fuc, while microarray data suggested sialic acid, 
Gal, GNB and/or another of the Gal-containing constituents of mucin may also be 
utilised. To determine which, if any, of these sugars was primarily responsible for 
growth of the strain in co-culture, insertion mutants were constructed in the fucP, 
lnbP and lacZ7 genes, resulting in strains B. breve UCC2003-fucP, B. breve 
UCC2003-lnbP and B. breve UCC2003-lacZ7. Two additional mutants, B. breve 
UCC2003-galT, which harbours a transposon in a predicted Gal-1-phosphate 
uridyltransferase-encoding gene, designated galT1 and was shown to be incapable of 
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growth in Gal (Ruiz et al., 2013), and the previously described insertion mutant, B. 
breve UCC2003-nanA, which cannot utilise sialic acid (Egan et al., 2014), were also 
tested. The insertion mutants were individually analysed for their ability to grow in 
mucin in the presence or absence of B. bifidum PRL2010-pPKCM7. In the absence 
of B. bifidum PRL2010-pPKCM7, the mutant strains behaved similarly to B. breve 
UCC2003-pAM5, as initial growth over the first 12 h was followed by a decline in 
viable cells to 104 CFU ml-1 or lower at 72 h (Fig. 4.3). It was also found that 
removing the ability of the strain to utilise a particular sugar did not significantly 
affect its ability to grow in co-culture with B. bifidum PRL2010-pPKCM7. Similar to 
B. breve UCC2003-pAM5, all mutant strains attained a viable count of between 107 
and 108 CFU ml-1 between 12 h and 30 h, and maintained a viable count of 106 CFU 
ml-1 until 72 h, with the exception of B. breve UCC2003-fucP which dropped to 105 
CFU ml-1 (Fig. 4.3). The carbohydrate profiles of each mutant grown in co-culture 
were also analysed by HPAEC-PAD and it was found that each mutant, with the 
exception of B. breve UCC2003-fucP, produced an identical carbohydrate profile to 
that produced by the B. breve UCC2003-pAM5. B. breve UCC2003-fucP, as 
expected, was not capable of utilising/transporting Fuc, as evident from the presence 





Early investigations into the degradation of mucin established the role of 
extracellular glycosidases produced by a sub-population of bacteria in the gut, 
suggesting that the remaining enteric bacteria may cross feed on the released 
oligosaccharides (Boulding & Hoskins, 1981; Hoskins et al., 1985). Since then, 
much of the research into bacterial degradation of mucin has focused on the 
characterisation of such extracellular glycosidases, such as two α-L-fucosidases and 
an exo-α-sialidase from B. bifidum JCM1254, and an endo-α-N-
acetylgalactosaminidase from B. longum JCM1217 (Ashida et al., 2009; Katayama 
et al., 2005; Katayama et al., 2004; Kiyohara et al., 2011). Another study identified, 
by a genomic as well as a transcriptomic and proteomic approach, a number of 
extracellular enzymes involved in mucin degradation by B. bifidum PRL2010, 
including a predicted cell wall-anchored endo-α-N-acetylgalactosamine, two α-L-
fucosidases, two exo-α-sialidases, a β-galactosidase and two putative N-acetyl-β-
hexosaminidases, all of which contained a signal peptide (Turroni et al., 2010b).  
Extracellular enzymes similar to those outlined above were not found in the genome 
of B. breve UCC2003 (O'Connell Motherway et al., 2011b). Therefore, it was not 
surprising that B. breve UCC2003-pAM5 was incapable of high density growth in a 
medium containing mucin as the sole carbon source. However, when B. bifidum 
PRL2010-pPKCM7 was included as a co-cultivating, mucin-degrading bacterium, 
the growth and viability of B. breve UCC2003-pAM5 was improved compared to the 
control situation. A combination of HPAEC-PAD and transcriptome analyses 
identified some of the possible monosaccharides and oligosaccharides which could 
support this enhanced co-cultivation growth/viability phenotype of B. breve 
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UCC2003-pAM5, represented by sialic acid, Fuc, Gal and/or Gal-containing 
constituents of mucin.  
HPAEC-PAD analysis identified two monosaccharides, namely Fuc and Gal, which 
were released from mucin by B. bifidum PRL2010-pPKCM7 activity. Fuc was 
shown to be internalised by B. breve UCC2003-pAM5 during growth in co-culture, 
suggesting a role in the enhanced growth/viability phenotype of the strain in co-
culture. Transcriptome and mutagenesis data supports this hypothesis, as shown by 
increased transcription of a cluster (Bbr_1740-1742) involved in the uptake and 
utilization of Fuc and by the inability of a mutant in the fucP gene to internalise Fuc 
from the growth medium. 
Gal has previously been shown to support the growth of B. breve UCC2003 (Ruiz et 
al., 2013). However, given that Gal is ubiquitous in mucin, it may be internalised by 
B. breve UCC2003-pAM5 as a monosaccharide and/or as a constituent of a larger 
oligosaccharide. Interestingly, transcriptome data revealed increased transcription of 
the Bbr_1585-1590 gene cluster, which includes predicted GalE, NahK and LnbP-
encoding genes, all of which are required for the metabolism of GNB (Nishimoto & 
Kitaoka, 2007), as well as an adjacent predicted ABC transport system. Outside of 
this cluster, the predicted galT2 gene (Bbr_1884) was also up-regulated. A previous 
study in B. bifidum hypothesised that GalT2 is specifically required for the 
metabolism of GNB from mucin (De Bruyn et al., 2013). Up-regulation of each of 
the required genes for the complete GNB pathway, as well as a predicted transport 
system, suggests that GNB might be the preferred source of Gal for B. breve 
UCC2003 in co-culture. A predicted β-galactosidase-encoding gene, lacZ7, was also 
up-regulated in co-culture, implying that B. breve UCC2003 may utilise another Gal-
containing oligosaccharide. However, the precise substrate or preferred linkage of 
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this enzyme is still a matter of speculation. Gal-containing oligosaccharides and 
GNB were not identified in the HPAEC-PAD data. However, the presence of four 
predicted β-galactosidases on the genome of B. bifidum PRL2010, as well as a clear 
homolog of the GNB pathway (Turroni et al., 2010b), suggests that B. bifidum 
PRL2010 also utilises these sugars, and it is therefore possible that in co-culture the 
two strains compete for such sugars.   
Interestingly, transcriptome data also revealed increased transcription of two clusters 
previously shown to be up-regulated in the presence of sialic acid (Egan et al., 
2014). This is inconsistent with the HPAEC-PAD data, in which sialic acid was not 
identified; however, it should be noted that the mucin from porcine stomach used in 
this study contains only 0.5 %- 1.5 % bound sialic acid, and it is thus possible that 
the released sialic acid is below the detection level of the HPAEC-PAD system. 
However, since B. bifidum PRL2010 has been shown to be incapable of using sialic 
acid (Egan et al., 2014; Turroni et al., 2010b), it seems likely that B. breve UCC2003 
would utilise this sugar, even if available in very low quantities. 
While accepting the HPAEC-PAD and transcriptome data are not definitive, the 
results suggest that B. breve UCC2003-pAM5 utilises a combination of sugars in co-
culture, a suggestion supported by the fact that none of the mutants tested displayed 
a different phenotype to B. breve UCC2003-pAM5 in co-culture. Construction of 
double or triple mutant strains is expected to result in strains that are impaired in 
growth/viability under co-culture conditions, however, at present such multiple 
mutant construction is not technically feasible for B. breve UCC2003 (and have to 
the best of our knowledge not been described for any bifidobacterial species/strain). 
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Our results highlight the different approaches taken by two species of bifidobacteria 
to proliferate and survive in the gut. B. bifidum PRL2010 has been shown to utilise 
mucin oligosaccharides (and structurally similar HMOs), a highly complex, yet 
ubiquitous carbohydrate source in the gut. Aside from host glycans such as mucin 
and HMO, however, the fermentation ability of B. bifidum PRL2010 is rather limited 
(Turroni et al., 2012a; Turroni et al., 2010b). B. breve UCC2003, on the other hand, 
is a more versatile bacterium from a metabolic perspective, capable of utilising a 
number of host and diet-derived carbohydrates. As seen in this study it can scavenge 
constituents of mucin released by the extracellular glycosidase activity of other 
bifidobacteria, as well as cross-feed on certain HMO (Egan et al., 2014), a 
characteristic which reflects the abundance of representatives of this species in the 
infant gut (Turroni et al., 2012b). However, B. breve UCC2003 also has the ability to 
utilise a number of dietary-derived carbohydrates such as starch, galactan, 
cellodextrins and raffinose (O'Connell et al., 2013; O'Connell Motherway et al., 
2011a; O'Connell Motherway et al., 2008; Pokusaeva et al., 2011b) and accordingly 
B. breve strains have been identified in the adult human bifidobacterial population, 
although the relative abundance is lower than in infants (Turroni et al., 2009; Turroni 
et al., 2012b). The similar phenotype of B. breve UCC2003-pAM5 and the mutant 
strains in co-culture also highlights the adaptability of the strain, emphasising its 
ability to switch to a different carbon source, depending on the carbohydrates 
available. This versatility is reflected on the genome of B. breve UCC2003, which 
contains a large number of carbohydrate utilisation clusters (O'Connell Motherway 
et al., 2011b), suggesting an ability to alternate between and/or co-utilise diet- and 
host- derived carbohydrates depending on availability. The gut commensal 
Bacteroides thetaiotaomicron, displays a remarkable metabolic flexibility, whereby 
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in the absence of a dietary-derived fibre, this bacterium will shift its metabolic 
activities towards the degradation of mucin (Sonnenburg et al., 2005). These results 
suggest that B. breve UCC2003 may also be capable of such flexibility, although 
further study is required.  
The ability to degrade mucin seems to be limited to particular gut commensals, such 
as certain species of Bacteroides, Bifidobacterium, Ruminococcus and Akkermansia 
(Crost et al., 2013; Derrien et al., 2004; Salyers et al., 1978; Salyers et al., 1977; 
Sonnenburg et al., 2005; Turroni et al., 2010b). Pathogenic bacteria appear to be 
poorly adapted to mucin degradation (Marcobal et al., 2013), however, multiple 
studies have shown pathogens utilising constituents of mucin released by commensal 
glycosidases. For example, C. jejuni has been shown to utilise Fuc as a substrate for 
growth (Stahl et al., 2011), while enterohaemorrhagic E. coli uses Fuc as a signal to 
induce virulence (Pacheco et al., 2012). Similarly, Salmonella typhimurium and 
Clostridium difficile have been shown to utilise sialic acid released by the sialidase 
activity of Bacteroides thetaotaomicron in a gnotobiotic mouse (Ng et al., 2013). 
The uptake of mucin-derived Fuc by B. breve UCC2003, as well as the presumable 
utilisation of mucin-derived sialic acid, suggests a potential role for B. breve 
UCC2003 in “mopping up” the released constituents of mucin, providing 
competition to potential pathogens and inhibiting or limiting their proliferation, 
although further study is required to expand on this hypothesis.  
The mutually beneficial relationship between the host and the intestinal bacteria has 
been well established (Bäckhed et al., 2005), however, it is of equal importance to 
acknowledge the symbiotic relationships formed between genera and species of the 
intestinal bacteria. Cross-feeding between B. breve UCC2003 and B. bifidum 
PRL2010 has now been shown for mucin in the present work and previously for 3’ 
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sialyllactose (Egan et al., 2014), and given the structural similarity between mucin 
oligosaccharides and HMOs, it may be assumed that B. breve UCC2003 has the 
ability to cross feed on other HMO-derived constituents that are released by B. 
bifidum PRL2010. These results highlight the compatibility of these two species of 
bifidobacteria, especially when viewed in contrast to the strategy employed by B. 
longum subsp. infantis, which assimilates HMOs in their intact form, leaving none 
for potential cross-feeding with another species (Sela & Mills, 2010). Interestingly, 
another type of cross-feeding has been described, whereby Eubacterium halii utilises 
lactate produced by Bifidobacterium adolescentis during growth on starch, resulting 
in butyrate production by Eu. halii (Belenguer et al., 2006). Butyrate is a major 
source of energy for colonocytes and has also been implicated in protection against 
colonic carcinogenesis (Roediger, 1980; Velázquez et al., 1996). Understanding such 
complex interactions between different members of the intestinal bacteria is of 
crucial importance when attempting to influence the activity or composition of the 
intestinal microbiota, such as in the use of probiotics.  
This study provides in vitro proof for the existence of a commensal relationship 
between two species of bifidobacteria in the large intestine, namely B. breve and B. 
bifidum, in which B. breve UCC2003 benefits from the carbohydrates released by the 
extracellular glycosidase activities of B. bifidum PRL2010. To our knowledge, this is 
the first study to describe the molecular details of such cross-feeding, with particular 
emphasis on the carbohydrate components which support the improved growth and 
survival in co-culture. The results shown here improve our knowledge on how B. 
breve UCC2003 colonises the (infant) gut in the absence of dietary-derived 
carbohydrates, and also emphasise this strain’s ability to switch between 
carbohydrate sources depending on availability. This is an advantageous 
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characteristic in terms of enhanced survival and colonisation ability in both the infant 
and adult gut, and may present an advantage to the host in limiting opportunities for 
pathogenic microbes to proliferate in the gut. 
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4.7 TABLES AND FIGURES 
Table 4.1: Bacterial strains and plasmids used in this study. 
Strains and plasmids Relevant features Reference or source 
Strains   
Escherichia coli strains   
E.coli EC101 Cloning host; repA+ kmr (Law et al., 1995) 
E.coli EC101-pNZ-
M.Bbrll+Bbr11 
EC101 harboring a pNZ8048 derivative containing bbrllM and bbrlllM (O'Connell Motherway et al., 2009) 
Bifidobacterium sp. strains   
B. breve UCC2003 Isolate from a nursling stool (Maze et al., 2007)  
B. breve UCC2003-pAM5 B. breve UCC2003 harboring pAM5 This study 
B. breve UCC2003-nanA pORI19-Tet-nanA (Bbr_0168) insertion mutant of B. breve UCC2003 (Egan et al., 2014) 
B. breve UCC2003-fucP pORI19-Tet-fucP (Bbr_1742) insertion mutant of B. breve UCC2003  This study 
B. breve UCC2003-lnbP pORI19-Tet-lnbP (Bbr_1587) insertion mutant of B. breve UCC2003 This study 
B. breve UCC2003-lacZ7 pORI19-Tet-lacZ7 (Bbr_1833) insertion mutant of B. breve UCC2003 This study 
B. breve UCC2003-galT Tetr transposon mutant of B. breve UCC2003  (Ruiz et al., 2013) 
B. bifidum PRL2010 Isolate from infant faeces (Turroni et al., 2010b) 
B. bifidum PRL2010-pPKCM7 B. bifidum PRL2010 harboring pPKCM7 This study 
   
Plasmids   
pAM5 pBC1-puC19-Tcr (Álvarez-Martín et al., 2007) 
pPKCM7 pblueCm harboring rep pCIBA089 (Cronin et al., 2007) 
pORI19 Emr, repA-, ori+, cloning vector (Law et al., 1995) 
pORI19-tetW-fucP Internal 400bp fragment of fucP and tetW cloned in pORI19 This study 
pORI19-tetW-lnbP Internal 479bp fragment of lnbP and tetW cloned in pORI19 This study 
pORI19-tetW-lacZ7 Internal 568bp fragment of lacZ7 and tetW cloned in pORI19 This study 
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Table 4.2: Oligonucleotide primers used in this study 
Purpose Primer Sequence 
Cloning of 400bp fragment of fucP (Bbr_1742) in pORI19 FucPF TAGCATAAGCTTGGCGAATCGTTCGTATCA 
 FucPR GATATCTCTAGAGCGCCCCAGTGCTTGAGC 
Cloning of 479bp fragment of lnbP  (Bbr_1587) in pORI19 LnbPF TAGCATAAGCTTCACACAGGTATTGGGAGGTTG 
 LnbPR CTAGTCTCTAGAGTTGTAGGCGCCACCATCC 
Cloning of 568bp fragment of lacZ7  (Bbr_1833) in pORI19 LacZ7F TAGCATAAGCTTCCAGGCCAAGAACTCCAGTG 
 LacZ7R CATGATTCTAGACAGCTTGGGCAGGTTGAACG 
Amplification of tetW TetWF TCAGCTGTCGACATGCTCATGTACGGTAAG 
 TetWR GCGACGGTCGACCATTACCTTCTGAAACATA 
Confirmation of site-specific homologous recombination FucPconfirm TGTTCGCCATGTTCGTTATC 
 LnbPconfirm GATCACTCTGCATATGGACG 
 LacZ7confirm GTACCGACATCGACGCGTTC 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in italics.
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Table 4.3: Effect of mucin (in co-culture with B. bifidum PRL2010) on the 
transcriptome of B. breve UCC2003 
Locus Tag (Gene 
Name) 
Predicted Function Level of 
upregulation 
(P<0.001) 
Bbr_0161 (nanK) Conserved hypothetical protein in ROK family 4.22 
Bbr_0162 (nanE) N-acetylmannosamine-6-phosphate 2-epimerase 5.46 
Bbr_0164 (nanB) ABC transport system, solute binding protein 14.08 
Bbr_0165 (nanC) ABC transport system, permease protein 11.82 
Bbr_0166 (nanD) ABC transport system, ATP-binding protein 18.92 
Bbr_0167 (nanF) ABC transport system, ATP-binding protein 22.14 
Bbr_0168 (nanA) N-acetylneuraminate lyase 15.17 
Bbr_0169 (nagB1) Glucosamine-6-phosphate isomerase 17.77 
Bbr_0171 (nanH) Sialidase 7.23 
Bbr_0173 (nanR) Transcriptional regulator, GntR family 4.80 
Bbr_1247 (nagA2) N-acetylglucosamine-6-phosphate deacetylase 4.59 
Bbr_1248 (nagB3) Glucosamine-6-phosphate isomerase 6.08 
Bbr_1585 (galE) UDP-Glc-4-epimerase 3.96 
Bbr_1586 (nahK) N-acetylhexosamine kinase 3.67 
Bbr_1587 (lnbP) Lacto-N-biose phosphorylase 3.19 
Bbr_1588 ABC transport system, permease protein 3.34 
Bbr_1589 ABC transport system, permease protein 2.88 
Bbr_1590 ABC transport system, solute binding protein 8.95 
Bbr_1740 (dapA4) Dihydrodipicolinate synthase 9.91 
Bbr_1741 Conserved hypothetical protein 8.83 
Bbr_1742 (fucP) L-fucose permease 7.81 
Bbr_1833 (lacZ7) Beta-galactosidase 4.31 
Bbr_1879 PTS system, glucose-specific IIABC component 6.97 
Bbr_1880 PTS system, GlcNAc-specific IIBC component 18.15 
Bbr_1884 (galT2) Gal-1-phosphate uridylyltransferase 3.86 





Table 4.4: Quantification of Fuc, Gal and Glc by HPAEC-PAD. 
 Fuc Gal Glc 
mMRS + 0.4 % mucin (non-fermented) n.d. 0.13 3.96 
mMRS + 0.4 % mucin (30 h growth of B. bifidum PRL2010) 34.94 51.73 n.d. 





Figure 4.1: Individual and co-culture growth profiles of B. breve UCC2003-pAM5 and B. bifidum PRL2010-pPKCM7 in mucin. All growth 
experiments were performed in mMRS supplemented with 0.4 % mucin from porcine stomach for 72 h. The results presented are the mean 




Figure 4.2: (A) HPLC profile of 2-AB -labelled (I) mMRS supplemented with 0.4 
% mucin and (II) the media from (I) after 30 h growth of B. bifidum PRL2010-
pPKCM7. The peak for Fuc is marked with *. (B) Qualitative HPAEC-PAD analysis 
of (I) mMRS supplemented with 0.4 % mucin, (II) the media from (I) following 30 h 
growth of B. bifidum PRL2010-pPKCM7 and B. breve UCC2003-pAM5 in co-
culture, (III) the media from (I) after 30 h growth of B. bifidum PRL2010-pPCM7. 







Figure 4.3: Growth profiles of the mutants (A) B. breve UCC2003-nanA, (B) B. 
breve UCC2003-fucP, (C) B. breve UCC2003-lacZ7, (D) B. breve UCC2003-lnbP 
and (E) B. breve UCC2003-galT in mMRS supplemented with 0.4 % mucin, 
separately or in co-culture with B. bifidum PRL2010-pPKCM7, over 72 h. The 












Figure 4.4: Qualitative HPAEC-PAD analysis of (I) mMRS supplemented with 0.4 
% mucin, (II) the media from (I) following 36 h growth of B. breve UCC2003-
pAM5 and B. bifidum PRL2010-pPKCM7 in co-culture, (III) the media from (I) 
following 36 h growth of B. bifidum PRL2010-pPKCM7, (IV) the media from (I) 
following 36 h growth of B. breve UCC2003-fucP and B. bifidum PRL2010-
pPKCM7 in co-culture. The peak for Fuc is marked with *.  
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A bacterial nursling stool isolate, Bifidobacterium breve UCC2003, encodes two 
putative sulfatases. Among members of the gut microbiota sulfatase activity has 
previously been thoroughly characterised in the Bacteroides genus, but has yet to be 
described in bifidobacteria. Using a combination of transcriptomic and functional 
genomic approaches, we identified a gene cluster, designated ats2, dedicated to the 
uptake and metabolism of the sulfated monosaccharide, N-acetylglucosamine-6-
sulfate. A transporter of the major facilitator superfamily is presumed to be required 
for uptake of this sulfated carbohydrate, while biochemical analysis showed that co-
expression of the atsA2-encoded sulfatase and the atsB2-encoded anSME (anaerobic 
sulfatase maturation enzyme) is required for sulfatase activity. Transcription of the 
ats2 cluster is regulated by a ROK-family transcriptional repressor. The substrate of 
the other presumed sulfatase cluster, ats1, has yet to be determined, however, using 
insertion mutagenesis, electrophoretic mobility shift assays and primer extension 





The Bifidobacterium genus represents the dominant bacterial group among the 
intestinal microbiota of infants (Turroni et al., 2012b; Vaishampayan et al., 2010), 
while also typically constituting between 2 % and 10 % of the adult intestinal 
microbiota (Agans et al., 2011; Andersson et al., 2008; Turroni et al., 2008; 
Zwielehner et al., 2009). Bifidobacteria are saccharolytic organisms whose ability to 
colonise and survive in the large intestine is presumed to depend on the ability to 
metabolise complex carbohydrates present in this environment. Certain 
bifidobacterial species including Bifidobacterium longum subsp. longum, 
Bifidobacterium adolescentis and Bifidobacterium breve utilise a range of plant/diet 
derived oligosaccharides such as raffinose, arbinoxylan, galactan and cellodextrins 
(O'Connell et al., 2013; O'Connell Motherway et al., 2011a; Pastell et al., 2009; 
Pokusaeva et al., 2011a; Pokusaeva et al., 2011b; Van Laere et al., 2000). 
Bifidobacterial metabolism of host-derived carbohydrates such as mucin and human 
milk oligosaccharides (HMOs) is also well-described, with the typically infant-
derived species B. longum subsp. infantis and Bifidobacterium bifidum particularly 
well-adapted to utilize these ubiquitous carbon sources in the infant gut (Sela et al., 
2008; Turroni et al., 2010). Extensive research has identified and characterised both 
transport systems and glycosyl hydrolases required for the uptake and breakdown (of 
components) of these host-derived carbohydrates (Ashida et al., 2009; Garrido et al., 
2011; Sela et al., 2011; Sela et al., 2012; Turroni et al., 2012a). 
Host-derived glycoproteins such as mucin and proteoglycans (e.g. chondroitin 
sulfate and heparan sulfate), which are found in the colonic mucosa and/or human 
milk, are often highly sulfated (Eliakim et al., 1986; Larsson et al., 2009; Newburg 
et al., 1995; Oshiro et al., 2001). Three sulfated oligosaccharide structures have also 
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been isolated from HMO, although they are present in only minute quantities (>100 
µg ml-1) (Guérardel et al., 1999). Human colonic mucin is heavily sulfated, which is 
in contrast to mucin from the stomach or small intestine, the presumed purpose of 
which is to protect mucin against degradation by bacterial glycosidases 
(Brockhausen, 2003; Filipe, 1978). Despite this apparent protective measure, 
glycosulfatase activity has been identified in various members of the gut microbiota, 
e.g. Bacteroides thetaiotaomicron, Bacteroides ovatus and Prevotella strain RS2 
(Roberton et al., 1993; Salyers et al., 1977). 
Sulfatases constitute a family of hydrolases that are highly conserved between 
prokaryotes and eukaryotes, and whose substrate specificity can range from 
glycoproteins and glycolipids to hydroxysteroids (von Figura et al., 1998). 
Sulfatases uniquely require a 3-oxoalanine (typically called Cα-formylglycine or 
FGly) residue at their active site, the absence of which results in dramatically 
decreased catalytic activity (Bond et al., 1997; Lukatela et al., 1998; Schmidt et al., 
1995). Eukaryotic sulfatases carry a conserved cysteine (Cys) residue, which is post-
translationally modified to FGly in the endoplasmic reticulum (Dierks et al., 1997; 
Schmidt et al., 1995). Prokaryotic sulfatases carry either a Cys or a serine (Ser) 
residue which requires post-translational conversion to FGly in the cytosol in order 
to convert the enzyme to an active state (Beil et al., 1995; Miech et al., 1998; 
Szameit et al., 1999).  
In bacteria, two distinct systems have been described for the post-translational 
modification of sulfatase enzymes. In Mycobacterium tuberculosis H37Rv, the 
conversion of the Cys58 residue to FGly is catalysed by an FGly-generating enzyme 
(FGE) which requires oxygen as a co-factor (Carlson et al., 2008; Dierks et al., 
2003). In Klebsiella pneumoniae DSM 681, the conversion of the Ser72 residue of 
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the atsA-encoded sulfatase is catalysed by the AtsB enzyme, which is a member of 
the S-adenosyl-L-methionine (AdoMet)-dependent family of radical enzymes (Fang 
et al., 2004; Szameit et al., 1999). Similar enzymes were also characterised from 
Clostridium perfringens ATCC13124 and Ba. thetaiotaomicron VPI-5481 which are 
active on both Cys and Ser-type sulfatases (Benjdia et al., 2008; Berteau et al., 
2006). Crucially these enzymes are active under anaerobic conditions and were thus 
designated anaerobic sulfatase maturing enzymes (anSME) (Berteau et al., 2006). 
Metagenomic sequence analysis has revealed that genes that are predicted to encode 
sulfatases and anSME enzymes are enriched in the gut microbiomes of humans 
compared to non-gut microbial communities (Kurokawa et al., 2007). However, 
despite extensive research into the metabolism of mucin and HMO, sulfatase activity 
has yet to be described in bifidobacteria. In the current study, we identify two 
predicted sulfatase and anSME-encoding gene clusters in B. breve UCC2003 (and 
other B. breve strains), and demonstrate that one such cluster is required for the 





5.3 MATERIALS AND METHODS 
Bacterial strains, plasmids, media and culture conditions. Bacterial strains and 
plasmids used in this study are listed in Table 5.1. B. breve UCC2003 was routinely 
cultured in Reinforced Clostridial Medium (RCM; Oxoid Ltd., Basingstoke, 
Hampshire, United Kingdom). Carbohydrate utilisation by B. breve UCC2003 was 
examined in modified deMan Rogosa Sharpe (mMRS) medium made from first 
principles (De Man et al., 1960), excluding a carbohydrate source, supplemented 
with 0.05 % (wt/vol) L-cysteine HCl and a particular carbohydrate source (0.5 % 
wt/vol). The carbohydrates used were lactose (Sigma Aldrich, Steinheim, Germany) 
and GlcNAc-6-S (Dextra Laboratories, Reading, United Kingdom). In order to 
determine bacterial growth profiles and final optical densities, 10 ml of freshly 
prepared mMRS medium, supplemented with a particular carbohydrate, was 
inoculated with 100 µl (1 %) of a stationary-phase culture of a particular strain. Un-
inoculated mMRS was used as a negative control. Cultures were incubated 
anaerobically for 24 h and the optical density (OD600nm) was recorded. 
Bifidobacterial cultures were incubated under anaerobic conditions in a modular 
atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 37°C. 
Escherichia coli was cultured in Luria Bertani broth (LB) at 37°C with agitation 
(Sambrook, 1989). Lactococcus lactis strains were grown in M17 medium 
supplemented with 0.5 % (wt/vol) glucose at 30°C (Terzaghi & Sandine, 1975). 
Where appropriate, growth media contained tetracycline (Tet; 10 µg ml-1), 
chloramphenicol (Cm; 5 µg ml-1 for E. coli and L. lactis, 2.5 µg ml-1 for B. breve), 
ampicillin (Amp; 100 µg ml-1), erythromycin (Em; 100 µg ml-1) or kanamycin (Kan; 
50 µg ml-1). Recombinant E. coli cells containing pORI19 were selected on LB agar 
containing Em and Kan, and supplemented with 40 µg ml-1 X-gal (5-bromo-4-
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chloro-3-indolyl-β-D-galactopyranoside) and 1 mM IPTG (isopropyl-β-D-
galactopyranoside). 
 
Nucleotide sequence analysis. Sequence data were obtained from the Artemis-
mediated genome annotations of B. breve UCC2003 (O'Connell Motherway et al., 
2011b; Rutherford et al., 2000). Database searches were performed using the non-
redundant sequence database accessible at the National Centre for Biotechnology 
Information website (http://www.ncbi.nlm.nih.gov) using BLAST (Altschul et al., 
1990). Sequence analysis was performed using the Seqbuilder and Seqman programs 
of the DNASTAR software package (DNASTAR, Madison, WI, USA). Inverted 
repeats were identified using the PrimerSelect program of the DNASTAR software 
package and a graphical representation of the identified motifs was obtained using 
WebLogo software (Crooks et al., 2004).  
 
DNA manipulations. Chromosomal DNA was isolated from B. breve UCC2003 as 
previously described (Riordan, 1998). Plasmid DNA was isolated from E. coli, L. 
lactis and B. breve using the Roche High Pure plasmid isolation kit (Roche 
Diagnostics, Basel, Switzerland). An initial lysis step was performed using 30 mg 
ml-1 of lysozyme for 30 min at 37°C prior to plasmid isolation from L. lactis or B. 
breve. Single stranded oligonucleotide primers used in this study were synthesised 
by Eurofins (Ebersberg, Germany) (Table 5.2). Standard PCRs were performed 
using Taq PCR master mix (Qiagen GmBH, Hilden, Germany). B. breve colony 
PCRs were carried out as described previously (O'Connell Motherway et al., 2009). 
PCR fragments were purified using the Roche High Pure PCR purification kit 
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(Roche Diagnostics). Electroporation of plasmid DNA into E. coli, L. lactis or B. 
breve was performed as previously described (Maze et al., 2007; Sambrook, 1989; 
Wells et al., 1993). 
 
Construction of B. breve UCC2003 insertion mutants. Internal fragments of 
Bbr_0351, designated here as atsR1 (this fragment encompassed 404 base pairs [bp], 
and represented codon numbers 102 through to 236 of the 354 codons of this gene), 
Bbr_0849, designated here as atsR2 (fragment encompassed 408 bp, representing 
codon numbers 134 through to 271 of the 395 codons of this gene), Bbr_0851, 
designated atsT (fragment encompassed 416 bp, representing codon numbers 149 
through to 288 of the 476 codons of this gene) and Bbr_0852, designated atsA2 
(fragment encompassed 402 bp, representing codon numbers 148 through to 281 of 
the 509 codons of this gene) were amplified by PCR using B. breve UCC2003 
chromosomal DNA as a template and primer pairs atsR1F and atsR1R, atsR2F and 
atsR2R, atsTF and atsTR and atsA2F and atsA2R, respectively (Table 5.2). The 
insertion mutants were constructed as described previously (O'Connell Motherway et 
al., 2009). Site-specific recombination of potential Tet-resistant mutant isolates was 
confirmed by colony PCR using primer combinations TetWF and TetWR to verify 
tetW gene integration, and the primers atsR1confirm, atsR2confirm, atsTconfirm and 
atsA2confirm (positioned upstream of the selected internal fragments of atsR1, 
atsR2, atsT and atsA2, respectively) in combination with primer TetWF to confirm 




Analysis of global gene expression using B. breve DNA microarrays. Global gene 
expression was determined during log-phase growth of B. breve UCC2003 in mMRS 
supplemented with 0.5 % GlcNAc-6-S and the obtained transcriptome was compared 
to that obtained from B. breve UCC2003 grown in mMRS supplemented with 0.5 % 
ribose. Similarly, global gene expression of the insertion mutants B. breve 
UCC2003-atsR1 and B. breve UCC2003-atsR2 was determined during log-phase 
growth of the mutants in mMRS supplemented with 0.5 % ribose and these 
transcriptomes were also compared to that from B. breve UCC2003 grown in 0.5 % 
ribose. DNA microarrays containing oligonucleotide primers representing each of 
the 1864 identified open reading frames on the genome of B. breve UCC2003 were 
designed and obtained from Agilent Technologies (Palo Alto, Ca., USA). Methods 
for cell disruption, RNA isolation, RNA quality control, complementary DNA 
(cDNA) synthesis and labelling were performed as described previously (Zomer et 
al., 2009). Labelled cDNA was hybridised using the Agilent Gene Expression 
hybridisation kit (part number 5188-5242) as described in the Agilent Two-Colour 
Microarray-Based Gene Expression Analysis v4.0 manual (publication number 
G4140-90050). Following hybridisation, microarrays were washed in accordance 
with Agilent’s standard procedures and scanned using an Agilent DNA microarray 
scanner (model G2565A). Generated scans were converted to data files with 
Agilent's Feature Extraction software (Version 9.5). DNA-microarray data were 
processed as previously described (García de la Nava et al., 2003; van Hijum et al., 
2003; van Hijum et al., 2005). Differential expression tests were performed with the 




Plasmid Constructions. For the construction of plasmids pNZ-atsR1 and pNZ-
atsR2, DNA fragments encompassing the complete coding region of the predicted 
transcriptional regulators atsR1 (Bbr_0351) and atsR2 (Bbr_0849) were generated 
by PCR amplification from chromosomal DNA of B. breve UCC2003 using PFUII 
DNA polymerase and the primer combinations atsR1FOR and atsR1REV, and 
atsR2FOR and atsR2REV, respectively (Table 5.2). The generated amplicons were 
digested with NcoI and XbaI, and ligated into the similarly digested, nisin-inducible 
translational fusion plasmid pNZ8048 (Mierau & Kleerebezem, 2005). The ligation 
mixtures were introduced into L. lactis NZ9000 by electrotransformation and 
transformants were selected based on Cm resistance. The plasmid content of a 
number of Cmr transformants was screened by restriction analysis and the integrity 
of positively identified clones was verified by sequencing. 
For the construction of the plasmids pQE-60-atsA2 and pBC1.2-atsB2, DNA 
fragments encompassing the complete coding region of the predicted sulfatase-
encoding gene atsA2 (Bbr_0852) and the predicted anSME-encoding gene atsB2 
(Bbr_0853) were generated by PCR amplification from B. breve UCC2003 
chromosomal DNA using PFUII DNA polymerase and the primer pairs AtsA2FOR 
and AtsA2REV, and AtsB2FOR and AtsB2REV, respectively (Table 5.2). The 
amplified 1.5 kb atsA2-encompassing fragment was digested with NcoI and BglII, 
and ligated to the similarly digested pQE-60 plasmid. The ligation mixtures were 
introduced into E. coli XL1-blue by electrotransformation and transformants were 
selected based on Tet and Amp resistance. The amplified 1.4 kb atsB2-encompassing 
fragment was digested with HindIII and XbaI, and ligated to the similarly digested 
pBC1.2 plasmid (Álvarez-Martín et al., 2007). The ligation mixtures were 
introduced into E. coli XL1-blue by electrotransformation and transformants were 
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selected based on Tet and Cm resistance. Transformants were screened by restriction 
analysis and the integrity of positively identified clones was verified by sequencing. 
A representative pBC1.2-atsB2 plasmid was introduced into E. coli XL1-blue-pQE-
60-atsA2 by electrotransformation and transformants were selected based on Tet, 
Amp and Cm resistance. 
To clone the Bbr_0849 promoter region, a DNA fragment encompassing the 
intergenic region between the Bbr_0849 and Bbr_0850 genes was generated by PCR 
amplification from B. breve UCC2003 chromosomal DNA using PFUII DNA 
polymerase and the primer pair, atsPromF and atsPromR (Table 5.2). The PCR 
product was digested with HindIII and XbaI, and ligated to the similarly digested 
pBC1.2 (Álvarez-Martín et al., 2007). The ligation mixture was introduced into E. 
coli XL1-blue by electrotransformation and transformants were selected based on 
Tet and Cm resistance. Transformants were checked for plasmid content by 
restriction analysis and the integrity of positively identified clones was verified by 
sequencing. Plasmid pBC1.2-atsProm was introduced into B. breve UCC2003-atsR2 
by electrotransformation and transformants were selected based on Tet and Cm 
resistance. 
 
Protein overproduction and purification. For the heterologous expression of AtsR1 
and AtsR2, 25 ml of M17 broth supplemented with 0.5 % (wt/vol) glucose was 
inoculated with a 2 % inoculum of L. lactis NZ9000 harbouring either pNZ-atsR1, 
pNZ-atsR2 or the empty vector pNZ8048 (used as a negative control), followed by 
incubation at 30°C until an OD600nm of 0.5 was reached, at which point protein 
expression was induced by addition of cell-free supernatant of a nisin-producing 
250 
 
strain (de Ruyter et al., 1996), followed by continued incubation for a further 2 h. 
Cells were harvested by centrifugation, resuspended in 10 mM Tris-HCl (pH 8.0), 
and disrupted with glass beads in a mini-bead beater (BioSpec Products, Bartlesville, 
OK). Cellular debris was removed by centrifugation to produce a crude cell extract. 
For the heterologous expression of AtsA2, AtsB2, or the co-expression of AtsA2 and 
AtsB2, 2 % inocula of the generated E. coli XL1-blue derivatives harbouring either 
pQE-60-atsA2, pBC1.2-atsB2 or pQE-60-atsA2-pBC1.2-atsB2 (see above) were 
used to inoculate a 25 ml volume of LB supplemented with the appropriate 
antibiotics. Cultures were incubated at 37°C until an OD600nm of 0.5 was reached, at 
which point protein expression was induced by the addition of 1 mM IPTG, followed 
by further incubation for 2 h. Preparation of crude cell extract was performed as 
described above. 
 
Enzyme assays. The predicted sulfatase activity of AtsA2 was analysed following 
IPTG-induced expression in the presence or absence of the predicted anSME, AtsB2. 
A 50 µl volume of crude cell extract of E. coli XL1-blue derivatives containing 
either pQE-60-atsA2, pBC1.2-atsB2 (used as a negative control) or pQE-60-atsA2-
pBC1.2-atsB2 was incubated with 0.1 mg ml-1 of GlcNAc-6-S. Enzymatic assays 
were performed at 37°C in a total volume of 500 µl in a reaction buffer containing 
50 mM morpholinepropanesulfonic acid (MOPS, pH 7.0). The reactions were 
terminated after 24 h by incubation at 65°C for 10 min and were stored at -20°C 
prior to high-performance anion-exchange chromatography with pulsed 




High-Performance Anion Exchange Chromatography with Pulsed 
Amperometric Detection (HPAEC-PAD). HPAEC-PAD was performed using a 
Dionex ICS-3000 system (Dionex, Sunnyvale, CA). Carbohydrate fractions (25 µl 
aliquots) were separated on a CarboPac PA1 (Dionex) analytical-exchange column 
(250 mm x 4 mm) with a CarboPac PA1 guard column (50 mm x 4 mm) and a 
pulsed electrochemical detector in the pulsed amperometric detection (PAD) mode. 
The elution was performed at a constant flow-rate of 1.0 ml min-1 at 30°C using the 
following eluents for the analysis (A) 200 mM NaOH, (B) 100 mM NaOH, 550 mM 
sodium acetate, and (C) Milli-Q water. The following linear gradient of NaAc was 
used: 100 mM NaOH: 0-50 min, 0 mM; 50-51 min, 16 mM; 51-56 min, 100 mM; 
56.1-61 min, 0 mM. Detection was achieved using a Dionex ED40 detector in PAD 
mode. The Chromeleon software-version 6.70 (Dionex Corporation) was used for 
the integration and evaluation of the chromatograms obtained. The chromatographic 
profiles corresponding to N-acetylglucosamine (GlcNAc) and GlcNAc-6-S were 
qualitatively examined to evaluate sulfatase activity. 
 
Electrophoretic mobility shift assays (EMSA). DNA fragments representing 
different portions of each of the promoter regions upstream of the atsA1, Bbr_0353, 
atsR2 and atsT genes were prepared by PCR using IRD-labelled primer pairs (Table 
5.3). EMSAs were essentially performed as described previously (Hamoen et al., 
1998). In all cases, the binding reactions were performed in a final reaction volume 
of 20 μl in the presence of poly (dI-dC) in binding buffer (20 mM Tris-HCl, 5 mM 
MgCl2, 0.5 mM dithiothreitol (DTT), 1 mM EDTA, 50 mM KCl, 10 % glycerol at 
pH 7.0). Various amounts of L. lactis NZ9000 crude cell extract containing pNZ-
atsR1, pNZ-atsR2 or pNZ8048 were mixed on ice with a fixed amount of DNA 
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probe (0.1 pmol) and subsequently incubated for 30 min at 37°C. Samples were 
loaded on a 6 % non-denaturing polyacrylamide (PAA) gel prepared in TAE buffer 
(40 mM Tris acetate (pH 8.0), 2 mM EDTA) and run in a 0.5 to 2.0 x gradient of 
TAE at 100 V for 120 min in an Atto Mini PAGE system (Atto Bioscience and 
Biotechnology, Tokyo, Japan). Signals were detected using an Odyssey Infrared 
Imaging System (Li-Cor Biosciences, United Kingdom Ltd., Cambridge, United 
Kingdom) and images were captured using the supplied Odyssey software v3.0. To 
determine the effector molecule of AtsR2, GlcNAc or GlcNAc-6-S was added to the 
binding reaction in concentrations ranging from 2.5 mM to 20 mM.  
 
Primer extension analysis. Total RNA was isolated from exponentially growing 
cells of B. breve UCC2003-atsR1, B. breve UCC2003-atsR2 or B. breve UCC2003-
atsR2-pBC1.2-atsProm in mMRS supplemented with 0.5 % ribose, as previously 
described (Zomer et al., 2009). Primer extension was performed by annealing 1 
pmol of an IRD-labelled synthetic oligonucleotide to 20 µg of RNA as previously 
described (Ventura et al., 2005), using primers AtsR1F1F, AtsR1F1R, AtsR2R1F or 
AtsR2T1R (Table 5.3). Sequence ladders of the presumed atsA1, Bbr_0353, atsR2 
and atsT promoter regions were produced using the same primer as in the primer 
extension reaction and a DNA cycle-sequencing kit (Jena Bioscience, Germany) and 
were run alongside the primer extension products to allow precise alignment of the 
transcriptional start site with the corresponding DNA sequence. Separation was 
achieved on a 6.5 % Li-Cor Matrix KB Plus acrylamide gel. Signal detection and 





Genetic organisation of the sulfatase gene clusters in B. breve UCC2003. Based on 
the presence of a sulfatase-associated PFAM domain PF00884 and the previously 
described N-terminally located sulfatase signature (CxPxR) (Dierks et al., 1999; 
Sardiello et al., 2005), two putative Cys-type sulfatase-encoding genes were 
identified on the genome of B. breve UCC2003. The first, repesented by the gene 
with the associated locus tag Bbr_0352 (and here designated as atsA1) is located in a 
cluster of four genes, designated the ats1 cluster, which also includes a gene 
encoding a predicted hypothetical membrane spanning protein (Bbr_0349), a gene 
(Bbr_0350, designated here as atsB1) specifying a putative anSME which contains 
the signature motif CxxxCxxC characteristic of the radical AdoMet-dependent 
superfamily (Sofia et al., 2001), and a gene specifying a predicted LacI-type 
transriptional regulator (Bbr_0351, designated atsR1). Adjacent to this gene cluster, 
a gene cluster encoding a predicted ABC-type transport system was identified 
(corresponding to locus tags Bbr_0353 through to Bbr_0355) (Fig. 5.1).  
The second predicted sulfatase-encoding gene, Bbr _0852 (designated atsA2 here), is 
located in another cluster of four genes (Bbr_0851 through to Bbr_0854), which was 
designated the ats2 gene cluster. Bbr_0851, designated here as atsT, encodes a 
predicted transporter from the major facilitator superfamily. Bbr_0853 (designated 
atsB2) encodes a second putative anSME, which also contains the signature 
CxxxCxxC motif. Bbr_0854 encodes a predicted membrane spanning protein of 
unknown function (Fig. 5.1). The AtsA1 and AtsA2 proteins share 28 % amino acid 
identity, while the AtsB1 and AtsB2 proteins exhibit 74 % identity between each 
other. The ats2 gene cluster has a notably different GC content (63.96 %) compared 
to the B. breve UCC2003 genome average (58.73 %), suggesting that this gene 
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cluster may have been acquired by horizontal transfer, whereas the GC content of the 
ats1 cluster (57.6 %) is comparable to that of the genome. 
BLASTP analysis revealed that the presence of potential sulfatase and anSME-
encoding genes in bifidobacteria is limited to the B. breve species. Based on the 
comparative genome analysis presented in Figure 5.1, we found that the putative 
sulfatase clusters are well conserved among the B. breve strains whose genomes 
were recently published (Bottacini et al., 2014). Of the currently available complete 
B. breve genomes, B. breve NCFB2258, B. breve 689B, B. breve 12L and B. breve 
S27 encode clear homologues of both identified putative sulfatase gene clusters 
described above. In contrast, the genomes of B. breve JCM7017, B. breve JCM7019 
and B. breve ACS-071-V-Sch8b contain just a single, but variable putative sulfatase 
cluster (Fig. 5.1).  
  
Growth of B. breve UCC2003 in mMRS supplemented with 0.5 % GlcNAc-6-S. 
The presence of two putative sulfatase-encoding clusters on the genome of B. breve 
UCC2003 suggests that this gut commensal is capable of removing a sulfate ester 
from a sulfated compound, possibly a sulfated carbohydrate. Therefore, in order to 
determine if B. breve UCC2003 is capable of metabolising the sulfated amino sugar 
GlcNAc-6-S (the only commercially available sulfated monosaccharide that could be 
obtained in affordable quantities for growth experiments), growth of the strain in 
mMRS supplemented with either 0.5 % lactose or GlcNAc-6-S as the sole carbon 
source was assessed by measuring the OD600nm after 24 h of anaerobic growth at 
37°C. The strain was shown to grow well on lactose (OD600nm > 1.5), while it was 
also capable of reasonable growth on GlcNAc-6-S (OD600nm > 0.8) (Fig. 5.2). This 
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result is consistent with the presence of predicted sulfatase and anSME-encoding 
genes on the B. breve UCC2003 genome. 
 
Genome response of B. breve UCC2003 to growth on GlcNAc-6-S. In order to 
investigate which genes are responsible for GlcNAc-6-S metabolism in B. breve 
UCC2003, global gene expression was determined by microarray analysis during 
growth of the strain in mMRS supplemented with GlcNAc-6-S and compared with 
gene expression when grown in mMRS supplemented with ribose. Ribose was 
considered an appropriate carbohydrate for comparative transcriptome analysis 
because the genes involved in ribose metabolism are known (Pokusaeva et al., 
2010), while it has furthermore been used in a number of transcriptome studies in 
this strain (Egan et al., 2014a; Egan et al., 2014b; O'Connell et al., 2013; O'Connell 
et al., 2014; O'Connell Motherway et al., 2013). Of the two predicted sulfatase and 
anSME-encoding gene clusters of B. breve UCC2003 (see above), the ats2 gene 
cluster was significantly up-regulated (fold change >3.0, P-value of <0.001) during 
growth on GlcNAc-6-S, while no (significant) difference in the level of transcription 
was observed for the ats1 gene cluster (Table 5.4). Three other gene clusters of 
interest were also significantly up-regulated (corresponding to locus tags Bbr_0846 
through to Bbr_0849, Bbr_1585 through to Bbr_1590, and Bbr_1247 through to 
Bbr_1249; see Fig. 5.3 and Table 5.4). 
Within the Bbr_0846-0849 gene cluster, which is separated from the ats2 cluster by 
a single gene (Fig. 5.3), Bbr_0846 (nagA1) and Bbr_0847 (nagB2) are predicted to 
encode an N-acetylglucosamine-6-phosphate deacetylase and a glucosamine-6-
phosphate deaminase, respectively. Bbr_0848 encodes a predicted ROK-family 
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kinase (designated nagK) which contains the characteristic DxGxT motif at the N-
terminal (Conejo et al., 2010). It exhibits 42 % similarity at protein level with the 
previously described ROK-family NagK characterised from E. coli K-12 which 
phosphorylates GlcNAc producing N-acetylglucosamine-6-phosphate (GlcNAc-6-P) 
(Uehara & Park, 2004). Therefore this cluster encodes putative enzymes for the 
complete GlcNAc catabolic pathway as previously described in E. coli, whereby 
GlcNAc is first phosphorylated by NagK producing GlcNAc-6-P, followed by 
NagA-mediated deacetylation to produce glucosamine-6-phosphate, and the NagB-
mediated deamination and isomerisation to produce fructose-6-phosphate (Uehara & 
Park, 2004; White, 1968). Bbr_0849 encodes a predicted transcriptional regulator 
from the ROK family (designated here as atsR2).  
The Bbr_1585-1590 cluster includes a predicted UDP-glucose-4-epimerase 
(Bbr_1585, galE), a predicted N-acetylhexosamine-1-kinase (Bbr_1586, nahK) and a 
predicted lacto-N-biose phosphorylase (Bbr_1586, lnbP), representing three of the 
four enzymes required for the degradation of galacto-N-biose (Galβ1-3GalNAc; 
GNB), which is found in mucin, or lacto-N-biose (Galβ1-3GlcNAc; LNB), a known 
HMO (Kitaoka et al., 2005; Nishimoto & Kitaoka, 2007). The final three genes of 
this cluster encode a predicted ABC transport system, including two predicted 
permease proteins and a solute binding protein, respectively (Fig. 5.3). This gene 
cluster was previously shown to be transcriptionally up-regulated when B. breve 
UCC2003 was grown in co-culture with B. bifidum PRL2010 in mucin (Egan et al., 
2014b).  
Finally, the Bbr_1247-1249 cluster contains a gene specifying an N-
acetylglucosamine-6-phosphate deacetylase (Bbr_1247) and a glucosamine-6-
phosphate deaminase (Bbr_1248)-encoding gene, designated nagA2 and nagB3, 
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respectively. These genes were previously up-regulated during B. breve UCC2003 
growth on sialic acid (Egan et al., 2014a). The NagA1 protein shares a 74 % identity 
with NagA2, while the NagB2 protein shares 84 % identity with NagB1 of the 
nan/nag cluster for sialic acid metabolism (Egan et al., 2014a) and 84 % identity 
with NagB3. Bbr_1249 encodes a predicted transcriptional regulator from the ROK 
family (Fig. 5.3). 
  
Disruption of the atsT and atsA2 genes. In order to investigate if disruption of 
individual genes from the ats2 gene cluster would affect the ability of B. breve 
UCC2003 to utilise GlcNAc-6-S, insertion mutants were constructed in the atsT and 
atsA2 genes, resulting in the strains B. breve UCC2003-atsT and B. breve UCC2003-
atsA2, respectively (see Materials and Methods). The insertion mutants were 
analysed for their ability to grow in mMRS supplemented with GlcNAc-6-S as 
compared to B. breve UCC2003. As expected, and in contrast to the wild type, there 
was a complete lack of growth of B. breve UCC2003-atsT and B. breve UCC2003-
atsA2 in media containing GlcNAc-6-S as the sole carbon source (Fig. 5.2), thus 
demonstrating the involvement of the disrupted genes in GlcNAc-6-S metabolism. 
However, it should be noted that construction of the insertion mutants in either of 
these genes is likely to have a polar effect on the downstream genes atsB2 and 
Bbr_0854 (Fig. 5.1), which may also contribute to the lack of growth of the mutant 
strains. Growth of the insertion mutants was not impaired on lactose, where all 
strains reached final OD600nm levels comparable to that reached by the wild type 




Biochemical analysis. In order to in vitro test the presumed sulfatase activity of 
AtsA2 and the role (if any) of AtsB2 in relation to AtsA2 activity, the predicted 
sulfatase and anSME-encoding genes atsA2 and atsB2 were cloned into separate, 
compatible plasmids pQE-60 and pBC1.2 to produce pQE-60-atsA2 and pBC1.2-
atsB2, with both genes under the control of the IPTG-inducible lac promoter (see 
Materials and Methods). Three E. coli XL1-blue derived strains were generated, 
harbouring pQE-60-atsA2, pBC1.2-atsB2 or pQE-60-atsA2-pBC1.2-atsB2. 
Following IPTG induction, crude cell extracts of these three strains were obtained 
and then used to investigate sulfatase activity. Under the HPAEC-PAD conditions 
used, it was not possible to visualise GlcNAc-6-S, yet the assumed product GlcNAc 
was identifiable. As expected, accumulation of GlcNAc was not observed when the 
substrate was incubated with the negative control, pBC1.2-atsB2. Incubation of 
crude cell extract containing pQE-60-atsA2-pBC1.2-atsB2 with GlcNAc-6-S 
resulted in an accumulation of GlcNAc, yet no such accumulation was observed 
when crude cell extract containing pQE-60-atsA2 was used (Fig. 5.4). This implies 
that atsA2 must be co-expressed with the anSME-encoding atsB2 in order to produce 
an active sulfatase enzyme. This is likely to be achieved through the modification of 
the Cys64 residue of AtsA2 to an FGly residue by AtsB2, as previously described for 
the atsB homologues from K. pneumoniae, C. perfringens and Ba. thetaiotaomicron 
(Benjdia et al., 2008; Berteau et al., 2006; Szameit et al., 1999). 
 
Transcriptome of B. breve UCC2003-atsR1 and B. breve UCC2003-atsR2. The 
Bbr_0846-0849 gene cluster, which is up-regulated when B. breve UCC2003 is 
grown on GlcNAc-6-S, and the ats2 gene cluster are separated by just a single gene 
(Fig. 5.1). As mentioned above, the Bbr_0849 gene encodes a predicted ROK-type 
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transcriptional regulator and was thus designated atsR2. To investigate if this 
predicted transcriptional regulator controls transcription of the ats2 and/or the 
Bbr_0846-0849 gene clusters, an insertion mutant was constructed, resulting in the 
strain B. breve UCC2003-atsR2. It was hypothesised that if this gene encoded a 
repressor, mutation of the gene would lead to increased transcription of the genes it 
controls even in the absence of the inducing carbohydrate. Microarray data revealed 
that in comparison to B. breve UCC2003, the ats2 operon was significantly up-
regulated (>9.0 fold change; P <0.001) in the mutant strain, thus identifying atsR2 as 
a transcriptional repressor (Table 5.5; Fig. 5.5). The Bbr_0846-0849 gene cluster 
was clearly down-regulated in the mutant strain, however, since the atsR2 gene 
represents the first gene of this presumed operon (Fig. 5.5), a polar effect on 
downstream located genes can be expected. Part of the B. breve UCC2003 locus 
responsible for the production of exopolysaccharide (EPS), Bbr_0435-0441, was 
also down-regulated in this insertion mutant, most likely due to the deletion of this 
cluster. This is an occasional occurrence in the construction of insertion mutants in 
this strain, possibly a stress-related effect of homologous recombination. 
As mentioned above, the ats1 operon includes a predicted LacI-type transcriptional 
regulator, designated atsR1 (Fig. 5.1). In order to determine if this predicted 
regulator controls transcription of the ats1 operon, an insertion mutant was 
constructed resulting in strain B. breve UCC2003-atsR1. Microarray data revealed 
that in comparison to B. breve UCC2003, the atsA1 and atsR1 genes as well as the 
predicted ABC-transport system encoded by the Bbr_0353-0355 genes, were 
significantly up-regulated (>9.0 fold change; P <0.001) in the mutant strain (Table 
5.5; Fig. 5.5). It is likely that the insertion mutant has a polar effect on the 
transcription of the two genes downstream of atsR1, namely atsB1 and Bbr_0347 
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(Fig. 5.5), and it is thus possible that these genes are also co-transcribed with atsA1 
and atsR1 in the wild type strain. 
 
Electrophoretic mobility shift assays. In order to determine if the AtsR1 and AtsR2 
proteins directly interact with promoter regions of the ats1 and ats2 gene clusters 
respectively, crude cell extracts of L. lactis NZ9000-pNZ-atsR1 or L. lactis NZ9000-
pNZ-atsR2 were used to perform EMSAs, with crude cell extracts of L. lactis 
NZ9000-pNZ8048 (empty vector) used as a negative control. As expected, the 
negative control did not alter the electrophoretic behaviour of any of the tested DNA 
fragments (Fig 5.6B, 5.7B). The results obtained with crude cell extract 
overexpressing AtsR2 demonstrate that this presumed regulator binds to DNA 
fragments encompassing the upstream regions of atsR2 and atsT (Fig. 5.6A, 5.6B). 
Dissection of the promoter region of atsR2 showed that AtsR2 binding required a 
184 bp region within which a 21 bp imperfect inverted repeat was identified. 
Similarly, dissection of the atsT promoter region revealed that AtsR2 binding 
required a 192 bp region which also includes a 21 bp imperfect inverted repeat, 
similar to that identified upstream of atsR2. When either of the inverted repeats were 
excluded, binding of AtsR2 to such DNA fragments was prevented, suggesting that 
these inverted repeats contained the operator sequence of AtsR2 (Fig. 5.6A, 5.6B).  
To demonstrate if AtsR2 binding to its DNA target is affected by the presence of a 
carbohydrate effector molecule, GlcNAc and GlcNAc-6-S were tested for their 
effects on the formation of the AtsR2-DNA complex. The ability of AtsR2 to bind to 
the promoter regions of atsR2 or atsT was abolished in the presence of 2.5 mM 
GlcNAc-6-S, the lowest concentration used in this assay. The presence of GlcNAc 
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was shown to inhibit binding of AtsR2 to the atsR2 and atsT promoter regions, yet 
only at GlcNAc concentrations above 5 mM (Fig. 5.6C). This suggests that while 
GlcNAc-6-S has the highest affinity for the regulator and is therefore the most likely 
effector of this repressor protein, the structurally similar GlcNAc is also able to bind 
this regulator, yet at concentrations that are probably not relevant from a cell 
physiology perspective. 
The results obtained with crude cell extract containing AtsR1 demonstrate that 
AtsR1 binds to a DNA fragment which encompasses the intergenic region between 
atsA1 and Bbr_0353, which is consistent with the transcriptome profile of B. breve 
UCC2003-atsR1 (Table 5.5, Fig. 5.7A, 5.7B). Dissection of this intergenic region 
revealed that AtsR1 binds to two distinct DNA fragments of 184 bp and 124 bp. 
Within these two fragments, a well conserved imperfect inverted repeat of 18 bp was 
identified. Further fragmentations to the point where the inverted repeats were 
excluded resulted in an absence of binding, suggesting that these inverted repeats 
represent the operator sequence of AtsR1 (Fig. 5.7A, 5.7B).  
  
Identification of the transcription start sites of atsA1, Bbr_0353, atsR2 and atsT. 
Based on the EMSA results and the transcriptomes of B. breve UCC2003-atsR1 and 
B. breve UCC2003-atsR2, it was deduced that the intergenic region between atsA1 
(Bbr_0352) and Bbr_0353 contains two AtsR1-dependent promoters, while an 
AtsR2-dependent promoter is located upstream of both atsR2 and atsT (Fig. 5.5). In 
order to determine the transcriptional start site of these presumed promoters, primer 
extension analysis was performed using RNA extracted from B. breve UCC2003-
atsR1, B. breve UCC2003-atsR2 or B. breve UCC2003-atsR2-pBC1.2-atsProm 
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grown in mMRS supplemented with 0.5 % ribose. Microarray analysis had shown 
that the expression levels of atsA1 and Bbr_0353 were high when B. breve 
UCC2003-atsR1 was grown on ribose and similarly, atsT was highly up-regulated in 
the B. breve UCC2003-atsR2 insertion mutant. For this reason, and because the 
inducer of the ats1 cluster is still unknown, the mutant strains were considered most 
suitable for primer extension analyis. For the atsR2 promoter region, initial attempts 
to attain a primer extension product from mRNA isolated from B. breve UCC2003-
atsR2 cells were unsuccessful. In an attempt to increase the amount of mRNA 
transcripts of this promoter region, a DNA fragment encompassing the promoter 
region was cloned into pBC1.2 and introduced into B. breve UCC2003-atsR2, 
generating the strain B. breve UCC2003-atsR2-pBC1.2-atsProm. Single extension 
products were identified upstream of atsR2 and atsT (Fig. 5.8A, 5.8B). Two 
extension products, only differing one nucleotide in length, were identified upstream 
of both atsA1 and Bbr_0353 (Fig. 5.8C, 5.8D). Potential promoter recognition 
sequences resembling consensus -10 and -35 hexamers were identified upstream of 
each of the transcription start sites (Fig. 5.8). In all cases, the deduced operator 
sequences of AtsR1 or AtsR2 overlap with the respective -35 or -10 sequences, 





5.5 DISCUSSION   
Metagenomic sequence analysis has revealed that genes predicted to encode 
sulfatases and anSMEs are enriched in the gut microbiomes of humans compared to 
non-gut microbial communities (Kurokawa et al., 2007). Ba. thetaiotaomicron has 
been used as a model strain for interesting studies into the importance of sulfatase 
activity to bacterial fitness in vivo. In the earlier studies of chondroitin sulfate and 
heparan sulfate metabolism by this species, mutagenesis of a gene designated chuR, 
which was then predicted to encode a regulatory protein, resulted in the inability to 
compete with wild type Ba. thetaiotaomicron in germ free mice (Cheng et al., 1992). 
The chuR gene was later found to encode an anSME (Benjdia et al., 2008). Recently, 
this anSME was again shown to have significant importance in this strain’s ability to 
colonise the gut, as an isogenic derivative of this strain (designated ∆anSME) 
carrying a deletion in the anSME-encoding gene displayed reduced fitness in vivo 
even in the presence of dietary glycans (Benjdia et al., 2011). This is a particularly 
interesting observation given that it was previously shown that Ba. thetaiotaomicron 
preferentially utilises plant polysaccharides over host glycans, even when both are 
available (Sonnenburg et al., 2005). The authors speculated that anSME activity and 
associated sulfatase activity are important as the bacterium adapts to the gut 
environment (Benjdia et al., 2011). 
The current study describes two gene clusters in B. breve UCC2003, each encoding a 
(predicted) sulfatase and accompanying anSME, as well as an associated transport 
system and transcriptional regulator. One of these gene clusters, ats2, is shown to be 
required for the metabolism of GlcNAc-6-S, a monosaccharide component of human 
colonic mucin and heparan sulfate (Hopwood & Elliott, 1983; Larsson et al., 2009). 
The substrate for the enzymes encoded by the ats1 gene cluster has yet to be 
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elucidated. We speculate that this cluster may be involved in the metabolism of other 
sulfated monosaccharides such as N-acetylgalactosamine-6-sulfate, which is found in 
chondroitin sulfate (Eliakim et al., 1986). It is also possible that the sulfatase enzyme 
encoded by the atsA1 gene is specific for other linkages between the sulfate ester and 
the monosaccharide. Four sulfatase enzymes recently characterised from Ba. 
thetaiotaomicron were shown to have strict specificity for either 2-O-sulfated, 4-O-
sulfated or 6-O-sulfated substrates (Ulmer et al., 2014). Therefore it would be 
interesting to test the growth and transcriptome response of B. breve UCC2003 to N-
acetylglucosamine-3-sulfate or N-acetylgalactosamine-3-sulfate.  
Interestingly, the two gene clusters, ats1 and ats2, are quite dissimilar in terms of 
their genetic organsiation. The organisation of the ats1 cluster resembles that of a 
typical bifidobacterial carbohydrate utilisation cluster as it includes genes encoding a 
predicted ABC-type transport system, a LacI-type repressor (atsR1) and the 
potentially carbohydrate-active atsA1-encoded sulfatase and atsB-encoded anSME, 
which in this case replace the typical glycosyl hydrolase-encoding gene(s) (Schell et 
al., 2002). The atsA1, atsR1 and atsB1 genes, and the genes specifying the ABC-
type transport system are located on adjacent, divergent gene clusters, yet their 
promoters are co-regulated by AtsR1. AtsR1 shares many of the features of a typical 
LacI-type transcription factor, as (i) it solely regulates adjacent genes representing a 
single carbohydrate catabolic pathway, (ii) it is autoregulated and (iii) its predicted 
binding sequence contains the conserved CG pair at its centre and is located within 
30 and 140 bp of the start codon (Ravcheev et al., 2014).  
In the ats2 cluster, the atsT gene encodes a predicted transporter of the major 
facilitator superfamily, while the atsA2 and atsB2 genes are adjacent, similar to their 
homologous genes in K. pneumoniae and Prevotella strain RS2 (Murooka et al., 
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1990; Wright et al., 2000). We obtained compelling evidence that the ats2 cluster is 
co-regulated with the Bbr_0846-0849 cluster by the ROK-family transcriptional 
repressor AtsR2. The only previously characterised bifidobacterial ROK-family 
transcriptional regulator is RafA, the transcriptional activator of the raffinose 
utilisation cluster in B. breve UCC2003 (O'Connell et al., 2014). The Bbr_0846-
0848 genes are presumably involved in the metabolism of GlcNAc following the 
removal of the sulfate residue from GlcNAc-6-S. The fructose-6-phosphate produced 
from GlcNAc by the combined activities of NagK, NagA1 and NagB2 is expected to 
enter the fructose-6-phosphate phosphoketolase pathway or bifid shunt, the central 
metabolic pathway of bifidobacteria (Scardovi & Trovatelli, 1965). It is interesting 
that B. breve UCC2003 is capable of growth on GlcNAc-6-S as a sole carbon source 
but apparently not on GlcNAc (Pokusaeva et al., 2011a). Since the B. breve 
UCC2003 genome seems to encode the enzymes required to metabolise GlcNAc, it 
suggests that the atsT transporter has (high) affinity for only the sulfated form of the 
sugar. 
The function (if any) of the Bbr_0850 gene, which encodes a predicted aldose-6-
phosphate epimerase and is located between the co-regulated Bbr_0846-0849 and 
ats2 gene clusters has yet to be elucidated. We speculate that this enzyme plays a 
role in the metabolism of sulfated N-acetylgalactosamine (GalNAc), a component of 
chondroitin sulfate (Eliakim et al., 1986), possibly by isomerisation of GalNAc-6-P 
to GlcNAc-6-P, similar to the isomerisation of N-acetylmannosamine-6-phosphate to 
GlcNAc-6-P in the sialic acid catabolic pathway by an N-acetylmannosamine-6-
phosphate epimerase (Egan et al., 2014a). This would also require the putative NagK 
ROK-family kinase to be active on both GlcNAc and GalNAc, or for a second kinase 
to be identifed elsewhere on the genome.  
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As mentioned above, sulfatase activity has not previously been described in the 
Bifidobacterium genus. In terms of the metabolism of host-derived carbohydrates 
such as mucin and HMO, the B. breve species has been described as a scavenger of 
mono- and oligosaccharides that are released by the activity of specialised mucin and 
HMO-degraders such as B. bifidum (Sela & Mills, 2010). Recent studies have shown 
that it employs this strategy to great effect, as B. breve UCC2003 utilises 
components of 3’ sialyllactose (a HMO) and mucin following the degradation of 
these sugars by B. bifidum PRL2010, whereas in the absence of B. bifidum 
PRL2010, it is not capable of utilising either of these sugars as a sole carbon source 
(Egan et al., 2014a; Egan et al., 2014b). Nonetheless, it is intruiging that within the 
Bifidobacterium genus, sulfatase-encoding genes appear to be restricted to and 
conserved within the B. breve species, allowing it to utilise sulfated 
monosaccharides such as GlcNAc-6-S (and possibly others) which are inaccessible 
to other Bifidobacterium species. This, combined with recent knowledge that B. 
breve strains can utilise complex N-glycans similar to those found in human milk 
(Garrido et al., 2012) and more constituents of HMO than was originally imagined 
(Ruiz-Moyano et al., 2013), suggests that the description as a scavenger may be 
underselling the metabolic flexibility of this species. Instead, it possible that this 
species employs a multifaceted approach to carbohydrate metabolism in the (infant) 
gut. 
Bacterial sulfatase activity has been well-described in the Bacteroides genus as well 
as Prevotella strain RS2 (Roberton et al., 1993; Salyers et al., 1977; Tsai et al., 
1991; Willis et al., 1996). 28 predicted sulfatase-encoding genes were identified on 
the genome of Ba. thetaiotaomicron, 20 of which are predicted extracellular 
enzymes, yet the previously described chuR gene is the sole anSME-encoding gene 
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(Benjdia et al., 2011). This gene was predicted to be constitutively expressed and the 
authors proposed that this would allow maturation of the various sulfatase proteins 
as they are produced in a substrate dependent manner (Benjdia et al., 2011; 
Sonnenburg et al., 2005; Sonnenburg et al., 2006). Interestingly, a novel method of 
desulfating mucin which does not require a sulfatase enzyme was characterised from 
the Prevotella strain, whereby a sulfoglycosidase removes GlcNAc-6-S from 
purified porcine gastric mucin (Rho et al., 2005). The presence of a signal sequence 
on this glycosulfatase, thus indicating extracellular activity, is interesting in relation 
to the current study, as it presents a source of GlcNAc-6-S to B. breve strains, 
suggestive of another cross-feeding opportunity for members of this species. This is 
particularly noteworthy when it is considered that the sulfatase enzymes produced by 
B. breve UCC2003 are intracellular, implying that B. breve UCC2003 is again reliant 
on the extracellular glycosyl hydrolase activity of other members of the gut 
microbiota in order to gain access to mucin-derived sulfated monosaccharides. 
The current study investigated a previously unexplored area of carbohydrate 
metabolism in bifidobacteria, namely the metabolism of sulfated carbohydrates. 
While future studies will first focus on the identification on the substrate(s) of the 
ats1 gene cluster, it would also be interesting to perform in vivo analysis, similar to 
that performed using Ba. thetaiotaomicron, of sulfatase or anSME insertion mutants 
of B. breve UCC2003 to investigate if these genes contribute to B. breve UCC2003 
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5.7 TABLES AND FIGURES 
Table 5.1: Bacterial strains and plasmids used in this study. 
Strains and plasmids Relevant features Reference or source 
Strains   
Escherichia coli strains   
E.coli EC101 Cloning host; repA+ kmr (Law et al., 1995) 
E.coli EC101-pNZ-M.Bbrll+Bbr11 EC101 harboring a pNZ8048 derivative containing bbrllM and bbrlllM (O'Connell Motherway et al., 2009) 
E. coli XL1-blue (supE44 hsdR17 recA1 gyrA96 thi relA1 lac F′ [proAB+ laclq lacZΔM15 
Tn10(Tetr)]) 
Stratagene 
E. coli XL1-blue-pQE-60-atsA2 XL1-blue containing pQE-60-atsA2 This study 
E. coli XL1-blue-pBC1.2-atsB2 XL1-blue containing pBC1.2-atsB2 This study 
E. coli XL1-blue-pQE-60-atsA2-pBC1.2-atsB2 XL1-blue containing pQE-60-atsA2 and  pBC1.2-atsB2 This study 
L. lactis strains   
               L. lactis NZ9000 MG1363, pepN::nisRK, nisin inducible overexpression host (de Ruyter et al., 1996) 
               L. lactis NZ9000-pNZ8048 NZ9000 containing pNZ8048 This study 
               L. lactis NZ9000-pNZ-atsR1 NZ9000 containing pNZ-atsR1 This study 
               L. lactis NZ9000-pNZ-atsR2 NZ9000 containing pNZ-atsR2 This study 
               L. lactis NZ97000 Nisin-A producing strain (de Ruyter et al., 1996) 
Bifidobacterium sp. strains   
B. breve UCC2003 Isolate from a nursling stool (Maze et al., 2007) 
B. breve UCC2003-atsR1 pORI19-tetW-atsR1 insertion mutant of B. breve UCC2003 This study 
B. breve UCC2003-atsR2 pORI19-tetW-atsR2 insertion mutant of B. breve UCC2003 This study 
B. breve UCC2003-atsT pORI19-tetW-atsT insertion mutant of B. breve UCC2003 This study 
B. breve UCC2003-atsA2 pORI19-tetW-atsA2 insertion mutant of B. breve UCC2003 This study 
B. breve UCC2003-atsR2-pBC1.2-atsProm pORI19-tetW-atsR2 insertion mutant of UCC2003 containing pBC1.2-atsProm This study 
Plasmids   
pAM5 pBC1-pUC19-Tcr (Álvarez-Martín et al., 2007) 
pNZ8048 Cmr, nisin-inducible translational fusion vector (Mierau & Kleerebezem, 2005) 
pNZ-atsR1 atsR1 cloned downstream of nisin-inducible promoter on pNZ8048 This study 
pNZ-atsR2 atsR2 cloned downstream of nisin-inducible promoter on pNZ8048 This study 
pORI19 Emr, repA-, ori+, cloning vector (Law et al., 1995) 
pORI19-tetW-atsR1 Internal 404 bp fragment of atsR1 and tetW cloned in pORI19 This study 
pORI19-tetW-atsR2 Internal 408 bp fragment of atsR2 and tetW cloned in pORI19 This study 
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pORI19-tetW-atsT Internal 416 bp fragment of atsT and tetW cloned in pORI19 This study 
pORI19-tetW-atsA2 Internal 402 bp fragment of atsA2 and tetW cloned in pORI19 This study 
pQE-60 Ampr, IPTG inducible vector Qiagen 
pQE-60-atsA2 atsA2 cloned into the IPTG inducible vector, pQE-60 This study 
pBC1.2 pBC1-pSC101-Cmr (Álvarez-Martín et al., 2007) 
pBC1.2-atsB2 atsB2 cloned into pBC1.2 This study 





Table 5.2: Oligonucleotide primers used in this study. 
Purpose Primer Sequence 
Cloning of 404 bp fragment of atsR1 in pORI19 AtsR1F TGATCAAAGCTTCGTCCGAGGAGAACAGCATC 
 AtsR1R TAGCTATCTAGACCACCCGACATCGATCAAC 
Cloning of 408 bp fragment of atsR2 in pORI19 AtsR2F GACTAGAAGCTTGCCATCACGATCGACGACG 
 AtsR2R TAGCATTCTAGAGCATCCCGGACGTCCACAG 
Cloning of 416 bp fragment of atsT in pORI19 AtsTF GACTAGAAGCTTGATCTCCTTCCGCCAGCTC 
 AtsTR TAGCATTCTAGACGTTGGTGCCGGTCAGCTG 
Cloning of 402 bp fragment of atsA2 in pORI19 AtsA2F GACTAGAAGCTTGAATACGTCGCCTGGCTCAAG 
 AtsA2R TAGCATTCTAGACCTCCACTGGTCGTTGTCG 
Amplification of tetW TetWF TCAGCTGTCGACATGCTCATGTACGGTAAG 
 TetWR GCGACGGTCGACCATTACCTTCTGAAACATA 
Confirmation of site-specific homologous recombination AtsR1confirm CAGCGGTCTTATCTCATTCGTC 
 AtsR2confirm CATCGACACGGCATACTGG 
 AtsTconfirm CATCTTCGGCGCGTTATG 
 AtsA2confirm GGAAACCGACTGGACCTACAC 
Cloning of atsR1 in pNZ8048 AtsR1FOR TGATCACCATGGCAACGACGCTCAAAGAC 
 AtsR1REV GCATCGTCTAGACAGCGCCGTCAGACATTG 
Cloning of atsR2 in pNZ8048 AtsR2FOR TACGTACCATGGTGCATTTCGCATCGG 
 AtsR2REV GCTAGCTCTAGAGTGGAATATGCGGTGCGTG 
Cloning of atsA2 in pQE-60 AtsA2FOR GATTAGCCATGGACAGCCAGACCAAACCGC 
 AtsA2REV TAGCATAGATCTCTTGGCGACTTGGTCCC 
Cloning of atsB2 in pBC1.2 AtsB2FOR TGCCTATCTAGAAAGGAGATGTATCGACGGAATGCGTTG 
 AtsB2REV GCTATAAAGCTTCACACGAGGAAAGCGGTCAC 
Cloning of atsProm in pBC1.2 AtsPromF GTACTAAAGCTTCCAGTATGCCGTGTCGATG 
 AtsPromR TAGCTATCTAGACGCAATGCCAGAAACTCAGC 




Table 5.3: IRD-labelled primers used to generate PCR products and primer 




























Table 5.4: Effect of GlcNAc-6-S on the transcriptome of B. breve UCC2003 
Locus tag  
(gene name) 
Predicted Function Level of 
upregulation 
Bbr_0846 (nagA1) N-acetylglucosamine-6-phosphate deacetylase  12.63 
Bbr_0847 (nagB2) Glucosamine-6-phosphate deaminase 6.17 
Bbr_0848 (nagK) Sugar kinase, ROK family  9.85 
Bbr_0849 (atsR2) Transcriptional regulator, ROK family 8.58 
Bbr_0851 (atsT) Carbohydrate transport protein  96.75 
Bbr_0852 (atsA2) Sulfatase 35.36 
Bbr_0853 (atsB2) anSME  31.25 
Bbr_0854 Hypothetical membrane spanning protein  4.175 
Bbr_1247 (nagA2) N-acetylglucosamine-6-phosphate deacetylase  10.84 
Bbr_1248 (nagB3) Glucosamine-6-phosphate deaminase  11.88 
Bbr_1249 Transcriptional regulator, ROK family  3.07 
Bbr_1585 (galE) UDP-glucose 4-epimerase  3.09 
Bbr_1586 (nahK) N-acetylhexosamine kinase 4.96 
Bbr_1587 (lnbP) lacto-N-biose phosphorylase  6.58 
Bbr_1588 Permease protein of ABC transporter system 6.24 
Bbr_1589 Permease protein of ABC transporter system 8.27 
Bbr_1590 Solute-binding protein of ABC transporter system  23.97 




Table 5.5: Transcriptome analysis of B. breve UCC2003-atsR1 and B. breve 
UCC2003-atsR2 as compared to B. breve UCC2003 grown on 0.5 % (wt/vol) 
ribose. 
Locus tag (gene 
name) Predicted Function 
Level of up-regulation 
atsR1 atsR2 
Bbr_0351 (atsR1) Transcriptional regulatory protein  14.95 - 
Bbr_0352 (atsA1) Sulfatase family protein 65.29 - 
Bbr_0353 Sugar-binding protein  105.0 - 
Bbr_0354 Permease of ABC transporter for sugars  86.23 - 
Bbr_0355 Permease of ABC transporter for sugars  53.23 - 
Bbr_0851 (atsT) Major facilitator transporter - 106.28 
Bbr_0852 (atsA2)  Sulfatase family protein - 59.58 
Bbr_0853 (atsB2) anSME - 15.57 
Bbr_0854 Conserved membrane spanning domain - 9.09 
The cutoff point is 9- fold with a P-value of <0.001; values below the cutoff are 






Figure 5.1: Comparison of the sulfatase and anSME-encoding gene clusters of B. breve UCC2003 with corresponding loci in the 
currently available complete B. breve genome sequences. Each solid arrow represents an open reading frame. The length of the arrows 
(which contain the locus tag number) is proportional to the size of the open reading frame. The corresponding gene name, which is 
indicative of putative function, is given above relevant arrows at the top of the figure. Orthologs are marked with the same colour. The 
amino acid identity of each predicted protein to its equivalent protein encoded by B. breve UCC2003, expressed as a percentage, is 






Figure 5.2: Final OD600nm values obtained following 24 h growth of B. breve 
UCC2003, B. breve UCC2003-atsT and B. breve UCC2003-atsA2 in mMRS without 
supplementation with a carbon source (negative control) or containing 0.5 % (wt/vol) 
lactose or GlcNAc-6-S as the sole carbon source. The results presented were 





Figure 5.3: Schematic representation of the four B. breve UCC2003 gene clusters up-regulated during growth on GlcNAc-6-S as the sole carbon 
source. The length of the arrows (which contain the locus tag number) is proportional to the size of the open reading frame and the gene locus 
name, which is indicative of its putative function, is given at the top. Genes are grouped by colour based on their predicted function in 




Figure 5.4: HPAEC-PAD analysis of the sulfatase activity of AtsA2, AtsB2 and co-
expressed AtsA2 and AtsB2. The chromatographic position of GlcNAc is indicated 
by an arrow. (I) 0.1 mg ml-1 GlcNAc standard in 50 mM MOPS buffer (II) 0.1 mg 
ml-1 of GlcNAc-6-S incubated with crude cell extract containing pQE-60-AtsA2 
(III) 0.1 mg ml-1 of GlcNAc-6-S incubated with crude cell extract containing 
pBC1.2-AtsB2 (IV) 0.1 mg ml-1 of GlcNAc-6-S incubated with crude cell extract 





Figure 5.5: Schematic representation of the gene clusters up- or down-regulated in 
the insertion mutant strains (A) B. breve UCC2003-atsR1 and (B) B. breve 
UCC2003-atsR2 as compared to B. breve UCC2003 during growth in mMRS 
supplemented with 0.5% (wt/vol) ribose. The genes in which the insertion mutants 
were constructed are marked with a red cross symbol. Red and blue arrows represent 
up- or down-regulation, respectively. The absence of an arrow indicates no change in 
the level of transcription compared to B. breve UCC2003. The gene locus name, 
which is indicative of its putative function, is given at the top. Genes are grouped by 







Figure 5.6: (A) Schematic representation of the ats2 gene cluster of B. breve 
UCC2003 and DNA fragments used in EMSAs for the atsR2 and atsT promoter 
regions, together with Weblogo representation of the predicted operator of AtsR2. 
Plus or minus signs indicate ability or inability of AtsR2 to bind to the DNA 
fragment. The bent arrows represent the position and direction of the proven 
promoter sequences (see Fig. 7). (B) EMSAs showing the interactions of (I) crude 
cell extract containing pNZ-AtsR2 with the DNA fragments R1, R2, R3,T1, T2 and 
T3 and (II) crude cell extract containing pNZ8048 (empty vector) with the DNA 
fragments R1 and T1. The minus symbol indicates reactions to which no crude cell 
extract was added, while the remaining lanes represent binding reactions with the 
respective DNA probes incubated with increasing amounts of crude cell extract. 
Each successive lane from right to left represents a doubling of the amount of crude 
cell extract. (C) EMSAs showing AtsR2 interaction with the DNA fragments R1 and 
T1 with the addition of GlcNAc or GlcNAc-6-S in concentrations ranging from 2.5 








Figure 5.7: (A) Schematic representation of the ats1 gene cluster of B. breve 
UCC2003 and DNA fragments used in EMSAs for the atsA1 and Bbr_0353 
promoter regions, together with Weblogo representation of the predicted operator of 
AtsR1. Plus or minus signs indicate ability or inability of AtsR1 to bind to the DNA 
fragment. The bent arrows represent the proven promoter regions (see Fig. 7). (B) 
EMSAs showing the interactions of (I) crude cell extract containing pNZ-atsR1 with 
the DNA fragments F1, F2, F3, F4 and F5 and (II) crude cell extract containing 
pNZ8048 (empty vector) with the DNA fragments F1, F2 and F4. The minus symbol 
indicates reactions to which no crude cell extract was added, while the remaining 
lanes represent binding reactions with the respective DNA probes incubated with 
increasing amounts of crude cell extract. Each successive lane from right to left 









Figure 5.8: Schematic representation of the atsR2 (panel A), atsT (panel B), atsA1 
(panel C) and Bbr_0353 (panel D) promoter regions. Boldface type and underlining 
indicate -10 and -35 hexamers (as deduced from the primer extension results) and 
ribosomal binding site (RBS); the transcriptional start site is indicated by an asterisk. 
The arrows underneath the indicated DNA sequences indicate the inverted repeats 
that represent the presumed AtsR1 or AtsR2 binding sites as displayed above the 
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With the ever-increasing number of publicly available bifidobacterial genomes (185 
genomes including complete and draft genome sequences as of NCBI, December 2014), 
there is a wealth of genomic information about this genus at our fingertips. Genomics-
based research has provided significant and insightful information into the 
phylogenomics of the Bifidobacterium genus (Lugli et al., 2014; Milani et al., 2014), 
while pan-genome and core-genome analyses have generated information on the DNA 
sequences that are common among or different between bifidobacterial species, 
including genetic traits such as those pertaining to ecological origin, carbohydrate 
utilisation and host-microbe interactions (Chapter I) (Bottacini et al., 2014; Duranti et 
al., 2012; Milani et al., 2013; Ventura et al., 2014). However, functional genomics still 
has a significant role to play in taking the information gleaned from genomic approaches 
towards the characterisation and understanding of the specific traits that define 
bifidobacterial physiology and permit its colonisation in the gut. In this thesis, a number 
of functional genomic approaches were taken to investigate the metabolism of host-
derived carbohydrates by a prototypical bifidobacterial isolate from nursling stool, 
Bifidobacterium breve UCC2003.  
Other bifidobacterial species of infant gut origin, namely Bifidobacterium longum subsp. 
infantis ATCC15697 and Bifidobacterium bifidum, were previously shown to be well-
adapted to utilise host-derived carbohydrates, particularly human milk oligosaccharides 
(HMOs) and/or mucin (Sela & Mills, 2010; Turroni et al., 2014). In silico analysis of 
the B. breve UCC2003 genome revealed putative gene clusters involved in the 
metabolism of host derived mono- and oligosaccharides such as sialic acid, lacto-N-
biose (LNB) and galacto-N-biose (GNB). Chapter II of this thesis focused on the 
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identification and characterisation of two gene clusters required for the metabolism of 
sialic acid in B. breve UCC2003. Metabolism of this nine-carbon monosaccharide was 
shown to occur by means of a five-step pathway, analogous to that originally described 
in Escherichia coli (Plumbridge & Vimr, 1999) and being well-conserved among 
commensals and pathogens of the gut microbiota, including Lactobacillus sakei (Anba-
Mondoloni et al., 2013), Staphylococcus aureus (Olson et al., 2013) and Haemophilus 
influenzae (Vimr et al., 2000). It is interesting to observe that among Bifidobacterium 
species, the sialic acid utilisation cluster is well conserved in the typically infant-derived 
species, B. breve and B. longum subsp. infantis (Egan et al., 2014a; Sela et al., 2008). 
Breast-fed infants typically have higher numbers of bifidobacteria compared to their 
formula-fed counterparts (Fanaro et al., 2003; Roger et al., 2010). Although the reason 
for such disparity is likely to be due to a number of factors, it is interesting to note that 
infant formula has previously been shown to contain only approximately a quarter of the 
sialic acid levels compared to that found in human milk. Significantly, 70 % of the sialic 
acid in infant formula is linked to glycoproteins whereas in human milk the majority of 
sialic acid is bound to oligosaccharides, possibly making the sialic acid in infant formula 
less accessible to bacterial sialidases (Wang et al., 2001). 
Chapter III is a follow on from Chapter II, and describes the mechanism by which the 
sialic acid utilisation gene cluster, or nan/nag cluster, is regulated. Unlike the sialic acid 
catabolic pathway, the transcriptional regulation of sialic acid utilisation may vary 
among bacterial components of the intestinal microbiota. In B. breve UCC2003, 
transcription of the nan/nag cluster is controlled by a GntR-family transcriptional 
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regulator, designated NanR, representing the first regulator of this kind to be 
characterised from bifidobacteria. 
From in silico analysis of the B. breve UCC2003 genome, it is notable that this strain 
encodes just three predicted extracellular glycosyl hydrolases (O'Connell Motherway et 
al., 2011b). Therefore it seems unlikely that B. breve UCC2003 follows the same 
strategy as that employed by B. bifidum PRL2010, whereby mucin and HMO are 
extracellularly degraded to their component mono- and oligosaccharides (Asakuma et 
al., 2011; Turroni et al., 2010). Instead, as described in Chapter II of this thesis, B. breve 
UCC2003 can take advantage of the extracellular sialidase activity of B. bifidum 
PRL2010 to scavenge sialic acid released from 3’ sialyllactose. Following a similar 
strategy, it was shown in Chapter IV that, while being itself incapable of degrading 
mucin, B. breve UCC2003 is a highly effective scavenger of the constituent mono- and 
oligosaccharides of mucin released by the extracellular glycosyl hydrolase activity of B. 
bifidum PRL2010. While such cross-feeding between genera and species of the 
intestinal microbiota had long been speculated (Hoskins et al., 1985; Sela & Mills, 
2010; Ward et al., 2007), these results provide conclusive proof that B. breve can indeed 
enhance its growth and survival abilities through the metabolism of mucin and HMO 
components, which are released by B. bifidum extracellular activity.  
Finally, Chapter V introduced a previously unexplored area of carbohydrate metabolism 
in bifidobacteria, namely the metabolism of sulfated carbohydrates. B. breve UCC2003 
was shown to metabolise the sulfated monosaccharide N-acetylglucosamine-6-sulfate 
(GlcNAc-6-S) through one of two sulfatase-encoding gene clusters identified on the B. 
breve UCC2003 genome, whereas the substrate of the second cluster has yet to be 
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determined. It is intriguing that within the Bifidobacterium genus, sulfatase-encoding 
genes are restricted to and conserved within the B. breve species only, apparently 
allowing members of this species to utilise sulfated components of mucin, HMOs and 
other glycans, which are inaccessible even to B. bifidum and B. longum subsp. infantis, 
representing known specialists of mucin and HMO metabolism.  
While each chapter of this thesis deals with a specific aspect of host-derived 
carbohydrate metabolism, there are connecting aspects of the studied metabolic 
activities. This became obvious when analysing the transcriptomic response of B. breve 
UCC2003 to growth on GlcNAc-6-S. Within the ats2 gene cluster and its neighbouring 
Bbr_0846-049 gene cluster, each of the genes required for the metabolism of this 
sulfated sugar to fructose-6-phosphate can be identified. We predict that the sulfate 
residue is removed by AtsA2-mediated sulfatase activity, followed by the catabolism of 
GlcNAc as previously described in E. coli (White, 1968), through the activities of the 
NagK, NagA1 and NagB2 enzymes, the genes for which are located within the 
Bbr_0846-0849 gene cluster (Chapter V). If GlcNAc-6-S is indeed metabolised through 
this pathway, the additional nagA2 and nagB3 genes, and the LNB/GNB gene cluster 
which are also up-regulated during growth on this sulfated sugar, do not appear to add 
any functionality. 
However, by analysis of sialic acid metabolism, as well as the NanR-mediated 
regulation of the nan/nag cluster, some logic for this apparent anomaly can be found. In 
Chapter II it was shown that by the combined activities of the NanA, NanK and NanE 
enzymes, N-acetylglucosamine-6-phosphate (GlcNAc-6-P) is produced from sialic acid, 
which is then converted to fructose-6-phosphate by the combined activities of NagA2 
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and NagB3 (Egan et al., 2014a). However in Chapter III it was found that only the 
nanA, nanK and nanE genes, which are part of the nan/nag cluster, are under the control 
of the NanR repressor, whereas transcription of the nagA2 and nagB3 genes is not. We 
hypothesise that the accumulation of the metabolic intermediate GlcNAc-6-P induces 
expression of the nagA2 and nagB3 genes, which are possibly under the transcriptional 
control of a predicted ROK-family transcriptional regulator, encoded by a gene that is 
located immediately downstream of the nagB3 gene. This hypothesis would also explain 
how the accumulation of GlcNAc-6-P by NagK activity causes the induction of the 
nagA2 and nagB3 genes during growth on GlcNAc-6-S. 
As mentioned above, there seems no metabolic reason for the induction of the predicted 
LNB/GNB gene cluster during growth on GlcNAc-6-S. However, a careful review of 
the previously performed microarrays of B. breve UCC2003 during growth on mucin in 
co-culture with B. bifidum PRL2010 and in sialic acid (when the imposed threshold for 
up-regulation was lowered slightly) revealed that the LNB/GNB gene cluster was also 
significantly up-regulated (fold change >2.5, P<0.001) during growth under the 
aforementioned conditions (Chapters II and IV). It is not surprising that these genes are 
induced during growth in co-culture as GNB is the primary disaccharide of the core 1 
and core 2 structures of mucin and it was hypothesised that it represents one of the 
mucin components supporting growth of B. breve UCC2003 under these conditions 
(Egan et al., 2014b). However, none of the genes encoded by the LNB/GNB gene 
cluster have a role in relation to sialic acid metabolism (Egan et al., 2014a). It seems 
that the up-regulation of this gene cluster is concurrent with the up-regulation of the 
nagA2 and nagB3 genes even during growth on substrates such as GlcNAc-6-S and 
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sialic acid which have no obvious need for the protein products of this gene cluster. This 
would imply that the nagA2 and nagB3 genes and the predicted LNB/GNB gene cluster 
are co-regulated and if our hypothesis is correct, the metabolic intermediate that controls 
this regulation is GlcNAc-6-P.  
From the information provided in this thesis, we can hypothesise that GlcNAc-6-P or its 
dephosphorylated form N-acetylglucosamine (GlcNAc) play an important role in the 
regulation of various gene clusters involved in the metabolism of host-derived 
carbohydrates. GlcNAc is a primary monosaccharide constituent in a wide range of 
host-derived carbohydrates including mucin (Varki et al., 2009), N-linked glycans 
(Morelle & Michalski, 2007) and in the majority of HMO species (Bode & Jantscher-
Krenn, 2012). Even in the metabolism of sugars which do not contain GlcNAc, such as 
sialic acid and GNB, GlcNAc-6-P is produced as an intermediate (Nishimoto & Kitaoka, 
2007; Plumbridge & Vimr, 1999). Therefore it seems that GlcNAc-6-P is a common 
intermediate in the metabolic pathways of a wide range of host-derived carbohydrates 
(Fig. 6.1) and perhaps it is unsurprising that it may play a role in the induction of a 
variety of genes related to host-derived carbohydrate metabolism. The first step towards 
proving this hypothesis would be the construction of an insertion mutant in the gene 
(with locus tag Bbr_1249), which is predicted to encode a ROK-family transcriptional 
regulator and is located immediately downstream of the nagA2 and nagB3 genes. If this 
protein functions as a transcriptional repressor, a microarray would reveal the gene 
clusters it regulates. If successful, this could then be followed by cloning and 
overproduction of the protein and electrophoretic mobility shift assays in the presence or 
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absence of GlcNAc-6-P to determine if it is the effector molecule of the transcriptional 
regulator.  
It was previously shown in E. coli that the metabolism of amino sugars such as GlcNAc, 
N-acetylmannosamine as well as sialic acid requires convergent pathways which 
ultimately result in the production of fructose-6-phosphate (Plumbridge & Vimr, 1999). 
It seems that a similar system of converging pathways exists in B. breve UCC2003. 
However, possibly due to horizontal gene transfer events, as speculated for the 
acquisition of the ats2 and Bbr_0846-0849 gene clusters (Chapter V), some of these 
pathways are partially redundant, thus resulting in the simultaneous up-regulation of 
homologous genes. Whilst this can be seen as inefficient (and perhaps explains the 
lower level of growth of the strain on GlcNAc-6-S compared to lactose), it also has its 
advantages, as the strain can cope with the loss of a copy of each gene. In fact such an 
event appeared to already have occurred in B. breve UCC2003. Within the sialic acid 
utilisation cluster, the Bbr_0170 gene encodes a truncated, and therefore a presumed 
non-functional nagA gene, yet the strain can still utilise sialic acid (Egan et al., 2014a). 
Furthermore, construction of an insertion mutant in the nagA2 gene did not result in the 
impairment of growth on sialic acid, presumably because the nagA1 gene compensates 





Figure 6.1: Proposed routes for the breakdown of GlcNAc-6-S, LNB and GNB as well as the proven catabolic pathway of sialic acid 
in B. breve UCC2003. Each metabolic pathway has GlcNAc-6-P as a common intermediate, which is converted to fructose-6-
phosphate by the combined activities of NagA and NagB and subsequently enters the bifid shunt. The galactose-1-phosphate produced 
from LnbP activity on LNB and GNB is presumably metabolised via the Leloir pathway. Enzymes are grouped by colour based on the 
proven or predicted transcriptional regulator of their encoding genes. Red: regulated by NanR (Chapter III); Green: regulated by 
AtsR2 (Chapter V); Blue: putatively regulated by a ROK family transcriptional repressor encoded by the Bbr_1249 gene. 
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On the B. breve UCC2003 genome, it is interesting to note the difference between the 
gene clusters involved in the metabolism of plant-derived carbohydrates and those 
involved in host-derived carbohydrate metabolism. The cld cluster for cellodextrin 
metabolism (Pokusaeva et al., 2011), the gal locus involved in galactan metabolism 
(O'Connell Motherway et al., 2011a), the raf cluster for raffinose metabolism and the 
melABCDE cluster for melezitose metabolism (O'Connell et al., 2013) are involved in 
the catabolism of various plant-derived carbohydrates. These gene clusters mirror the 
typical carbohydrate utilisation cluster as described in B. longum subsp. longum as they 
include a LacI-type transcriptional regulator (with the exception of the RafR ROK-
family activator of the raf cluster), an ABC-type uptake system and between one and six 
genes encoding glycosyl hydrolases (Schell et al., 2002). Therefore, the genes required 
for the uptake, metabolism and regulation of these plant-derived sugars are all 
specifically confined within these gene clusters. This is in contrast to the metabolism of 
host-derived carbohydrates, which as described in this thesis can involve multiple 
unconnected gene clusters and metabolic pathways. Notably, Bacteroides 
thetaiotaomicron, another member of the intestinal microbiota which can utilise both 
dietary and host glycans, was shown to preferentially utilise plant-derived 
polysaccharides when both such carbon/energy sources are available (Sonnenburg et al., 
2005). It would be interesting to perform similar analyses for B. breve UCC2003, the 
results of which may be useful in the development of new prebiotic or synbiotic 
products. 
From the work presented in this thesis, it can be concluded that B. breve UCC2003 is a 
highly versatile microorganism which employs a very flexible and multifaceted 
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approach to carbohydrate utilisation in the gut. As we continue to employ a functional 
genomic approach to increase our understanding of this strategy, it is interesting to 
observe and investigate the complex, interactive network of metabolic and regulatory 
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